

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Abilify

Products Affected

- ABILIFY ORAL SOLUTION

PA Criteria	Criteria Details
Covered Uses	Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, Tourette's Disorder
Exclusion Criteria	
Required Medical Information	A Documented diagnosis of Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, or Tourette's Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR A DIAGNOSIS OF BIPOLAR DISORDER OR SCHIZOPHRENIA: A documented step through one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) add Latuda. FOR ALL OTHER DIAGNOSIS: A documented step through one month of one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone)
QL Criteria	30 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Abilify

Products Affected

- ABILIFY ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, Tourette's Disorder
Exclusion Criteria	
Required Medical Information	A Documented diagnosis of Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, or Tourette's Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Abilify

Products Affected

- ABILIFY ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, Tourette's Disorder
Exclusion Criteria	
Required Medical Information	A Documented diagnosis of Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, or Tourette's Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR A DIAGNOSIS OF BIPOLAR DISORDER OR SCHIZOPHRENIA: A documented step through one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) add Latuda. FOR ALL OTHER DIAGNOSIS: A documented step through one month of one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone)
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Abilify Discmelt

Products Affected

- ABILIFY DISCMELT

PA Criteria	Criteria Details
Covered Uses	Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, Tourette's Disorder
Exclusion Criteria	
Required Medical Information	A Documented diagnosis of Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, or Tourette's Disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	FOR A DIAGNOSIS OF BIPOLAR DISORDER OR SCHIZOPHRENIA: A documented step through one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) add Latuda. FOR ALL OTHER DIAGNOSIS: A documented step through one month of one generic medication (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone)
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Absorica

Products Affected

- ABSORICA

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Abstral

Products Affected

- ABSTRAL

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	4 tablets Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: July 15, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Abstral

Products Affected

- ABSTRAL

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	A documented step through one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)
QL Criteria	4 tablets Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Abstral

Products Affected

- ABSTRAL

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	4 tablets Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Acamprosate Calcium

Products Affected

- *acamprosate calcium*

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Accu-Chek Active

Products Affected

- ACCU-CHEK ACTIVE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Advantage Test

Products Affected

- ACCU-CHEK ADVANTAGE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Aviva

Products Affected

- ACCU-CHEK AVIVA IN VITRO STRIP

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Aviva Plus

Products Affected

- ACCU-CHEK AVIVA PLUS

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Accu-Chek Aviva Plus

Products Affected

- ACCU-CHEK AVIVA PLUS IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Comfort Curve

Products Affected

- ACCU-CHEK COMFORT CURVE IN VITRO STRIP

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Accu-Chek Compact

Products Affected

- ACCU-CHEK COMPACT

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Compact Plus

Products Affected

- ACCU-CHEK COMPACT PLUS

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Compact Plus Care

Products Affected

- ACCU-CHEK COMPACT PLUS CARE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Compact Test Drum

Products Affected

- ACCU-CHEK COMPACT TEST DRUM

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Multiclix Lancet Dev

Products Affected

- ACCU-CHEK MULTICLIX LANCET DEV

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Nano SmartView

Products Affected

- ACCU-CHEK NANO SMARTVIEW

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Accu-Chek SmartView

Products Affected

- ACCU-CHEK SMARTVIEW

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Accu-Chek Voicemate

Products Affected

- ACCU-CHEK VOICEMATE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Accutrend Glucose

Products Affected

- ACCUTREND GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aciphex

Products Affected

- ACIPHEX

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer- reviewed medical literature for use of a higher dose.
ST Criteria	Documented step through 2 generic PPI or OTC (i.e. omeprazole, pantoprazole, esomeprazole, lansoprazole, Prevacid 24H, Nexium)
QL Criteria	1 capsule Per 1 DAY
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aciphex

Products Affected

- ACIPHEX

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer- reviewed medical literature for use of a higher dose.
ST Criteria	A documented step through 2 generic RX or OTC proton pump inhibitors (i.e. esomeprazole mag, lansoprazole, omeprazole, pantoprazole, rabeprazole)
QL Criteria	1 capsule Per 1 DAY
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

AcipHex Sprinkle

Products Affected

- ACIPHEX SPRINKLE

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer- reviewed medical literature for use of a higher dose.
ST Criteria	A documented step through 2 generic RX or OTC proton pump inhibitors (i.e. esomeprazole mag, lansoprazole, omeprazole, pantoprazole, rabeprazole)
QL Criteria	1 capsule Per 1 Day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

AcipHex Sprinkle

Products Affected

- ACIPHEX SPRINKLE

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer- reviewed medical literature for use of a higher dose.
ST Criteria	Documented step through 2 generic PPI or OTC (i.e. omeprazole, pantoprazole, esomeprazole, lansoprazole, Prevacid 24H, Nexium)
QL Criteria	1 capsule Per 1 Day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Acitretin

Products Affected

- *acitretin*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actemra

Products Affected

- ACTEMRA INTRAVENOUS*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actemra

Products Affected

- ACTEMRA SUBCUTANEOUS*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 SYRINGES Per 28 DAYSs
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Actiq

Products Affected

- ACTIQ

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone
QL Criteria	4 loz Per 1 DAYS

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Actiq

Products Affected

- ACTIQ

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone
QL Criteria	4 loz Per 1 DAYS

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Activella

Products Affected

- ACTIVELLA

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actonel

Products Affected

- ACTONEL ORAL TABLET 35 MG

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	4 tablets Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Actonel

Products Affected

- ACTONEL ORAL TABLET 150 MG

ST Criteria	A documented step through alendronate 70mg
QL Criteria	0.04 tabs Per 1 DAYS
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Actonel

Products Affected

- ACTONEL ORAL TABLET 30 MG, 5 MG

ST Criteria	A documented step through alendronate 70mg
QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Actonel

Products Affected

- ACTONEL ORAL TABLET 35 MG

ST Criteria	A documented step through alendronate 70mg
QL Criteria	4 tablets Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Actonel

Products Affected

- ACTONEL ORAL TABLET 5 MG, 30 MG

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Actonel

Products Affected

- ACTONEL ORAL TABLET 150 MG

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	0.04 tabs Per 1 DAYS
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actoplus Met

Products Affected

- ACTOPLUS MET

QL Criteria	2 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actoplus met XR

Products Affected

- ACTOPLUS MET XR

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actos

Products Affected

- ACTOS

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Acura Blood Glucose Test

Products Affected

- ACURA BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adalat CC

Products Affected

- ADALAT CC ORAL TABLET EXTENDED
RELEASE 24 HR* 60 MG

QL Criteria	2 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Adalat CC

Products Affected

- ADALAT CC ORAL TABLET EXTENDED
RELEASE 24 HR* 90 MG, 30 MG

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adcirca

Products Affected

- ADCIRCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Adcirca

Products Affected

- ADCIRCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adcirca

Products Affected

- ADCIRCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Adderall

Products Affected

- ADDERALL

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adderall XR

Products Affected

- ADDERALL XR

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adefovir Dipivoxil

Products Affected

- *adefovir dipivoxil*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adempas

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Adempas

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Adempas

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Adoxa

Products Affected

- ADOXA ORAL TABLET 50 MG
- ADOXA ORAL CAPSULE

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adrenaclick

Products Affected

- ADRENACLICK INJECTION

QL Criteria	1 DEVI Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advair Diskus

Products Affected

- ADVAIR DISKUS INHALATION AEROSOL
POWDER, BREATH ACTIVATED 100-50
MCG/DOSE, 250-50 MCG/DOSE

QL Criteria	1 diskus Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advair Diskus

Products Affected

- ADVAIR DISKUS INHALATION AEROSOL
POWDER, BREATH ACTIVATED 500-50
MCG/DOSE

QL Criteria	2 diskus Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advair HFA

Products Affected

- ADVAIR HFA

QL Criteria	1 inhaler Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advance Intuition Meter

Products Affected

- ADVANCE INTUITION METER

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Advance Intuition Test

Products Affected

- ADVANCE INTUITION TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advance Micro-Draw Test

Products Affected

- ADVANCE MICRO-DRAW TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advate

Products Affected

- ADVATE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advicor

Products Affected

- ADVICOR ORAL TABLET EXTENDED
RELEASE 24 HR* 1000-40 MG, 500-20 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Advicor

Products Affected

- ADVICOR ORAL TABLET EXTENDED
RELEASE 24 HR* 750-20 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advicor

Products Affected

- ADVICOR ORAL TABLET EXTENDED
RELEASE 24 HR* 1000-20 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Advocate Blood Glucose Monitor

Products Affected

- ADVOCATE BLOOD GLUCOSE MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advocate Duo

Products Affected

- ADVOCATE DUO DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Advocate Redi-Code

Products Affected

- ADVOCATE REDI-CODE IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advocate Redi-Code

Products Affected

- ADVOCATE REDI-CODE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Advocate Redi-Code+

Products Affected

- ADVOCATE REDI-CODE+

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advocate Redi-Code+ Test

Products Affected

- ADVOCATE REDI-CODE+ TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advocate Test

Products Affected

- ADVOCATE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adynovate

Products Affected

- *adynovate*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Adzenys XR-ODT

Products Affected

- ADZENYS XR-ODT

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aerospan

Products Affected

- AEROSPAN

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
ST Criteria	Documented step through one month of ASMANEX AND QVAR
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Afeditab CR

Products Affected

- *afeditab cr oral tablet extended release 24 hr**
30 mg

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afeditab CR

Products Affected

- *afeditab cr oral tablet extended release 24 hr**
60 mg

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Afinitor

Products Affected

- AFINITOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afinitor Disperz

Products Affected

- AFINITOR DISPERZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Afrezza

Products Affected

- AFREZZA

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes, Type 2 Diabetes
Exclusion Criteria	
Required Medical Information	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin (e.g., Levamir or Lantus), (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afrezza

Products Affected

- AFREZZA

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes, Type 2 Diabetes
Exclusion Criteria	
Required Medical Information	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin (e.g., Levamir or Lantus), (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Afstyla

Products Affected

- AFSTYLA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AgaMatrix AMP Test

Products Affected

- AGAMATRIX AMP TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AgaMatrix Jazz Test

Products Affected

- AGAMATRIX JAZZ TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AgaMatrix KeyNote Test

Products Affected

- AGAMATRIX KEYNOTE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AgaMatrix Presto

Products Affected

- AGAMATRIX PRESTO

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AgaMatrix Presto Pro Meter

Products Affected

- AGAMATRIX PRESTO PRO METER

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

AgaMatrix Presto Test

Products Affected

- AGAMATRIX PRESTO TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Akynzeo

Products Affected

- AKYNZEO

PA Criteria	Criteria Details
Covered Uses	Prophylaxis of chemotherapy-induced nausea and vomiting
Exclusion Criteria	
Required Medical Information	A documented diagnosis of nausea and vomiting associated with cancer chemotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of Akynzeo will be considered medically necessary for those members who have adocumented chemotherapy regimen that requires more than two cycles of antiemetic per 30 days
QL Criteria	2 capsules Per 1 month
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Aldara

Products Affected

- ALDARA

QL Criteria	48 packet Per 112 DAYSs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aldurazyme

Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Alecensa

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alendronate Sodium

Products Affected

- *alendronate sodium oral tablet 35 mg*

QL Criteria	4 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Alendronate Sodium

Products Affected

- *alendronate sodium oral tablet 5 mg, 40 mg, 10 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alfuzosin HCl ER

Products Affected

- *alfuzosin hcl er*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Almotriptan Malate

Products Affected

- *almotriptan malate*

QL Criteria	6 tablets Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alogliptin Benzoate

Products Affected

- *alogliptin benzoate*

QL Criteria	1 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Alogliptin-Metformin HCl

Products Affected

- *alogliptin-metformin hcl*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alogliptin-Pioglitazone

Products Affected

- *alogliptin-pioglitazone*

QL Criteria	1 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Alora

Products Affected

- ALORA

QL Criteria	8 patches Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alosetron HCl

Products Affected

- *alose tron hcl*

PA Criteria	Criteria Details
Covered Uses	severe diarrhea-predominant irritable bowel syndrome (IBS)
Exclusion Criteria	
Required Medical Information	Patient is female, and has a documented diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) including one or more of the following: frequent and severe abdominal pain/discomfort, frequent urgency or fecal incontinence or disability or restriction of daily activities due to IBS, AND patient has chronic IBS symptoms generally lasting 6 months or longer, AND anatomic or biochemical abnormalities of the gastrointestinal tract have been excluded
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each diphenoxylate/atropine and loperamide
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Alosetron HCl

Products Affected

- *alose tron hcl*

PA Criteria	Criteria Details
Covered Uses	severe diarrhea-predominant irritable bowel syndrome (IBS)
Exclusion Criteria	
Required Medical Information	Patient is female, and has a documented diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) including one or more of the following: frequent and severe abdominal pain/discomfort, frequent urgency or fecal incontinence or disability or restriction of daily activities due to IBS, AND patient has chronic IBS symptoms generally lasting 6 months or longer, AND anatomic or biochemical abnormalities of the gastrointestinal tract have been excluded
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented trial of 2 alternatives: diphenoxylate/atropine, loperamide
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alphanate/VWF Complex/Human

Products Affected

- ALPHANATE/VWF COMPLEX/HUMAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

AlphaNine SD

Products Affected

- ALPHANINE SD

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ALPRAZolam ER

Products Affected

- *alprazolam er*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ALPRAZolam XR

Products Affected

- *alprazolam xr*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alprolix

Products Affected

- ALPROLIX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Altavera

Products Affected

- *altavera*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Altoprev

Products Affected

- ALTOPREV

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Alvesco

Products Affected

- ALVESCO

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
ST Criteria	Documented step through one month of ASMANEX AND QVAR
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alyacen 1/35

Products Affected

- *alyacen 1/35*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alyacen 7/7/7

Products Affected

- *alyacen 7/7/7*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ambien

Products Affected

- AMBIEN ORAL TABLET 10 MG

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ambien

Products Affected

- AMBIEN ORAL TABLET 5 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ambien CR

Products Affected

- AMBIEN CR

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amerge

Products Affected

- AMERGE

QL Criteria	9 tablets Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amethia

Products Affected

- *amethia*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amethia Lo

Products Affected

- *amethia lo*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amethyst

Products Affected

- *amethyst*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amitiza

Products Affected

- AMITIZA

ST Criteria	Documented step through Lactulose or Miralax
QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amlodipine Besylate-Valsartan

Products Affected

- *amlodipine besylate-valsartan*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amlodipine-Valsartan-HCTZ

Products Affected

- *amlodipine-valsartan-hctz*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amnesteem

Products Affected

- *amnesteem*

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
QL Criteria	2 capsules Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Amphetamine-Dextroamphet ER

Products Affected

- *amphetamine-dextroamphet er*

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amphetamine-Dextroamphetamine

Products Affected

- *amphetamine-dextroamphetamine*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ampyra

Products Affected

- AMPYRA

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amturnide

Products Affected

- AMTURNIDE

ST Criteria	Documented step thru 2 preferred ACE-I or ARB . Formulary Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations include: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril),Univasc (moexipril). Formulary Angiotensin Receptor Blocker (ARB) & ARB combinations include: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Androderm

Products Affected

- ANDRODERM TRANSDERMAL PATCH 24 HR 2 MG/24HR, 4 MG/24HR

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Androderm

Products Affected

- ANDRODERM TRANSDERMAL PATCH 24 HR 5 MG/24HR, 2.5 MG/24HR

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL GEL 20.25 MG/1.25GM (1.62%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 1.25 gm packet Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL GEL 25 MG/2.5GM (1%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
QL Criteria	1 25 gram packet Per 1 day
Notes/References	Annual Review: 02/2016

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL GEL 40.5 MG/2.5GM (1.62%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	5 grams-2 packets Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL GEL 50 MG/5GM (1%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of AndroGel 1.62%
QL Criteria	2 10 gm packets Per 1 day
Notes/References	Annual Review: 02/2016

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

AndroGel Pump

Products Affected

- ANDROGEL PUMP TRANSDERMAL GEL
12.5 MG/ACT (1%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
QL Criteria	10 grams Per 1 day
Notes/References	Annual Review: 02/2016

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

AndroGel Pump

Products Affected

- ANDROGEL PUMP TRANSDERMAL GEL
20.25 MG/ACT (1.62%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	4 pumps Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Angeliq

Products Affected

- ANGELIQ

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Anoro Ellipta

Products Affected

- ANORO ELLIPTA

QL Criteria	60 BLISTERS Per 30 DAYSs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Antara

Products Affected

- ANTARA ORAL CAPSULE 30 MG, 90 MG

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Anzemet

Products Affected

- ANZEMET ORAL

QL Criteria	5 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

APAP-Caff-Dihydrocodeine

Products Affected

- *apap-caff-dihydrocodeine oral capsule*

QL Criteria	10 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Apidra

Products Affected

- APIDRA

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Apidra SoloStar

Products Affected

- APIDRA SOLOSTAR SUBCUTANEOUS*

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Aplenzin

Products Affected

- APLENZIN

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Apri

Products Affected

- *apri*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Apriso

Products Affected

- APRISO

QL Criteria	4 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptensio XR

Products Affected

- APTENSIO XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Aptiom

Products Affected

- APTIOM ORAL TABLET 400 MG, 800 MG

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptiom

Products Affected

- APTIOM ORAL TABLET 600 MG, 200 MG

QL Criteria	2 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aranelle

Products Affected

- *aranelle*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aranesp (Albumin Free)

Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 10 MCG/0.4ML, 60 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 100 MCG/ML, 200 MCG/ML, 150 MCG/0.75ML
- ARANESP (ALBUMIN FREE) INJECTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Arava

Products Affected

- ARAVA

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Arcalyst

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/immunomodulators_CAP.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Arcapta Neohaler

Products Affected

- ARCAPTA NEOHALER

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Trial of one month of Serevent
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Arcapta Neohaler

Products Affected

- ARCAPTA NEOHALER

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Serevent
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Aricept

Products Affected

- ARICEPT

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aricept ODT

Products Affected

- ARICEPT ODT

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ARIPiprazole

Products Affected

- *aripiprazole oral tablet*
- *aripiprazole oral tablet dispersible*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ARIPiprazole

Products Affected

- *aripiprazole oral solution*

QL Criteria	30 ml Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Arixtra

Products Affected

- ARIXTRA

QL Criteria	2 syringes Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Armodafinil

Products Affected

- *armodafinil oral tablet 150 mg, 200 mg, 250 mg*

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Armodafinil

Products Affected

- *armodafinil oral tablet 50 mg*

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Arnuity Ellipta

Products Affected

- ARNUITY ELLIPTA

QL Criteria	1 blister Per 1 Day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Asacol HD

Products Affected

- ASACOL HD

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ascensia Autodisc Test

Products Affected

- ASCENSIA AUTODISC TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Assure 3 Test

Products Affected

- ASSURE 3 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Assure 4 Meter

Products Affected

- ASSURE 4 METER

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Assure 4 Test

Products Affected

- ASSURE 4 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Assure II

Products Affected

- ASSURE II

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Assure II Check

Products Affected

- ASSURE II CHECK

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Assure Platinum

Products Affected

- ASSURE PLATINUM

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Assure Platinum Meter

Products Affected

- ASSURE PLATINUM METER

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Assure Prism multi Test

Products Affected

- ASSURE PRISM MULTI TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Assure Pro Blood Glucose Meter

Products Affected

- ASSURE PRO BLOOD GLUCOSE METER

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Assure Pro Test

Products Affected

- ASSURE PRO TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Astagraf XL

Products Affected

- ASTAGRAF XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 0.5 MG

QL Criteria	1 CP24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Astagraf XL

Products Affected

- ASTAGRAF XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 1 MG

QL Criteria	4 CP24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

At Last Test

Products Affected

- AT LAST TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atacand

Products Affected

- ATACAND ORAL TABLET 32 MG

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Atacand

Products Affected

- ATACAND ORAL TABLET 16 MG, 8 MG, 4 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atacand HCT

Products Affected

- ATACAND HCT ORAL TABLET 32-12.5 MG, 32-25 MG

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Atacand HCT

Products Affected

- ATACAND HCT ORAL TABLET 16-12.5
MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atelvia

Products Affected

- ATELVIA

QL Criteria	4 tablets Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Atorvastatin Calcium

Products Affected

- *atorvastatin calcium oral*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atripla

Products Affected

- ATRIPLA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Aubagio

Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Aubagio

Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Aubagio

Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Auvi-Q

Products Affected

- AUVI-Q INJECTION

QL Criteria	2 pens Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avalide

Products Affected

- AVALIDE ORAL TABLET 300-12.5 MG

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avalide

Products Affected

- AVALIDE ORAL TABLET 150-12.5 MG

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Avandamet

Products Affected

- AVANDAMET ORAL TABLET 2-1000 MG

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	An adult patient with a documented diagnosis of type 2 diabetes mellitus and all of the following: unable to achieve adequate glycemic control (HbA1C lab value greater than 6.5%) despite the use of other medications, and, in consultation with their healthcare provider, has decided not to take Actos (pioglitazone) for medical reasons.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avandia

Products Affected

- AVANDIA

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	An adult patient with a documented diagnosis of type 2 diabetes mellitus and all of the following: unable to achieve adequate glycemic control (HbA1C lab value greater than 6.5%) despite the use of other medications, and, in consultation with their healthcare provider, has decided not to take Actos (pioglitazone) for medical reasons.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Avapro

Products Affected

- AVAPRO

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aviane

Products Affected

- *aviane*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

AVINza

Products Affected

- AVINZA

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avita

Products Affected

- *avita external cream*

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	50 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Avita

Products Affected

- *avita external gel*

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avodart

Products Affected

- AVODART

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avonex

Products Affected

- AVONEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avonex

Products Affected

- AVONEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Avonex

Products Affected

- AVONEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Avonex Pen

Products Affected

- AVONEX PEN INTRAMUSCULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Avonex Prefilled

Products Affected

- AVONEX PREFILLED INTRAMUSCULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

Avonex Prefilled

Products Affected

- AVONEX PREFILLED INTRAMUSCULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Avonex Prefilled

Products Affected

- AVONEX PREFILLED INTRAMUSCULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Axert

Products Affected

- AXERT

QL Criteria	3 tablets Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Axiron

Products Affected

- AXIRON

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Azilect

Products Affected

- AZILECT

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azor

Products Affected

- AZOR

ST Criteria	Documented step through amlodipine in combination with TWO of the following: Atacand, Avapro, Cozaar, Micardis
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azulfidine

Products Affected

- AZULFIDINE

QL Criteria	8 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Azulfidine EN-tabs

Products Affected

- AZULFIDINE EN-TABS

QL Criteria	8 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azurette

Products Affected

- *azurette*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Balsalazide Disodium

Products Affected

- *balsalazide disodium*

QL Criteria	9 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Balziva

Products Affected

- *balziva*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Banzel

Products Affected

- BANZEL ORAL TABLET

QL Criteria	8 tablets Per 1 day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Baraclude

Products Affected

- BARACLUDGE ORAL TABLET

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bayer Breeze 2 Test

Products Affected

- BAYER BREEZE 2 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bayer Contour Link Monitor

Products Affected

- BAYER CONTOUR LINK MONITOR

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bayer Contour Monitor

Products Affected

- BAYER CONTOUR MONITOR DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bayer Contour Monitor

Products Affected

- BAYER CONTOUR MONITOR KIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bayer Contour Next EZ

Products Affected

- BAYER CONTOUR NEXT EZ

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bayer Contour next Link

Products Affected

- BAYER CONTOUR NEXT LINK

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bayer Contour Next Monitor

Products Affected

- BAYER CONTOUR NEXT MONITOR

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bayer Contour Next Test

Products Affected

- BAYER CONTOUR NEXT TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Bayer Contour Next USB Monitor

Products Affected

- BAYER CONTOUR NEXT USB MONITOR

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bayer Contour Test

Products Affected

- BAYER CONTOUR TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Bayer Contour USB

Products Affected

- BAYER CONTOUR USB

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bebulin

Products Affected

- BEBULIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Bebulin VH

Products Affected

- BEBULIN VH

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Beconase AQ

Products Affected

- BECONASE AQ

ST Criteria	A documented step through 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Belbuca

Products Affected

- BELBUCA

PA Criteria	Criteria Details
Covered Uses	Pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Exclusion Criteria	Acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, including paralytic ileus
Required Medical Information	(1)Patient is 18 years of age or older and has a documented diagnosis of chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment, (2)Alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain (i.e. non-opioid analgesics or immediate-release opioids), (3)Is not being used in combination with other long-acting opioid therapy, and (4)Is NOT being used for the treatment of opioid dependence
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 films Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Belsomra

Products Affected

- BELSOMRA

ST Criteria	A documented step through zolpidem, zolpidem er, or zaleplon
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Belsomra

Products Affected

- BELSOMRA

ST Criteria	Trial of 1 month of one preferred generic alternative (zolpidem, zolpidem er, eszopiclone, zaleplon)
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BeneFIX

Products Affected

- BENEFIX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Benicar

Products Affected

- BENICAR

ST Criteria	Documented step through TWO of the following: ATACAND*, AVAPRO*, COZAAR*, MICARDIS*
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Benicar HCT

Products Affected

- BENICAR HCT

ST Criteria	A documented step through one month each of any two preferred alternatives from the following: candesartan/hctz, eprosartan/hctz, irbesartan/hctz, losartan/hctz, telmisartan/hctz, or valsartan/hctz
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Benicar HCT

Products Affected

- BENICAR HCT

ST Criteria	Documented step through TWO of the following: ATACAND HCT*, AVALIDE*, HYZAAR*, MICARDIS HCT*
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Benlysta

Products Affected

- BENLYSTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/benlysta.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Berinert

Products Affected

- BERINERT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angi_oedema.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Betaseron

Products Affected

- BETASERON SUBCUTANEOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Betaseron

Products Affected

- BETASERON SUBCUTANEOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

Betaseron

Products Affected

- BETASERON SUBCUTANEOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bethkis

Products Affected

- BETHKIS

QL Criteria	56 ampules Per 30 DAYSS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bevespi Aerosphere

Products Affected

- BEVESPI AEROSPHERE

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Trial of 1 month each of Anoro Ellipta and Stiolto
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bevespi Aerosphere

Products Affected

- BEVESPI AEROSPHERE

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Trial of 1 month each of Anoro Ellipta and Stiolto
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

Beyaz

Products Affected

- BEYAZ

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BG Star Test

Products Affected

- BG STAR TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bicalutamide

Products Affected

- *bicalutamide*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bimatoprost

Products Affected

- *bimatoprost ophthalmic*

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bioscanner Glucose Test

Products Affected

- BIOSCANNER GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

BL Test

Products Affected

- *bl test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Blood Glucose Test

Products Affected

- *blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Boniva

Products Affected

- BONIVA ORAL TABLET 150 MG

QL Criteria	0.04 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bosulif

Products Affected

- BOSULIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bosulif

Products Affected

- BOSULIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Bosulif

Products Affected

- BOSULIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Botox

Products Affected

- BOTOX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bravelle

Products Affected

- BRAVELLE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Breeze 2 Blood Glucose System

Products Affected

- BREEZE 2 BLOOD GLUCOSE SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Breo Ellipta

Products Affected

- BREO ELLIPTA

QL Criteria	2 blister Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Breo Ellipta

Products Affected

- BREO ELLIPTA

QL Criteria	2 inhalation Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brevicon (28)

Products Affected

- BREVICON (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Briellyn

Products Affected

- *briellyn*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brilinta

Products Affected

- BRILINTA

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Brintellix

Products Affected

- BRINTELLIX

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	1 tablet Per 1 Day
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Brisdelle

Products Affected

- BRISDELLE

PA Criteria	Criteria Details
Covered Uses	Vasomotor symptoms associated with menopause
Exclusion Criteria	
Required Medical Information	Documented diagnosis of moderate to severe vasomotor symptoms associated with menopause
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Briviact

Products Affected

- BRIVIACT ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Briviact

Products Affected

- BRIVIACT ORAL SOLUTION

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brovana

Products Affected

- BROVANA

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Serevent
QL Criteria	4 milliliters Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Brovana

Products Affected

- BROVANA

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Trial of one month of Serevent
QL Criteria	4 milliliters Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Budesonide

Products Affected

- *budesonide inhalation*

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	For ages 5-8 documented inability to use metered dose inhalers
Age Restrictions	Less than 8 years of age
Prescriber Restrictions	
Coverage Duration	Up to the age of 8
Other Criteria	No prior authorization required for children 1-4 years of age. Medical Exception for Pulmicort Respules: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bunavail

Products Affected

- BUNAVAIL BUCCAL FILM 2.1-0.3 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
ST Criteria	A documented step through one month each of the preferred alternatives, buprenorphine-naloxone sublingual tablet and Suboxone SL film
QL Criteria	6 films Per 1 Day
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Bunavail

Products Affected

- BUNAVAIL BUCCAL FILM 6.3-1 MG, 4.2-0.7 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
ST Criteria	A documented step through one month each of the preferred alternatives, buprenorphine-naloxone sublingual tablet and Suboxone SL film
QL Criteria	3 films Per 1 Day
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Buphenyl

Products Affected

- BUPHENYL ORAL TABLET
- BUPHENYL ORAL POWDER 3 GM/TSP

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Buprenorphine HCl

Products Affected

- *buprenorphine hcl sublingual tablet sublingual 8 mg*

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	0.27 tabs Per 1 DAYS
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Buprenorphine HCl

Products Affected

- *buprenorphine hcl sublingual tablet sublingual*
2 mg

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	0.8 tabs Per 1 DAYS
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Buprenorphine HCl-Naloxone HCl

Products Affected

- *buprenorphine hcl-naloxone hcl*

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	3 tablets Per 1 day
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Buproban

Products Affected

- *buproban*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

BuPROPion HCl

Products Affected

- *bupropion hcl oral*

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BuPROPion HCl ER (Smoking Det)

Products Affected

- *bupropion hcl er (smoking det)*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

BuPROPion HCl ER (SR)

Products Affected

- *bupropion hcl er (sr)*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BuPROPion HCl ER (XL)

Products Affected

- *bupropion hcl er (xl)*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Butorphanol Tartrate

Products Affected

- *butorphanol tartrate nasal*

QL Criteria	2 bottles Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Butrans

Products Affected

- BUTRANS

QL Criteria	4 patches Per 28 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Bydureon

Products Affected

- BYDUREON SUBCUTANEOUS*
SUSPENSION RECONSTITUTED

ST Criteria	Trial and failure of 1 month each of Victoza and Trulicity
QL Criteria	4 vials Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bydureon

Products Affected

- BYDUREON SUBCUTANEOUS* 2 MG

ST Criteria	Trial and failure of 1 month each of Victoza and Trulicity
QL Criteria	4 pens Per 1 month
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Byetta 10 MCG Pen

Products Affected

- BYETTA 10 MCG PEN SUBCUTANEOUS*

ST Criteria	Trial and failure of 1 month each of Victoza and Trulicity
QL Criteria	1 pen Per 1 month
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Byetta 5 MCG Pen

Products Affected

- BYETTA 5 MCG PEN SUBCUTANEOUS*

ST Criteria	Trial and failure of 1 month each of Victoza and Trulicity
QL Criteria	1 pen Per 1 month
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Bystolic

Products Affected

- BYSTOLIC ORAL TABLET 2.5 MG, 5 MG, 10 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bystolic

Products Affected

- BYSTOLIC ORAL TABLET 20 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Byvalson

Products Affected

- BYVALSON

PA Criteria	Criteria Details
Covered Uses	Hypertension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through 2 generic beta-blockers and 2 generic angiotensin receptor blockers (ARBs)
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cabometyx

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Caduet

Products Affected

- CADUET

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Calcipotriene

Products Affected

- *calcipotriene external ointment*
- *calcipotriene external cream*

ST Criteria	Documented step through a MEDIUM TO HIGH POTENCY TOPICAL STEROID
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Calcipotriene-Betameth Diprop

Products Affected

- *calcipotriene-betameth diprop*

ST Criteria	Documented trial and failure of 1 medium to high potency steroid indicated for patients condition.
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Calcitonin (Salmon)

Products Affected

- *calcitonin (salmon)*

QL Criteria	1 bottle Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Calcitrene

Products Affected

- *calcitrene*

ST Criteria	Documented step through a MEDIUM TO HIGH POTENCY TOPICAL STEROID
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Camila

Products Affected

- *camila*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Camrese

Products Affected

- *camrese*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Camrese Lo

Products Affected

- *camrese lo*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Canasa

Products Affected

- CANASA

QL Criteria	1 suppository Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Candesartan Cilexetil

Products Affected

- *candesartan cilexetil oral tablet 16 mg, 8 mg, 4 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Candesartan Cilexetil-HCTZ

Products Affected

- *candesartan cilexetil-hctz*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Caprelsa

Products Affected

- CAPRELSA ORAL TABLET 300 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Caprelsa

Products Affected

- CAPRELSA ORAL TABLET 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Carbaglu

Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/metabolic_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Cardizem CD

Products Affected

- CARDIZEM CD

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardizem LA

Products Affected

- CARDIZEM LA ORAL TABLET
EXTENDED RELEASE 24 HR* 180 MG, 300
MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardizem LA

Products Affected

- CARDIZEM LA ORAL TABLET
EXTENDED RELEASE 24 HR* 120 MG

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardizem LA

Products Affected

- CARDIZEM LA ORAL TABLET
EXTENDED RELEASE 24 HR* 240 MG

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cardizem LA

Products Affected

- CARDIZEM LA ORAL TABLET
EXTENDED RELEASE 24 HR* 360 MG

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardura XL

Products Affected

- CARDURA XL

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CareSens N Glucose System

Products Affected

- CARESENS N GLUCOSE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CareSens N Glucose Test

Products Affected

- CARESENS N GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cartia XT

Products Affected

- *cartia xt oral capsule extended release 24 hour*
120 mg, 300 mg, 180 mg

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cartia XT

Products Affected

- *cartia xt oral capsule extended release 24 hour
240 mg*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Casodex

Products Affected

- CASODEX

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Caziant

Products Affected

- *caziant*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cefixime

Products Affected

- *cefixime*

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CeleBREX

Products Affected

- CELEBREX

QL Criteria	2 CAPS Per 1 DAY
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Celecoxib

Products Affected

- *celecoxib oral*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CeleXA

Products Affected

- CELEXA ORAL TABLET

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cenestin

Products Affected

- CENESTIN ORAL TABLET 0.9 MG, 0.45 MG, 0.625 MG, 0.3 MG

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cenestin

Products Affected

- CENESTIN ORAL TABLET 1.25 MG

QL Criteria	2 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cerdelga

Products Affected

- CERDELGA

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cerezyme

Products Affected

- CERZYME INTRAVENOUS* SOLUTION
RECONSTITUTED 400 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cesamet

Products Affected

- CESAMET

QL Criteria	2 capsules Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cesia

Products Affected

- *cesia*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cetrotide

Products Affected

- CETROTIDE SUBCUTANEOUS* KIT 0.25
MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cevimeline HCl

Products Affected

- *cevimeline hcl*

QL Criteria	3 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Chantix

Products Affected

- CHANTIX

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Chantix Continuing Month Pak

Products Affected

- CHANTIX CONTINUING MONTH PAK

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Chantix Starting Month Pak

Products Affected

- CHANTIX STARTING MONTH PAK

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Chateal

Products Affected

- *chateal*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Chenodal

Products Affected

- CHENODAL

PA Criteria	Criteria Details
Covered Uses	For treatment of cholesterol-type gallstones in patients over 18 years of age and have tried and failed 2 years of generic Actigall (ursodiol) therapy and are not able to undergo surgery due to systemic disease or age, and for treatment of diagnosed Cerebrotendinous Xanthomatosis (CTX) in patients over 18 years of age
Exclusion Criteria	Intrahepatic duct calculus, Chronic constipation in patients with cholesterol gallstones, Prophylaxis of recurrent gallstones, Hyperlipidemia, Rheumatoid Arthritis
Required Medical Information	Prior to initial coverage for gallstone disease, a cholecystogram or other appropriate imaging studies is required to determine presence of radiolucent gallstones, stones that are transparent to x-rays. Due to high risk of hepatotoxicity and adverse effects, for the first 3 months, authorization is required each month pending hepatic function tests (for both gallstones and CTX). After initial 3 months, authorization required every 3 months for length of treatment, pending hepatic function tests. At 6 months prior to authorization, the following results are required, serum cholesterol levels, hepatic function test, and cholecystogram (monitor dissolution of stones). Safety of use beyond a total of 24 months has not been established
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month (initial authorization), 3 month (reauthorization)
Other Criteria	Max authorization up to 2 years
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Choice DM Fora G20 Test Strips

Products Affected

- CHOICE DM FORA G20 TEST STRIPS

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cholbam

Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Cholbam.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Chorionic Gonadotropin

Products Affected

- *chorionic gonadotropin intramuscular**

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Cialis

Products Affected

- CIALIS ORAL TABLET 5 MG, 2.5 MG

PA Criteria	Criteria Details
Covered Uses	diagnosis of benign prostatic hyperplasia
Exclusion Criteria	Erectile dysfunction (ED) diagnosis is not covered except for members with ED benefit rider or Fully Insured (FI) members in the state of NY.
Required Medical Information	A documented diagnosis of diagnosis of benign prostatic hyperplasia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year (30 tablets every 30 days)
Other Criteria	Member has failed two alpha blockers (e.g. Cardura (doxazosin), Hytrin (terazosin), Flomax (tamsulosin), Uroxatral (alfuzosin), Rapaflo (silodosin) and failed one 5-alpha reductase inhibitor (e.g. Avodart (dutasteride), Proscar (finasteride), Jalyn (dutasteride/tamsulosin).
QL Criteria	1 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cimzia

Products Affected

- CIMZIA SUBCUTANEOUS* KIT 2 X 200 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Cimzia Prefilled

Products Affected

- CIMZIA PREFILLED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cimzia Starter Kit

Products Affected

- CIMZIA STARTER KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cinqair

Products Affected

- CINQAIR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/RESP/Cinqair.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cinryze

Products Affected

- CINRYZE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Citalopram Hydrobromide

Products Affected

- *citalopram hydrobromide oral tablet 10 mg, 20 mg*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Citalopram Hydrobromide

Products Affected

- *citalopram hydrobromide oral tablet 40 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Claravis

Products Affected

- *claravis*

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
QL Criteria	2 capsules Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Clarinet

Products Affected

- CLARINEX ORAL TABLET

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clarinet-D 12 Hour

Products Affected

- CLARINEX-D 12 HOUR

QL Criteria	2 TB12 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clever Chek Auto-Code

Products Affected

- CLEVER CHEK AUTO-CODE

QL Criteria	1 meter Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Clever Chek Auto-Code System

Products Affected

- CLEVER CHEK AUTO-CODE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clever Chek Auto-Code Test

Products Affected

- CLEVER CHEK AUTO-CODE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Clever Chek Auto-Code Voice

Products Affected

- CLEVER CHEK AUTO-CODE VOICE IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clever Chek Auto-Code Voice

Products Affected

- CLEVER CHEK AUTO-CODE VOICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Clever Chek Test

Products Affected

- CLEVER CHEK TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clever Choice Auto-Code System

Products Affected

- CLEVER CHOICE AUTO-CODE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Clever Choice Auto-Code Test

Products Affected

- CLEVER CHOICE AUTO-CODE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clever Choice Micro System

Products Affected

- CLEVER CHOICE MICRO SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Clever Choice Micro Test

Products Affected

- CLEVER CHOICE MICRO TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clever Choice Mini System

Products Affected

- CLEVER CHOICE MINI SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Climara

Products Affected

- CLIMARA

QL Criteria	0.15 patch Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Climara Pro

Products Affected

- CLIMARA PRO

QL Criteria	1 box (4 patches) Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

CloNIDine HCl ER

Products Affected

- *clonidine hcl er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy applies to brand
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clopidogrel Bisulfate

Products Affected

- *clopidogrel bisulfate*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet 100 mg*
- *clozapine oral tablet dispersible 100 mg*

QL Criteria	9 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet 25 mg, 50 mg*
- *clozapine oral tablet dispersible 25 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 12.5 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 150 mg*

QL Criteria	6 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

CloZAPine

Products Affected

- *clozapine oral tablet 200 mg*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 200 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Clozaril

Products Affected

- CLOZARIL ORAL TABLET 25 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clozaril

Products Affected

- CLOZARIL ORAL TABLET 100 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	9 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Coagadex

Products Affected

- COAGADEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Colazal

Products Affected

- COLAZAL

QL Criteria	9 caps Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Colchicine

Products Affected

- *colchicine oral tablet*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Colcrlys

Products Affected

- COLCRYS

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Colyte with Flavor Packs

Products Affected

- COLYTE WITH FLAVOR PACKS ORAL SOLUTION RECONSTITUTED 227.1 GM

QL Criteria	4 liters Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CombiPatch

Products Affected

- COMBIPATCH

QL Criteria	8 patches Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cometriq (100 mg Daily Dose)

Products Affected

- COMETRIQ (100 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 kits Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cometriq (140 mg Daily Dose)

Products Affected

- COMETRIQ (140 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Cometriq (60 mg Daily Dose)

Products Affected

- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 kits Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Complera

Products Affected

- COMPLERA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Concerta

Products Affected

- CONCERTA ORAL TABLET
EXTENDEDRELEASE* 27 MG, 54 MG, 18
MG

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Concerta

Products Affected

- CONCERTA ORAL TABLET
EXTENDEDRELEASE* 36 MG

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Control AST

Products Affected

- CONTROL AST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Control Test

Products Affected

- CONTROL TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ConZip

Products Affected

- CONZIP

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cool Blood Glucose Test Strips

Products Affected

- COOL BLOOD GLUCOSE TEST STRIPS

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Copaxone

Products Affected

- COPAXONE SUBCUTANEOUS* 20 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Copaxone

Products Affected

- COPAXONE SUBCUTANEOUS* 20 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Copaxone

Products Affected

- COPAXONE SUBCUTANEOUS* 20 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

Cordran

Products Affected

- CORDRAN EXTERNAL TAPE

QL Criteria	1 roll Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Coreg CR

Products Affected

- COREG CR

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Corifact

Products Affected

- CORIFACT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Corlanor

Products Affected

- CORLANOR

PA Criteria	Criteria Details
Covered Uses	FDA labeled use for heart failure
Exclusion Criteria	
Required Medical Information	Documentation of stable, symptomatic chronic heart failure with left ventricular ejection fraction less than or equal to 35%, who are in sinus rhythm with resting heart rate greater than or equal to 70 beats per minute, and who are on maximally tolerated doses of beta-blockers (bisoprolol/bisoprolol-HCTZ, carvedilol, carvedilol CR, metoprolol succinate/metoprolol succinate-HCTZ, nebivolol) or have a documented contraindication to beta-blocker use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Have a documented trial of one month of one of the following: ACE Inhibitor or ACE Inhibitor/HCTZ combination or Angiotensin-Receptor Blocker or Angiotensin-Receptor Blocker/HCTZ combination
Notes/References	
Revision Date	Prior Authorization: July 25, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cosentyx

Products Affected

- COSENTYX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Cosentyx Sensoready Pen

Products Affected

- COSENTYX SENSOREADY PEN
SUBCUTANEOUS* 150 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cotellic

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	63 tablets Per 28 Days
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Cozaar

Products Affected

- COZAAR ORAL TABLET 50 MG, 25 MG

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Crestor

Products Affected

- CRESTOR

ST Criteria	A documented step through two generic statin medications: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Crestor

Products Affected

- CRESTOR

ST Criteria	A documented step through two generic statin medications: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cryselle-28

Products Affected

- *cryselle-28*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CVS Advanced Glucose Test

Products Affected

- CVS ADVANCED GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CVS Blood Glucose Test

Products Affected

- *cvs blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

CVS Nicotine

Products Affected

- *cvs nicotine transdermal patch 24 hr 14 mg/24hr, 7 mg/24hr*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CVS Nicotine Polacrilex

Products Affected

- *cvs nicotine polacrilex mouth/throat lozenge 4 mg*

QL Criteria	20 EA Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

CVS NTS Step 1

Products Affected

- *cv s nts step 1*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cyclafem 1/35

Products Affected

- *cyclafem 1/35*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cyclafem 7/7/7

Products Affected

- *cyclafem 7/7/7*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cyclessa

Products Affected

- CYCLESSA

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cycloset

Products Affected

- CYCLOSET

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cymbalta

Products Affected

- CYMBALTA ORAL CAPSULE DELAYED
RELEASE PARTICLES 20 MG

QL Criteria	2 CAPS Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cymbalta

Products Affected

- CYMBALTA ORAL CAPSULE DELAYED
RELEASE PARTICLES 60 MG

QL Criteria	1 CAPS Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cymbalta

Products Affected

- CYMBALTA ORAL CAPSULE DELAYED
RELEASE PARTICLES 30 MG

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Cystagon

Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cystaran

Products Affected

- CYSTARAN

QL Criteria	2 ML Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Daklinza

Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Daklinza

Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Daklinza

Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 31, 2016 Quantity Limits: August 25, 2015

Daklinza

Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Daklinza

Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 31, 2016 Quantity Limits: August 25, 2015

Daklinza

Products Affected

- DAKLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Daliresp

Products Affected

- DALIRESP

PA Criteria	Criteria Details
Covered Uses	Severe COPD (GOLD stage 3 or 4)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of severe (Stage III) or very severe (StageIV) chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented trial of 2 preferred alternatives: Dulera, Symbicort, Spiriva, Incruse, Anoro, or Stiolto
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Darifenacin Hydrobromide ER

Products Affected

- *darifenacin hydrobromide er*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Dasetta 1/35

Products Affected

- *dasetta 1/35*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dasetta 7/7/7

Products Affected

- *dasetta 7/7/7*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Daysee

Products Affected

- *daysee*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Daytrana

Products Affected

- DAYTRANA

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Deblitane

Products Affected

- DEBLITANE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Delzicol

Products Affected

- DELZICOL

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Depo-Provera

Products Affected

- DEPO-PROVERA INTRAMUSCULAR*
SUSPENSION 150 MG/ML

QL Criteria	1 syringe Per 90 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Depo-SubQ Provera 104

Products Affected

- DEPO-SUBQ PROVERA 104

QL Criteria	1 syringe Per 90 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Descovy

Products Affected

- DESCOVY

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desloratadine

Products Affected

- *desloratadine*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Desogen

Products Affected

- DESOGEN

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desoxyn

Products Affected

- DESOXYN

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of ADHD or Narcolepsy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	4 tablets Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Desvenlafaxine ER

Products Affected

- *desvenlafaxine er*

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desvenlafaxine Fumarate ER

Products Affected

- *desvenlafaxine fumarate er*

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Detrol LA

Products Affected

- DETROL LA

QL Criteria	1 capsule Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexedrine

Products Affected

- *dexedrine oral tablet*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of ADHD or Narcolepsy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	4 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Dexedrine

Products Affected

- DEXEDRINE ORAL CAPSULE EXTENDED RELEASE 24 HOUR

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	3 CAPS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Dexilant

Products Affected

- DEXILANT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer-reviewed medical literature for use of a higher dose.
ST Criteria	A documented step through 2 generic RX or OTC proton pump inhibitors (i.e. esomeprazole mag, lansoprazole, omeprazole, pantoprazole, rabeprazole)
QL Criteria	1 capsule Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Dexilant

Products Affected

- DEXILANT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer- reviewed medical literature for use of a higher dose.
ST Criteria	Documented step through 2 generic PPI or OTC (i.e. omeprazole, pantoprazole, esomeprazole, lansoprazole, Prevacid 24H, Nexium)
QL Criteria	1 capsule Per 1 day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexmethylphenidate HCl

Products Affected

- *dexmethylphenidate hcl*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexmethylphenidate HCl ER

Products Affected

- dexmethylphenidate hcl er oral capsule
extended release 24 hour 10 mg, 15 mg, 5 mg,
30 mg, 40 mg*

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dextroamphetamine Sulfate

Products Affected

- *dextroamphetamine sulfate oral tablet*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dextroamphetamine Sulfate

Products Affected

- *dextroamphetamine sulfate oral solution*

QL Criteria	40 milliliters Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dextroamphetamine Sulfate ER

Products Affected

- *dextroamphetamine sulfate er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	4 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

DiaTrue Plus Test

Products Affected

- *diatruue plus test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diazepam

Products Affected

- *diazepam gel*

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Diclegis

Products Affected

- DICLEGIS

QL Criteria	4 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diclofenac Sodium

Products Affected

- *diclofenac sodium transdermal gel 1 %*

QL Criteria	200 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Diclofenac Sodium

Products Affected

- *diclofenac sodium transdermal solution*

QL Criteria	10 ML Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diclofenac Sodium

Products Affected

- *diclofenac sodium transdermal gel 3 %*

QL Criteria	200 GM Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Differin

Products Affected

- DIFFERIN EXTERNAL GEL
- DIFFERIN EXTERNAL LOTION

ST Criteria	A documented step through Epiduo
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Dificid

Products Affected

- DIFICID

QL Criteria	20 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Dihydroergotamine Mesylate

Products Affected

- *dihydroergotamine mesylate nasal*

QL Criteria	8 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem CD

Products Affected

- *diltiazem cd oral capsule extended release 24 hour 120 mg, 180 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Diltiazem CD

Products Affected

- *diltiazem cd oral capsule extended release 24 hour 240 mg*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER

Products Affected

- *diltiazem hcl er oral capsule extended release 12 hour 120 mg*
- *diltiazem hcl er oral capsule extended release 24 hour 120 mg, 180 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Diltiazem HCl ER

Products Affected

- *diltiazem hcl er oral capsule extended release*
24 hour 240 mg

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Beads

Products Affected

- diltiazem hcl er beads oral capsule extended release 24 hour 360 mg, 120 mg, 420 mg, 180 mg, 300 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Diltiazem HCl ER Beads

Products Affected

- *diltiazem hcl er beads oral capsule extended release 24 hour 240 mg*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Coated Beads

Products Affected

- *diltiazem hcl er coated beads oral capsule
extended release 24 hour 240 mg*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Diltiazem HCl ER Coated Beads

Products Affected

- diltiazem hcl er coated beads oral capsule
extended release 24 hour 180 mg, 120 mg, 360
mg, 300 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dilt-XR

Products Affected

- *dilt-xr oral capsule extended release 24 hour*
120 mg, 180 mg

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Dilt-XR

Products Affected

- *dilt-xr oral capsule extended release 24 hour*
240 mg

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diovan

Products Affected

- DIOVAN

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Diovan HCT

Products Affected

- DIOVAN HCT

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dipentum

Products Affected

- DIPENTUM

QL Criteria	4 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ditropan XL

Products Affected

- DITROPAN XL

QL Criteria	2 tablets Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dolophine

Products Affected

- DOLOPHINE

QL Criteria	6 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Donepezil HCl

Products Affected

- *donepezil hcl oral tablet 10 mg*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Donepezil HCl

Products Affected

- *donepezil hcl oral tablet 5 mg, 23 mg*
- *donepezil hcl oral tablet dispersible*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Doryx MPC

Products Affected

- DORYX MPC

ST Criteria	A documented step through 1 of the following: minocycline caps 50mg, 75mg, or 100mg, doxycycline monohydrate caps 50mg or 100mg, doxycycline hyclate caps 50mg or 100mg, or doxycycline hyclate tabs 100mg
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dovonex

Products Affected

- DOVONEX EXTERNAL CREAM

ST Criteria	Documented step through a MEDIUM TO HIGH POTENCY TOPICAL STEROID
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Doxycycline

Products Affected

- *doxycycline*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Doxycycline Monohydrate

Products Affected

- *doxycycline monohydrate oral capsule 75 mg, 150 mg*
- *doxycycline monohydrate oral tablet 50 mg*

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Dronabinol

Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Covered Uses	Anorexia associated with weight loss in patients with AIDS, Chemotherapy-induced nausea and vomiting
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Anorexia associated with weight loss in patients with AIDS, or Chemotherapy-induced nausea and vomiting
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
QL Criteria	2 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Drospirenone-Ethinyl Estradiol

Products Affected

- *drospirenone-ethinyl estradiol oral tablet*
3-0.03 mg

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Duavee

Products Affected

- DUAVEE

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duetact

Products Affected

- DUETACT

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Duexis

Products Affected

- DUEXIS

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dulera

Products Affected

- DULERA

QL Criteria	1 inhaler Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

DULoxetine HCl

Products Affected

- *duloxetine hcl oral capsule delayed release particles 40 mg, 30 mg*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

DULoxetine HCl

Products Affected

- *duloxetine hcl oral capsule delayed release particles 60 mg, 20 mg*

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Duo-Care Test

Products Affected

- DUO-CARE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-100

Products Affected

- DURAGESIC-100

QL Criteria	20 patches Per 30 DAYs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-12

Products Affected

- DURAGESIC-12

QL Criteria	20 patches Per 30 DAYSs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-25

Products Affected

- DURAGESIC-25

QL Criteria	20 patches Per 30 DAYSs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Duragesic-50

Products Affected

- DURAGESIC-50

QL Criteria	20 patches Per 30 DAYs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-75

Products Affected

- DURAGESIC-75

QL Criteria	20 patches Per 30 DAYSs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Dutasteride

Products Affected

- *dutasteride*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dyanavel XR

Products Affected

- DYANAVEL XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	240 ML Per 30 days
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Dysport

Products Affected

- DYSPOORT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Plus Blood Glucose Test

Products Affected

- *easy plus blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Plus II Glucose System

Products Affected

- *easy plus ii glucose system*

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Plus II Glucose Test

Products Affected

- *easy plus ii glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Step Glucose Monitor

Products Affected

- EASY STEP GLUCOSE MONITOR DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Step Test

Products Affected

- EASY STEP TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Talk Blood Glucose System

Products Affected

- *easy talk blood glucose system device*

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Talk Blood Glucose Test

Products Affected

- *easy talk blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Easy Touch HealthPro Test

Products Affected

- EASY TOUCH HEALTHPRO TEST

QL Criteria	300 strips Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Easy Touch Test

Products Affected

- EASY TOUCH TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Easy Trak Blood Glucose Test

Products Affected

- *easy trak blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EasyGluco

Products Affected

- EASYGLUCO IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EasyGluco Plus

Products Affected

- EASYGLUCO PLUS IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EasyMax 15 Test

Products Affected

- EASYMAX 15 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EasyMax L Blood Glucose

Products Affected

- EASYMAX L BLOOD GLUCOSE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EasyMax N Blood Glucose

Products Affected

- EASYMAX N BLOOD GLUCOSE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EasyMax NG Blood Glucose

Products Affected

- EASYMAX NG BLOOD GLUCOSE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EASYMax Test

Products Affected

- EASYMAX TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EasyMax V Blood Glucose

Products Affected

- EASYMAX V BLOOD GLUCOSE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EasyMax V2 Blood Glucose

Products Affected

- EASYMAX V2 BLOOD GLUCOSE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EasyPlus Blood Glucose Test

Products Affected

- *easyplus blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EasyPRO Blood Glucose Test

Products Affected

- EASYPRO BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EasyPRO Plus

Products Affected

- EASYPRO PLUS IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Eclipse Test

Products Affected

- ECLIPSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Edarbi

Products Affected

- EDARBI

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Edarbyclor

Products Affected

- EDARBYCLOR

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Edurant

Products Affected

- EDURANT

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Effexor XR

Products Affected

- EFFEXOR XR ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 150 MG

QL Criteria	2 caps Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Effexor XR

Products Affected

- EFFEXOR XR ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 37.5 MG,
75 MG

QL Criteria	1 caps Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Effient

Products Affected

- EFFIENT

PA Criteria	Criteria Details
Covered Uses	Acute coronary syndrome (ACS), which includes angina or myocardial infarction [MI].
Exclusion Criteria	History of Stroke or TIA
Required Medical Information	Member has a documented diagnosis of acute coronary syndrome (ACS), which includes angina or myocardial infarction [MI]) managed by percutaneous coronary intervention (PCI) AND Member has no prior history of stroke or transient ischemic attack (TIA)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Elaprase

Products Affected

- ELAPRASE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Elelyso

Products Affected

- ELELYSO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Elelyso

Products Affected

- ELELYSO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Elelyso

Products Affected

- ELELYSO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Element Compact Test

Products Affected

- *element compact test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Element Plus

Products Affected

- ELEMENT PLUS

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Element Plus Test

Products Affected

- ELEMENT PLUS TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Element Test

Products Affected

- ELEMENT TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Elestrin

Products Affected

- ELESTRIN

QL Criteria	52 GM Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Elidel

Products Affected

- ELIDEL

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required), or a documented diagnosis of atopic dermatitis (eczema) in an adult or child 2 years of age or older with one of the following: A documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Elinest

Products Affected

- *elinest*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ella

Products Affected

- ELLA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Eloctate

Products Affected

- ELOCTATE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Embeda

Products Affected

- EMBEDA

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each of two preferred alternatives which include Butrans, Hysingla ER, and Oxycontin
QL Criteria	2 capsules Per 1 day
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Embrace Blood Glucose Monitor

Products Affected

- EMBRACE BLOOD GLUCOSE MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Embrace Blood Glucose Test

Products Affected

- EMBRACE BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Embrace Evo Blood Glucose Test

Products Affected

- EMBRACE EVO BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Embrace Pro Glucose Test

Products Affected

- EMBRACE PRO GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emend

Products Affected

- EMEND ORAL CAPSULE 40 MG, 125 MG, 80 MG

QL Criteria	9 capsules Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emend

Products Affected

- EMEND ORAL CAPSULE 80 & 125 MG

QL Criteria	3 tri-packs Per 30 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EMLA

Products Affected

- EMLA

PA Criteria	Criteria Details
Covered Uses	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
Exclusion Criteria	Documentation of any of the following: Planned area of application includes non-intact skin, Sensitivity to amide-type local anesthetics or any other component of the product, Planned use on large surface area of the body or for a period of time over 3 hours as this can lead to increased toxicity, the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), Use in situations where the drug may migrate into the middle ear, beyond the tympanic membrane, History of methemoglobinemia, or if the product will be compounded with other products that would alter the total dose/dosage form being administered
Required Medical Information	A documented need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	*Topical lidocaine/prilocaine cream is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Up to an additional 30 grams per 30 days. Higher additional quantities are not approvable.
QL Criteria	30 GM Per 30 Days
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Emoquette

Products Affected

- *emoquette*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emsam

Products Affected

- EMSAM

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Emtriva

Products Affected

- EMTRIVA ORAL CAPSULE

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enablex

Products Affected

- ENABLEX

ST Criteria	A documented step through Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Enablex

Products Affected

- ENABLEX

ST Criteria	A documented step through Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
QL Criteria	1 tablet Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Enablex

Products Affected

- ENABLEX

ST Criteria	Documented trial of 2 preferred alternatives: Vesicare OR Myrbetriq AND one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin)
QL Criteria	1 tablet Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Enablex

Products Affected

- ENABLEX

ST Criteria	Documented trial of 2 preferred alternatives: Vesicare OR Myrbetriq AND one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enbrel

Products Affected

- ENBREL SUBCUTANEOUS* 25 MG/0.5ML

QL Criteria	4 syringes Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Enbrel

Products Affected

- ENBREL SUBCUTANEOUS* 50 MG/ML
- ENBREL SUBCUTANEOUS* KIT

QL Criteria	8 syringes Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enbrel

Products Affected

- ENBREL SUBCUTANEOUS* SOLUTION
RECONSTITUTED

QL Criteria	8 injections Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Enbrel SureClick

Products Affected

- ENBREL SURECLICK SUBCUTANEOUS*

QL Criteria	8 syringes Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enjuvia

Products Affected

- ENJUVIA ORAL TABLET 0.3 MG, 0.9 MG, 0.45 MG, 0.625 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Enjuvia

Products Affected

- ENJUVIA ORAL TABLET 1.25 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enoxaparin Sodium

Products Affected

- *enoxaparin sodium*

QL Criteria	2 syringes Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enpresse-28

Products Affected

- *enpresse-28*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Entecavir

Products Affected

- *entecavir*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Entecavir

Products Affected

- *entecavir*

QL Criteria	1 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Entresto

Products Affected

- ENTRESTO

PA Criteria	Criteria Details
Covered Uses	Heart Failure
Exclusion Criteria	Known or suspected pregnancy
Required Medical Information	A documented diagnosis of chronic heart failure (NYHA Class II-IV) and reduced ejection fraction
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Entyvio

Products Affected

- ENTYVIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Envision Autocode Test

Products Affected

- ENVISION AUTOCODE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Epclusa

Products Affected

- EPCLUSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Epiduo

Products Affected

- EPIDUO

QL Criteria	45 GM Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Epiduo Forte

Products Affected

- EPIDUO FORTE

QL Criteria	45 GM Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EPINEPHrine

Products Affected

- *epinephrine injection 0.3 mg/0.3ml, 0.15 mg/0.15ml*

QL Criteria	2 pens Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Epogen

Products Affected

- EPOGEN INJECTION SOLUTION 20000 UNIT/ML, 4000 UNIT/ML, 2000 UNIT/ML, 10000 UNIT/ML, 3000 UNIT/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Eprosartan Mesylate

Products Affected

- *eprosartan mesylate*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EQ Nicotine

Products Affected

- *eq nicotine transdermal*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EQL Nicotine

Products Affected

- *eql nicotine*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EQL TRUEtest Test

Products Affected

- EQL TRUETEST TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Erivedge

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Errin

Products Affected

- *errin*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Esbriet

Products Affected

- ESBRIET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Idiopathic_Pulmonary_Fibrosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	9 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Escitalopram Oxalate

Products Affected

- *escitalopram oxalate oral tablet 20 mg, 5 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Escitalopram Oxalate

Products Affected

- *escitalopram oxalate oral solution*

QL Criteria	20 ml Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Escitalopram Oxalate

Products Affected

- *escitalopram oxalate oral tablet 10 mg*

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Esomeprazole Magnesium

Products Affected

- *esomeprazole magnesium oral capsule delayed release 40 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Estraderm

Products Affected

- ESTRADERM

QL Criteria	8 patches Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estradiol

Products Affected

- *estradiol transdermal patch biweekly*

QL Criteria	8 patches Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estradiol

Products Affected

- *estradiol transdermal patch weekly 0.05 mg/24hr*

QL Criteria	4 patches Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estradiol

Products Affected

- *estradiol transdermal patch weekly 0.06 mg/24hr, 0.1 mg/24hr, 0.075 mg/24hr, 0.0375 mg/24hr, 0.025 mg/24hr*

QL Criteria	1 box (4 patches) Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Estradiol-Norethindrone Acet

Products Affected

- *estradiol-norethindrone acet*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estrogel

Products Affected

- ESTROGEL

QL Criteria	50 grams Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Estrostep Fe

Products Affected

- ESTROSTEP FE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Eszopiclone

Products Affected

- *eszopiclone*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Euflexxa

Products Affected

- EUFLEXXA INTRA-ARTICULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Evamist

Products Affected

- EVAMIST

QL Criteria	2 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Evekeo

Products Affected

- EVEKEO

QL Criteria	120 tablets Per 30 Days
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EvenCare + Blood Glucose Test

Products Affected

- EVENCARE + BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EvenCare Blood Glucose Test

Products Affected

- EVENCARE BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EvenCare G2 Monitor

Products Affected

- EVENCARE G2 MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EvenCare G2 Test

Products Affected

- EVENCARE G2 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EvenCare G3 Monitor

Products Affected

- EVENCARE G3 MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

EvenCare G3 Test

Products Affected

- EVENCARE G3 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EvenCare Mini Glucose Test

Products Affected

- EVENCARE MINI GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Evolution Autocode

Products Affected

- EVOLUTION AUTOCODE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Evolution Autocode

Products Affected

- EVOLUTION AUTOCODE IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Evoxac

Products Affected

- EVOXAC

QL Criteria	3 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exalgo

Products Affected

- EXALGO ORAL 32 MG, 8 MG, 12 MG

QL Criteria	2 tablets Per 2 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Exalgo

Products Affected

- EXALGO ORAL 16 MG

QL Criteria	4 tablets Per 2 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exelon

Products Affected

- EXELON ORAL CAPSULE
- EXELON TRANSDERMAL

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Exforge

Products Affected

- EXFORGE

QL Criteria	1 TABS Per 1 DAY
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exjade

Products Affected

- EXJADE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/Antidotes.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Extavia

Products Affected

- EXTAVIA SUBCUTANEOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Extavia

Products Affected

- EXTAVIA SUBCUTANEOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Extavia

Products Affected

- EXTAVIA SUBCUTANEOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Ez Smart Blood Glucose Test

Products Affected

- EZ SMART BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ez Smart Monitoring System

Products Affected

- EZ SMART MONITORING SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ez Smart Plus Glucose Test

Products Affected

- EZ SMART PLUS GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ez Smart Plus Monitoring Sys

Products Affected

- EZ SMART PLUS MONITORING SYS

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fabior

Products Affected

- FABIOR

ST Criteria	A documented step through Epiduo
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Fabrazyme

Products Affected

- FABRAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FaLessa

Products Affected

- FALESSA ORAL KIT 20-1-0.1 MCG-MG

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Falmina

Products Affected

- *falmina*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Famciclovir

Products Affected

- *famciclovir oral tablet 125 mg, 250 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Famciclovir

Products Affected

- *famciclovir oral tablet 500 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Famvir

Products Affected

- FAMVIR ORAL TABLET 500 MG

QL Criteria	3 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Famvir

Products Affected

- FAMVIR ORAL TABLET 250 MG, 125 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fanapt

Products Affected

- FANAPT

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fanapt Titration Pack

Products Affected

- FANAPT TITRATION PACK

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	0.27 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Farxiga

Products Affected

- FARXIGA

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Farydak

Products Affected

- FARYDAK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	12 EA Per 30 Days
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
25 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	3 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
100 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	9 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
150 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
200 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
12.5 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Felodipine ER

Products Affected

- *felodipine er*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Femcon Fe

Products Affected

- FEMCON FE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Femhrt Low Dose

Products Affected

- FEMHRT LOW DOSE

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Femring

Products Affected

- FEMRING

QL Criteria	1 ring Per 90 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fenofibrate

Products Affected

- *fenofibrate oral tablet 54 mg, 145 mg, 160 mg, 48 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fenofibrate

Products Affected

- *fenofibrate oral capsule*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fenofibrate Micronized

Products Affected

- *fenofibrate micronized*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fenofibric Acid

Products Affected

- *fenofibric acid oral tablet*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fenoglide

Products Affected

- FENOGLIDE

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FentaNYL

Products Affected

- *fentanyl*

QL Criteria	20 patches Per 30 MONTHs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FentaNYL Citrate

Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
QL Criteria	4 lozenge Per 1 Day
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FentaNYL Citrate

Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone
QL Criteria	4 lozenges Per 1 day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FentaNYL Citrate

Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone
QL Criteria	4 lozenges Per 1 day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fentora

Products Affected

- FENTORA

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	A documented step through one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)
QL Criteria	4 tablets Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fentora

Products Affected

- FENTORA

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	4 tablets Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: July 15, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fentora

Products Affected

- FENTORA

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	4 tablets Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fentora

Products Affected

- FENTORA

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ferriprox

Products Affected

- FERRIPROX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Antidotes.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fetzima

Products Affected

- FETZIMA

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
ST Criteria	A documented step through three different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 capsule Per 1 Day
Notes/References	Annual Review: 05/2016

Revision Date	Prior Authorization: April 22, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015
----------------------	---

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fetzima

Products Affected

- FETZIMA

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
ST Criteria	Documented step through THREE different antidepressants from at least TWO different therapeutic subclasses, i.e., SSRIs (FLUOXETINE, CITALOPRAM), SNRIs (DULOXETINE, VENLAFAXINE), TCAs (AMITRIPTYLINE, NORTRIPTYLINE), Heterocyclic Antidepressants (MIRTAZAPINE, TRAZODONE)
QL Criteria	1 capsule Per 1 Day
Notes/References	Annual Review: 05/2016

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fetzima Titration

Products Affected

- FETZIMA TITRATION

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
ST Criteria	Documented step through THREE different antidepressants from at least TWO different therapeutic subclasses, i.e., SSRIs (FLUOXETINE, CITALOPRAM), SNRIs (DULOXETINE, VENLAFAXINE), TCAs (AMITRIPTYLINE, NORTRIPTYLINE), Heterocyclic Antidepressants (MIRTAZAPINE, TRAZODONE)
QL Criteria	1 CP24 Per 1 DAYS
Notes/References	Annual Review: 05/2016

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fetzima Titration

Products Affected

- FETZIMA TITRATION

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
ST Criteria	A documented step through three different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 CP24 Per 1 DAYS
Notes/References	Annual Review: 05/2016

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 22, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015
----------------------	---

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fibricor

Products Affected

- FIBRICOR

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fifty50 Glucose Test 2.0

Products Affected

- FIFTY50 GLUCOSE TEST 2.0

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Firazyr

Products Affected

- FIRAZYR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 syringes Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Flebogamma DIF

Products Affected

- FLEBOGAMMA DIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/ivig.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Flector

Products Affected

- FLECTOR

QL Criteria	2 patches Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Flolan

Products Affected

- FLOLAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Flonase Allergy Relief

Products Affected

- FLONASE ALLERGY RELIEF

QL Criteria	1 bottle Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Flovent Diskus

Products Affected

- FLOVENT DISKUS

QL Criteria	2 diskus Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fluocinonide

Products Affected

- *fluocinonide external cream*

ST Criteria	Documented step through TWO VERY HIGH POTENCY TOPICAL STEROIDS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral tablet 60 mg*

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral capsule delayed release*

QL Criteria	4 capsules Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral tablet 20 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fluvastatin Sodium

Products Affected

- *fluvastatin sodium*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fluvoxamine Maleate

Products Affected

- *fluvoxamine maleate oral tablet 25 mg, 50 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FluvoxaMINE Maleate

Products Affected

- *fluvoxamine maleate oral tablet 100 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FluvoxaMINE Maleate ER

Products Affected

- *fluvoxamine maleate er*

QL Criteria	2 cap Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Focalin

Products Affected

- FOCALIN

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Focalin XR

Products Affected

- FOCALIN XR

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Follistim AQ

Products Affected

- FOLLISTIM AQ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fondaparinux Sodium

Products Affected

- *fondaparinux sodium*

QL Criteria	2 syringes Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA D10 2-in-1 Monitor

Products Affected

- FORA D10 2-IN-1 MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA D10 Blood Glucose Test

Products Affected

- FORA D10 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA D15C Blood Glucose Test

Products Affected

- FORA D15C BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA D15g 2-in-1 Monitor

Products Affected

- FORA D15G 2-IN-1 MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA D15g Blood Glucose Test

Products Affected

- FORA D15G BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA D15z Blood Glucose Test

Products Affected

- FORA D15Z BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA D20 2-in-1 Monitor

Products Affected

- FORA D20 2-IN-1 MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA D20 Blood Glucose Test

Products Affected

- FORA D20 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fora D40/G31 Blood Glucose

Products Affected

- FORA D40/G31 BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA G20 Blood Glucose Test

Products Affected

- FORA G20 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA G30a Blood Glucose System

Products Affected

- FORA G30A BLOOD GLUCOSE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA G30a Blood Glucose Test

Products Affected

- FORA G30A BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA G71a Blood Glucose Test

Products Affected

- FORA G71A BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA G90 Blood Glucose Test

Products Affected

- FORA G90 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fora GD20 Blood Glucose System

Products Affected

- FORA GD20 BLOOD GLUCOSE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fora GD20 Test

Products Affected

- FORA GD20 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA GD50 Blood Glucose Test

Products Affected

- FORA GD50 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA Test N' Go Glucose Test

Products Affected

- FORA TEST N' GO GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fora TN'G/TN'G Voice

Products Affected

- FORA TN'G/TN'G VOICE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA V10 Blood Glucose System

Products Affected

- FORA V10 BLOOD GLUCOSE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA V10 Blood Glucose Test

Products Affected

- FORA V10 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA V12 Blood Glucose System

Products Affected

- FORA V12 BLOOD GLUCOSE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA V12 Blood Glucose Test

Products Affected

- FORA V12 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA V20 Blood Glucose System

Products Affected

- FORA V20 BLOOD GLUCOSE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA V20 Blood Glucose Test

Products Affected

- FORA V20 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA V22 Blood Glucose Test

Products Affected

- FORA V22 BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FORA V30a Blood Glucose System

Products Affected

- FORA V30A BLOOD GLUCOSE SYSTEM DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FORA V30a Blood Glucose Test

Products Affected

- FORA V30A BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ForaCare GD40 Monitor

Products Affected

- FORACARE GD40 MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ForaCare GD40 Test

Products Affected

- FORACARE GD40 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ForaCare premium V10

Products Affected

- FORACARE PREMIUM V10

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ForaCare premium V10 Test

Products Affected

- FORACARE PREMIUM V10 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ForaCare Test N Go Test

Products Affected

- FORACARE TEST N GO TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Foradil Aerolizer

Products Affected

- FORADIL AEROLIZER

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Forfivo XL

Products Affected

- FORFIVO XL

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fortamet

Products Affected

- FORTAMET ORAL TABLET EXTENDED
RELEASE 24 HR* 500 MG

QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fortamet

Products Affected

- FORTAMET ORAL TABLET EXTENDED
RELEASE 24 HR* 1000 MG

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Forteo

Products Affected

- FORTEO SUBCUTANEOUS* SOLUTION
600 MCG/2.4ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fortesta

Products Affected

- FORTESTA

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Fortical

Products Affected

- *fortical*

QL Criteria	1 bottle Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FortisCare Test

Products Affected

- FORTISCARE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fosamax

Products Affected

- FOSAMAX ORAL TABLET 70 MG

QL Criteria	0.15 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Fosamax Plus D

Products Affected

- FOSAMAX PLUS D

QL Criteria	4 tablets Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fragmin

Products Affected

- FRAGMIN

QL Criteria	2 syringes Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FreeStyle Flash System

Products Affected

- FREESTYLE FLASH SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FreeStyle Freedom Lite

Products Affected

- FREESTYLE FREEDOM LITE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

FreeStyle InsuLinx System

Products Affected

- FREESTYLE INSULINX SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FreeStyle InsuLinx Test

Products Affected

- FREESTYLE INSULINX TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FreeStyle Lite

Products Affected

- FREESTYLE LITE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 meter Per 1 year
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FreeStyle Lite Test

Products Affected

- FREESTYLE LITE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

FreeStyle Precision Neo Test

Products Affected

- FREESTYLE PRECISION NEO TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FreeStyle System

Products Affected

- FREESTYLE SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

FreeStyle Test

Products Affected

- FREESTYLE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Frova

Products Affected

- FROVA

QL Criteria	9 tablets Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Frovatriptan Succinate

Products Affected

- *frovatriptan succinate*

QL Criteria	9 tablets Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fulyzaq

Products Affected

- FULYZAQ

PA Criteria	Criteria Details
Covered Uses	Diarrhea
Exclusion Criteria	
Required Medical Information	Fulyzaq is covered for adult members who meet the following criteria: (1) Diagnosis of noninfectious diarrhea associated with HIV/AIDS infection that has lasted at least for one month, and (2) Currently taking antiviral therapy with adherence of at least 80%, and (3) Documentation of unsatisfactory effects with, intolerability to, or inability to take at least one anti-motility agent (loperamide, diphenoxylate/atropine, bismuth subsalicylate) or one or more watery bowel movements per day without regular ADM use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Fycompa

Products Affected

- FYCOMPA ORAL TABLET

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	Annual Review: 03/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabapentin

Products Affected

- *gabapentin oral capsule*

QL Criteria	6 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gabapentin

Products Affected

- *gabapentin oral solution 250 mg/5ml*

QL Criteria	40 ml Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabapentin

Products Affected

- *gabapentin oral tablet*

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gabitril

Products Affected

- GABITRIL ORAL TABLET 4 MG, 12 MG

QL Criteria	4 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabitril

Products Affected

- GABITRIL ORAL TABLET 2 MG

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gabitril

Products Affected

- GABITRIL ORAL TABLET 16 MG

QL Criteria	3 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Galantamine Hydrobromide

Products Affected

- *galantamine hydrobromide oral tablet*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Gammagard S/D Less IgA

Products Affected

- GAMMAGARD S/D LESS IGA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/ivig.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ganirelix Acetate

Products Affected

- *ganirelix acetate*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Gattex

Products Affected

- GATTEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Gattex.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GaviLyte-C

Products Affected

- *gavilyte-c*

QL Criteria	4 liters Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

GaviLyte-G

Products Affected

- *gavilyte-g*

QL Criteria	4 liters Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GE100 Blood Glucose Test

Products Affected

- *ge100 blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gelnique

Products Affected

- GELNIQUE

ST Criteria	A documented step through Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Gel-One

Products Affected

- GEL-ONE INTRA-ARTICULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gelsyn-3

Products Affected

- GELSYN-3

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Generess FE

Products Affected

- GENERESS FE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Genotropin

Products Affected

- GENOTROPIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Genotropin MiniQuick

Products Affected

- GENOTROPIN MINIQUICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

GenStrip 50

Products Affected

- GENSTRIP 50

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Genvoya

Products Affected

- GENVOYA

PA Criteria	Criteria Details
Covered Uses	Human Immunodeficiency Virus (HIV)
Exclusion Criteria	
Required Medical Information	A. A documented resistance test within the past 3 months demonstrating virologic susceptibility to all of the following components of Stribild: elvitegravir, emtricitabine, and tenofovir AND; 1) A documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Atripla (efavirenz-emtricitabine-tenofovir) or a documented resistance test within the past 3 months demonstrating virologic resistance to efavirenz, OR; 2) A documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Truvada, Reyataz, and Norvir (emtricitabine-tenofovir, atazanavir, ritonavir) in combination or documented resistance test within the past 3 months demonstrating virological resistance to atazanavir.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year, extended approval upon Review every 1 year meeting the following criteria: A documented
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Geodon

Products Affected

- GEODON ORAL

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	2 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GHT Test

Products Affected

- *ght test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gianvi

Products Affected

- *gianvi*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Giazo

Products Affected

- GIAZO

PA Criteria	Criteria Details
Covered Uses	Ulcerative colitis
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild to moderate ulcerative colitis in males. Note: Per Product Labeling, Giazo effectiveness was not demonstrated in female patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month of mesalamine DR (generic Asacol HD), Delzicol, Lialda, or Pentasa
QL Criteria	6 tablets Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Giazo

Products Affected

- GIAZO

PA Criteria	Criteria Details
Covered Uses	Ulcerative colitis
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild to moderate ulcerative colitis in males. Note: Per Product Labeling, Giazo effectiveness was not demonstrated in female patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of APRISO, ASACOL, ASACOL HD, DELZICOL, LIALDA, OR PENTASA (NSO)
QL Criteria	6 tablets Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gildagia

Products Affected

- *gildagia*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gildess 1.5/30

Products Affected

- *gildess 1.5/30*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gildess 1/20

Products Affected

- *gildess 1/20*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gildess FE 1.5/30

Products Affected

- *gildess fe 1.5/30*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gildess FE 1/20

Products Affected

- *gildess fe 1/20*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gilenya

Products Affected

- GILENYA

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gilotrif

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Gleevec

Products Affected

- GLEEVEC ORAL TABLET 100 MG

ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Gleevec

Products Affected

- GLEEVEC ORAL TABLET 100 MG

ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gleevec

Products Affected

- GLEEVEC ORAL TABLET 400 MG

ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gleevec

Products Affected

- GLEEVEC ORAL TABLET 400 MG

ST Criteria	pending
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gleevec

Products Affected

- GLEEVEC ORAL TABLET 400 MG

ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Gleevec

Products Affected

- GLEEVEC ORAL TABLET 100 MG

ST Criteria	pending
QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

GlucaGen Diagnostic

Products Affected

- GLUCAGEN DIAGNOSTIC

QL Criteria	1 vial Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GlucaGen HypoKit

Products Affected

- GLUCAGEN HYPOKIT

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gluco Perfect 3 Test

Products Affected

- GLUCO PERFECT 3 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glucocard 01 Blood Glucose

Products Affected

- GLUCOCARD 01 BLOOD GLUCOSE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Glucocard 01 Sensor Plus

Products Affected

- GLUCOCARD 01 SENSOR PLUS

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glucocard 01 Test

Products Affected

- GLUCOCARD 01 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glucocard Expression Test

Products Affected

- GLUCOCARD EXPRESSION TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glucocard Shine Test

Products Affected

- GLUCOCARD SHINE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glucocard Vital Test

Products Affected

- GLUCOCARD VITAL TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glucocard X-Sensor

Products Affected

- GLUCOCARD X-SENSOR

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

GlucoCom Blood Glucose Monitor

Products Affected

- GLUCOCOM BLOOD GLUCOSE MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GlucoCom Test

Products Affected

- GLUCOCOM TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Glucolab Test

Products Affected

- GLUCOLAB TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GlucoNavii Blood Glucose Test

Products Affected

- GLUCONAVII BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Glumetza

Products Affected

- GLUMETZA ORAL TABLET EXTENDED
RELEASE 24 HR* 1000 MG

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glumetza

Products Affected

- GLUMETZA ORAL TABLET EXTENDED
RELEASE 24 HR* 500 MG

QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Glyxambi

Products Affected

- GLYXAMBI

ST Criteria	A documented step through one month each of Invokana/Invokamet and either Januvia/Janumet or Onglyza/Kombiglyze
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glyxambi

Products Affected

- GLYXAMBI

ST Criteria	A documented step through one month each of Invokana/Invokamet and either Januvia/Janumet and either Tradjenta/Jentadueto
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gmate Blood Glucose Test

Products Affected

- GMATE BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gonal-f

Products Affected

- GONAL-F

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gonal-f RFF

Products Affected

- GONAL-F RFF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gonal-f RFF Pen

Products Affected

- GONAL-F RFF PEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Gonal-f RFF Rediject

Products Affected

- GONAL-F RFF REDIJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gralise

Products Affected

- GRALISE ORAL TABLET 600 MG

QL Criteria	3 tablets Per 1 day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Gralise

Products Affected

- GRALISE ORAL TABLET 300 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gralise Starter

Products Affected

- GRALISE STARTER

QL Criteria	1 starter pack Per 1 month
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Granisetron HCl

Products Affected

- *granisetron hcl oral*

QL Criteria	10 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GuanFACINE HCl ER

Products Affected

- *guanfacine hcl er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy applies to brand
ST Criteria	A documented step through 14 days each of any three of the following preferred products: clonidine, clonidine sr, guanfacine, amphetamine/dextroamphetamine, amphetamine/dextroamphetamine sr, dexmethylphenidate, dexmethylphenidate sr, dextroamphetamine, methamphetamine, methylphenidate, methylphenidate er, methylphenidate sr, Daytrana, Strattera, or Vyvanse
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

GuanFACINE HCl ER

Products Affected

- *guanfacine hcl er*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy applies to brand
ST Criteria	Documented step through CLONIDINE, CLONIDINE SR, GUANFACINE, AMPHETAMINE/DEXTROAMPHETAMINE, AMPHETAMINE/DEXTROAMPHETAMINE SR, DEXMETHYLPHENIDATE, DEXMETHYLPHENIDATE SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE, METHYLPHENIDATE ER, METHYLPHENIDATE SR, STRATTERA, or VYVANSE
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Harvoni

Products Affected

- HARVONI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Heather

Products Affected

- *heather*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Helixate FS

Products Affected

- HELIXATE FS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Hemangeol

Products Affected

- HEMANGEOL

PA Criteria	Criteria Details
Covered Uses	infantile hemangioma
Exclusion Criteria	
Required Medical Information	(1) Documented diagnosis of proliferating infantile hemangioma requiring systemic therapy, and (2) Documentation that the member was not born prematurely with a corrected age of less than 5 weeks, and (3) Documentation that the member does not weight less than 2kg, have sustained heart rate of less than 80 beats per minutes, have greater than first degree heart block, or have decompensated heart failure, and (4) Member does not have sustained blood pressure less than 50/30mmHg
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hemofil M

Products Affected

- HEMOFIL M INTRAVENOUS* SOLUTION
RECONSTITUTED 401-800 UNIT, 220-400
UNIT, 250 UNIT, 1000 UNIT, 1700 UNIT,
1501-2000 UNIT, 801-1500 UNIT, 500 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hepsera

Products Affected

- HEPSERA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hetlioz

Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Covered Uses	Non-24 sleep wake-disorder
Exclusion Criteria	Documentation of concomitant sleep disorders (sleep apnea, insomnia)
Required Medical Information	Documentation of non-24 sleep wake-disorder, and documentation of total-blindness with no light perception, and documentation of at least 3 months of difficulty initiating sleep, difficulty awakening in the morning, or excessive daytime sleepiness.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

HM Nicotine

Products Affected

- *hm nicotine*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

HM Nicotine Polacrilex

Products Affected

- *hm nicotine polacrilex mouth/throat lozenge 2 mg*

QL Criteria	20 EA Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Horizant

Products Affected

- HORIZANT ORAL TABLET
EXTENDEDRELEASE* 300 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Horizant

Products Affected

- HORIZANT ORAL TABLET
EXTENDEDRELEASE* 600 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Humate-P

Products Affected

- HUMATE-P INTRAVENOUS* SOLUTION
RECONSTITUTED 500-1200 UNIT,
1000-2400 UNIT, 250-600 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humatrope

Products Affected

- HUMATROPE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Humira

Products Affected

- HUMIRA SUBCUTANEOUS* 20 MG/0.4ML

QL Criteria	2 injections Per 28 kit (2 pens)s
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira

Products Affected

- HUMIRA SUBCUTANEOUS* 40 MG/0.8ML

QL Criteria	6 injections Per 28 kit (2 pens)s
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Humira

Products Affected

- HUMIRA SUBCUTANEOUS* 10 MG/0.2ML

QL Criteria	2 EA Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira Pediatric Crohns Start

Products Affected

- HUMIRA PEDIATRIC CROHNS START
SUBCUTANEOUS* 40 MG/0.8ML

QL Criteria	4 injections Per 21 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Humira Pen

Products Affected

- HUMIRA PEN SUBCUTANEOUS*

QL Criteria	6 injections Per 28 kit (2 pens)s
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira Pen-Crohns Starter

Products Affected

- HUMIRA PEN-CROHNS STARTER
SUBCUTANEOUS*

QL Criteria	4 injections Per 21 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Humira Pen-Psoriasis Starter

Products Affected

- HUMIRA PEN-PSORIASIS STARTER
SUBCUTANEOUS*

QL Criteria	6 injections Per 28 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

HumuLIN 70/30

Products Affected

- HUMULIN 70/30

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

HumuLIN N

Products Affected

- HUMULIN N

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hyalgan

Products Affected

- HYALGAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Hycamtin

Products Affected

- HYCAMTIN ORAL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hydrocod Polst-CPM Polst ER

Products Affected

- *hydrocod polst-cpm polst er oral liquid extendedrelease**

QL Criteria	120 milliliters Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

HYDRORmorphone HCl ER

Products Affected

- *hydromorphone hcl er oral 8 mg, 32 mg, 12 mg*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

HYDRomorphone HCl ER

Products Affected

- *hydromorphone hcl er oral 16 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Hymovis

Products Affected

- HYMOVIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Hymovis

Products Affected

- HYMOVIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Hymovis

Products Affected

- HYMOVIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

Hyqvia

Products Affected

- HYQVIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/ivig.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Hysingla ER

Products Affected

- HYSINGLA ER

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ibandronate Sodium

Products Affected

- *ibandronate sodium oral*

QL Criteria	1 tablet Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ibrance

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	21 EA Per 28 Days
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 45 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 45 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 45 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Idelvion

Products Affected

- IDELVION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ilaris

Products Affected

- ILARIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/immunomodulators_CAP.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imatinib Mesylate

Products Affected

- *imatinib mesylate oral tablet 400 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Imatinib Mesylate

Products Affected

- *imatinib mesylate oral tablet 100 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imbruvica

Products Affected

- IMBRUVICA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Imiquimod

Products Affected

- *imiquimod external*

QL Criteria	48 packets Per 112 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imitrex

Products Affected

- IMITREX ORAL

QL Criteria	9 tablets Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Imitrex

Products Affected

- IMITREX NASAL SOLUTION 20 MG/ACT

QL Criteria	0.27 ml Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imitrex

Products Affected

- IMITREX NASAL SOLUTION 5 MG/ACT

QL Criteria	0.21 ml Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Impavido

Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Covered Uses	Leishmaniasis
Exclusion Criteria	Known or suspected pregnancy
Required Medical Information	A documented diagnosis of any of the following leishmaniasis infections: Visceral leishmaniasis due to <i>Leishmania donovani</i> , Cutaneous leishmaniasis due to <i>Leishmania braziliensis</i> , <i>Leishmania guyanensis</i> , and <i>Leishmania panamensis</i> , or Mucosal leishmaniasis due to <i>Leishmania braziliensis</i>
Age Restrictions	12 years of age or older
Prescriber Restrictions	
Coverage Duration	28 days
Other Criteria	
QL Criteria	84 capsules Per 28 days
Notes/References	
Revision Date	Prior Authorization: August 16, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Implanon

Products Affected

- IMPLANON

QL Criteria	1 implant Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

In Touch Blood Glucose Test

Products Affected

- IN TOUCH BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Increlex

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ENDO/Increlex.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Inderal XL

Products Affected

- INDERAL XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 80 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Infinity Blood Glucose Test

Products Affected

- INFINITY BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Inlyta

Products Affected

- INLYTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

InnoPran XL

Products Affected

- INNOPRAN XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 80 MG

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

InnoPran XL

Products Affected

- INNOPRAN XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 120 MG

QL Criteria	1 CP24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Intelligence

Products Affected

- INTELENCE ORAL TABLET 25 MG, 100 MG

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Intelligence

Products Affected

- INTELENCE ORAL TABLET 200 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Intermezzo

Products Affected

- INTERMEZZO

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Intron A

Products Affected

- INTRON A

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Introvale

Products Affected

- *introvale*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Intuniv

Products Affected

- INTUNIV

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy applies to brand
ST Criteria	A documented step through 14 days each of any three of the following preferred products: clonidine, clonidine sr, guanfacine, amphetamine/dextroamphetamine, amphetamine/dextroamphetamine sr, dexamethylphenidate, dexamethylphenidate sr, dextroamphetamine, methamphetamine, methylphenidate, methylphenidate er, methylphenidate sr, Daytrana, Strattera, or Vyvanse
QL Criteria	1 TABS Per 1 DAY
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Intuniv

Products Affected

- INTUNIV

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy applies to brand
ST Criteria	Documented step through CLONIDINE, CLONIDINE SR, GUANFACINE, AMPHETAMINE/DEXTROAMPHETAMINE, AMPHETAMINE/DEXTROAMPHETAMINE SR, DEXMETHYLPHENIDATE, DEXMETHYLPHENIDATE SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE, METHYLPHENIDATE ER, METHYLPHENIDATE SR, STRATTERA, or VYVANSE
QL Criteria	1 TABS Per 1 DAY
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Invega

Products Affected

- INVEGA ORAL TABLET EXTENDED
RELEASE 24 HR* 1.5 MG, 9 MG, 3 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Invega

Products Affected

- INVEGA ORAL TABLET EXTENDED
RELEASE 24 HR* 6 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Invokamet

Products Affected

- INVOKAMET

QL Criteria	2 tablets Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Invokana

Products Affected

- INVOKANA

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ipratropium Bromide

Products Affected

- *ipratropium bromide nasal*

QL Criteria	1 bottle Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Iprivask

Products Affected

- IPRIVASK

QL Criteria	2 syringes Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Irbesartan

Products Affected

- *irbesartan*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Irbesartan-Hydrochlorothiazide

Products Affected

- *irbesartan-hydrochlorothiazide*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Irenka

Products Affected

- IRENKA

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Iressa

Products Affected

- IRESSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Isentress

Products Affected

- ISENTRESS ORAL TABLET

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Isentress

Products Affected

- ISENTRESS ORAL TABLET CHEWABLE

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Itraconazole

Products Affected

- *itraconazole oral*

QL Criteria	4 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ixinity

Products Affected

- IXINITY INTRAVENOUS* SOLUTION
RECONSTITUTED 1500 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Jadenu

Products Affected

- JADENU

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/Antidotes.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jakafi

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Janumet

Products Affected

- JANUMET

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Janumet XR

Products Affected

- JANUMET XR ORAL TABLET EXTENDED
RELEASE 24 HR* 50-500 MG, 100-1000 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Janumet XR

Products Affected

- JANUMET XR ORAL TABLET EXTENDED
RELEASE 24 HR* 50-1000 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Januvia

Products Affected

- JANUVIA

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Jardiance

Products Affected

- JARDIANCE

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jentaduetto

Products Affected

- JENTADUETO

QL Criteria	2 tablets Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Jentaduetto XR

Products Affected

- JENTADUETO XR ORAL TABLET
EXTENDED RELEASE 24 HR* 2.5-1000 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jentaduetto XR

Products Affected

- JENTADUETO XR ORAL TABLET
EXTENDED RELEASE 24 HR* 5-1000 MG

QL Criteria	1 tablet Per 1 Day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Jinteli

Products Affected

- *jinteli*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jolessa

Products Affected

- *jolessa*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jolivette

Products Affected

- *jolivette*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jublia

Products Affected

- JUBLIA

PA Criteria	Criteria Details
Covered Uses	onychomycosis
Exclusion Criteria	
Required Medical Information	(1)Diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection, and (2) A documented contraindication or intolerance or allergy or failure of an adequate trial of one systemic (oral) alternative such as terbinafine, itraconazole, griseofulvin, or fluconazole defined as (a) Failure of an adequate trial of one systemic (oral) alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), or (b) Presence of hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or (c) Member is female and is pregnant and/or breastfeeding
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Junel 1.5/30

Products Affected

- *Junel 1.5/30*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Junel 1/20

Products Affected

- *junel 1/20*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Junel FE 1.5/30

Products Affected

- *junel fe 1.5/30*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Junel FE 1/20

Products Affected

- *junel fe 1/20*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Juxtapid

Products Affected

- JUXTAPID ORAL CAPSULE 20 MG, 40 MG, 30 MG, 5 MG, 60 MG

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Juxtapid

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kadian

Products Affected

- KADIAN ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 130 MG, 150 MG, 50
MG, 80 MG, 100 MG, 20 MG, 60 MG, 200
MG, 30 MG, 40 MG, 70 MG

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kalbitor

Products Affected

- KALBITOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angi_oedema.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kalydeco

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kalydeco

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Kanuma

Products Affected

- KANUMA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kapvay

Products Affected

- KAPVAY ORAL TABLET EXTENDED RELEASE 12 HR*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy applies to brand
ST Criteria	Documented step through CLONIDINE, CLONIDINE SR, GUANFACINE, AMPHETAMINE/DEXTROAMPHETAMINE, AMPHETAMINE/DEXTROAMPHETAMINE SR, DEXMETHYLPHENIDATE, DEXMETHYPHENIDATE SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE, METHYLPHENIDATE ER, METHYLPHENIDATE SR, STRATTERA, OR VYVANSE
QL Criteria	4 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kariva

Products Affected

- *kariva*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kazano

Products Affected

- KAZANO

ST Criteria	Documented trial of 1 month each of 2 preferred alternatives: Januvia and Onglyza (single entity or combination)
QL Criteria	2 tablets Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kelnor 1/35

Products Affected

- *kelnor 1/35*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Keppra XR

Products Affected

- KEPPRA XR ORAL TABLET EXTENDED
RELEASE 24 HR* 750 MG

QL Criteria	4 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Keppra XR

Products Affected

- KEPPRA XR ORAL TABLET EXTENDED
RELEASE 24 HR* 500 MG

QL Criteria	6 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kerydin

Products Affected

- KERYDIN

PA Criteria	Criteria Details
Covered Uses	onychomycosis
Exclusion Criteria	
Required Medical Information	(1)Diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection, and (2) A documented contraindication or intolerance or allergy or failure of an adequate trial of one systemic (oral) alternative such as terbinafine, itraconazole, griseofulvin, or fluconazole defined as (a) Failure of an adequate trial of one systemic (oral) alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), or (b) Presence of hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or (c) Member is female and is pregnant and/or breastfeeding
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Ketoconazole

Products Affected

- *ketoconazole oral*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ketorolac Tromethamine

Products Affected

- *ketorolac tromethamine ophthalmic*

QL Criteria	1 vial Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ketorolac Tromethamine

Products Affected

- *ketorolac tromethamine oral*

QL Criteria	20 tablets Per 28 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Keveyis

Products Affected

- KEVEYIS

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Khedeza

Products Affected

- KHEDEZLA

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
QL Criteria	1 TB24 Per 1 DAYS
Notes/References	Annual Review: 05/2016
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kineret

Products Affected

- KINERET SUBCUTANEOUS*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 syringe Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Koate-DVI

Products Affected

- KOATE-DVI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kogenate FS

Products Affected

- KOGENATE FS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Kogenate FS Bio-Set

Products Affected

- KOGENATE FS BIO-SET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kombiglyze XR

Products Affected

- KOMBIGLYZE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 5-1000 MG,
5-500 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kombiglyze XR

Products Affected

- KOMBIGLYZE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 2.5-1000 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Korlym

Products Affected

- KORLYM

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kovaltry

Products Affected

- KOVALTRY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kroger Blood Glucose

Products Affected

- KROGER BLOOD GLUCOSE KIT
W/DEVICE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kroger Blood Glucose Test

Products Affected

- *kroger blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kroger Premium Blood Glucose

Products Affected

- KROGER PREMIUM BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Kroger Test

Products Affected

- *kroger test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kurvelo

Products Affected

- *kurvelo*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Kuvan

Products Affected

- KUVAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/metabolic_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kynamro

Products Affected

- KYNAMRO SUBCUTANEOUS*

QL Criteria	4 SOLN Per 30 DAYSS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL TABLET
DISPERSIBLE 200 MG, 100 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL TABLET
DISPERSIBLE 50 MG

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL TABLET
DISPERSIBLE 25 MG

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 200 MG

QL Criteria	3 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 25 MG, 100
MG, 50 MG

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 250 MG, 300
MG

QL Criteria	2 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LamISIL

Products Affected

- LAMISIL ORAL PACKET 187.5 MG

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamISIL

Products Affected

- LAMISIL ORAL PACKET 125 MG

QL Criteria	2 packs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LamoTRIGine

Products Affected

- *lamotrigine oral tablet dispersible 200 mg, 100 mg*

QL Criteria	2 TAB Per 1 DAILY
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRIGine

Products Affected

- *lamotrigine oral tablet dispersible 25 mg*

QL Criteria	6 TAB Per 1 DAILY
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRIGine

Products Affected

- *lamotrigine oral tablet dispersible 50 mg*

QL Criteria	3 TAB Per 1 DAILY
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRIGine ER

Products Affected

- *lamotrigine er oral tablet extended release 24 hr* 100 mg, 25 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LamoTRIGine ER

Products Affected

- *lamotrigine er oral tablet extended release 24 hr* 200 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRIGine ER

Products Affected

- *lamotrigine er oral tablet extended release 24 hr* 300 mg, 250 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LamoTRIGine ER

Products Affected

- *lamotrigine er oral tablet extended release 24 hr* 50 mg*

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lansoprazole

Products Affected

- *lansoprazole oral capsule delayed release*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Larin Fe 1.5/30

Products Affected

- LARIN FE 1.5/30

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Latuda

Products Affected

- LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, and clozapine
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Latuda

Products Affected

- LATUDA ORAL TABLET 60 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, and clozapine
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Latuda

Products Affected

- LATUDA ORAL TABLET 80 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, and clozapine
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lazanda

Products Affected

- LAZANDA NASAL SOLUTION 300 MCG/ACT

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
QL Criteria	4 bottles Per 30 days
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lazanda

Products Affected

- LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	A documented step through one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

QL Criteria	15 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lazanda

Products Affected

- LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	15 bottles Per 1 fill

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lazanda

Products Affected

- LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	15 bottles Per 1 fill

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: July 15, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Leena

Products Affected

- *leena*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Leflunomide

Products Affected

- *leflunomide oral*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lemtrada

Products Affected

- LEMTRADA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	6 ML Per 365 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lenvima 10 MG Daily Dose

Products Affected

- LENVIMA 10 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Lenvima 14 MG Daily Dose

Products Affected

- LENVIMA 14 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lenvima 18 MG Daily Dose

Products Affected

- LENVIMA 18 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Prevention of acute or delayed nausea or vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: May 23, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Lenvima 20 MG Daily Dose

Products Affected

- LENVIMA 20 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lenvima 24 MG Daily Dose

Products Affected

- LENVIMA 24 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Lenvima 8 MG Daily Dose

Products Affected

- LENVIMA 8 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Prevention of acute or delayed nausea or vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	30 day supply Per 1 prescription
Notes/References	
Revision Date	Prior Authorization: May 23, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lescol

Products Affected

- LESCOL

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lescol XL

Products Affected

- LESCOL XL

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lessina

Products Affected

- *lessina*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Leuprolide Acetate

Products Affected

- *leuprolide acetate injection*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LevETIRAcetam ER

Products Affected

- *levetiracetam er oral tablet extended release 24 hr* 500 mg*

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LevETIRAcetam ER

Products Affected

- *levetiracetam er oral tablet extended release 24 hr* 750 mg*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levocetirizine Dihydrochloride

Products Affected

- *levocetirizine dihydrochloride oral tablet*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonest

Products Affected

- *levonest*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonorgest-Eth Estrad 91-Day

Products Affected

- *levonorgest-eth estrad 91-day oral tablet*
0.1-0.02 & 0.01 mg, 0.15-0.03 mg

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Levonorgestrel-Ethinyl Estrad

Products Affected

- *levonorgestrel-ethinyl estrad oral tablet*
0.15-30 mg-mcg

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levora 0.15/30 (28)

Products Affected

- *levora 0.15/30 (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lexapro

Products Affected

- LEXAPRO ORAL TABLET 10 MG

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lexapro

Products Affected

- LEXAPRO ORAL TABLET 20 MG, 5 MG

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lialda

Products Affected

- LIALDA

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Liberty Blood Glucose Meter

Products Affected

- *liberty blood glucose meter*

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Liberty Blood Glucose Monitor

Products Affected

- *liberty blood glucose monitor*

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Liberty Next Generation Test

Products Affected

- LIBERTY NEXT GENERATION TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Liberty Nxt Generation Monitor

Products Affected

- LIBERTY NXT GENERATION MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Liberty Test

Products Affected

- *liberty test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lidex

Products Affected

- LIDEX

ST Criteria	Documented step through TWO VERY HIGH POTENCY TOPICAL STEROIDS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lidocaine

Products Affected

- *lidocaine external patch 5 %*

QL Criteria	3 patches Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lidocaine

Products Affected

- *lidocaine external ointment*

PA Criteria	Criteria Details
Covered Uses	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for anesthesia for any of the following: Accessible mucous membranes of the oropharynx, skin and mucous membranes or stomatitis, or pain associated with a minor burns, including sunburn, abrasions of the skin, and insect bites.
Exclusion Criteria	Documentation of any of the following: Planned area of application includes non-intact skin, sensitivity to amide-type local anesthetics or any other component of the product, planned use on large surface area of the body as this can lead to increased toxicity, planned area of application includes severely traumatized skin (e.g., mucosal or skin abrasion, eczema, burns), the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), or if the product will be compounded with other products that would alter the total dose/dosage form being administered
Required Medical Information	A documented need for temporary anesthesia for any of the following: Accessible mucous membranes of the oropharynx, skin and mucous membranes or stomatitis, or pain associated with a minor burns, including sunburn, abrasions of the skin, and insect bites.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months

PA Criteria	Criteria Details
Other Criteria	<p>*Topical lidocaine ointment is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Approval can made up to an additional 50gms per 30 days. Higher additional quantities are not approvable</p> <p>*FOR ADULTS: A single application should not exceed 5 g of Lidocaine Ointment 5%, containing 250 mg of lidocaine base (equivalent chemically to approximately 300 mg of lidocaine hydrochloride). This is roughly equivalent to squeezing a six (6) inch length of ointment from the tube. In a 70 kg adult this dose equals 3.6 mg/kg (1.6 mg/lb) lidocaine base. No more than one-half tube, approximately 17-20 g of ointment or 850-1000 mg lidocaine base, should be administered in any one day. FOR CHILDREN: For children less than ten years who have a normal lean body mass and a normal lean body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark's rule). For example a child of five years weighing 50 lbs., the dose of lidocaine should not exceed 75-100 mg when calculated according to Clark's rule. In any case, the maximum amount of lidocaine administered should not exceed 4.5 mg/kg (2.0 mg/lb) of body weight</p> <p>***Lidocaine toxicity resulting from transcutaneous absorption is theoretically possible. Signs and symptoms of systemic lidocaine toxicity include CNS excitation and/or depression, nervousness, confusion, dizziness, tinnitus, blurred or double vision, vomiting, twitching, tremors, seizures, unconsciousness, respiratory depression, bradycardia, hypotension, and cardiopulmonary arrest. If there is suspicion of lidocaine-related systemic toxicity, check lidocaine blood concentrations</p>
QL Criteria	50 GM Per 30 Days
Notes/References	
Revision Date	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Lidocaine PAK

Products Affected

- *lidocaine pak*

QL Criteria	90 GM Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lidocaine-Prilocaine

Products Affected

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
Covered Uses	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
Exclusion Criteria	Documentation of any of the following: Planned area of application includes non-intact skin, Sensitivity to amide-type local anesthetics or any other component of the product, Planned use on large surface area of the body or for a period of time over 3 hours as this can lead to increased toxicity, the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), Use in situations where the drug may migrate into the middle ear, beyond the tympanic membrane, History of methemoglobinemia, or if the product will be compounded with other products that would alter the total dose/dosage form being administered
Required Medical Information	A documented need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	*Topical lidocaine/prilocaine cream is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Up to an additional 30 grams per 30 days. Higher additional quantities are not approvable.
QL Criteria	30 GM Per 30 Days
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Lidoderm

Products Affected

- LIDODERM

QL Criteria	3 patches Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lindane

Products Affected

- *lindane external lotion*

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Linezolid

Products Affected

- *linezolid oral suspension reconstituted*

QL Criteria	150 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Linezolid

Products Affected

- *linezolid oral tablet*

QL Criteria	28 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Linzess

Products Affected

- LINZESS

ST Criteria	Documented step through LACTULOSE AND AMITIZA
QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lipitor

Products Affected

- LIPITOR

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lipofen

Products Affected

- LIPOFEN

QL Criteria	1 CAPS Per 1 DAY
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Liptruzet

Products Affected

- LIPTRUZET

QL Criteria	1 TAB Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Livalo

Products Affected

- LIVALO

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lo Loestrin Fe

Products Affected

- LO LOESTRIN FE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Loestrin 1.5/30 (21)

Products Affected

- LOESTRIN 1.5/30 (21)

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Loestrin 1/20 (21)

Products Affected

- LOESTRIN 1/20 (21)

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Loestrin Fe 1.5/30

Products Affected

- LOESTRIN FE 1.5/30

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Loestrin Fe 1/20

Products Affected

- LOESTRIN FE 1/20

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lofibra

Products Affected

- LOFIBRA

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lofibra

Products Affected

- LOFIBRA

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lomedia 24 FE

Products Affected

- *lomedia 24 fe*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lonsurf

Products Affected

- LONSURF ORAL TABLET 15-6.14 MG

QL Criteria	100 tablets Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lonsurf

Products Affected

- LONSURF ORAL TABLET 20-8.19 MG

QL Criteria	80 tablets Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Loryna

Products Affected

- *loryna*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Losartan Potassium

Products Affected

- *losartan potassium oral tablet 25 mg, 50 mg*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LoSeasonique

Products Affected

- LOSEASONIQUE

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lotronex

Products Affected

- LOTRONEX

PA Criteria	Criteria Details
Covered Uses	severe diarrhea-predominant irritable bowel syndrome (IBS)
Exclusion Criteria	
Required Medical Information	Patient is female, and has a documented diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) including one or more of the following: frequent and severe abdominal pain/discomfort, frequent urgency or fecal incontinence or disability or restriction of daily activities due to IBS, AND patient has chronic IBS symptoms generally lasting 6 months or longer, AND anatomic or biochemical abnormalities of the gastrointestinal tract have been excluded
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented trial of 2 alternatives: diphenoxylate/atropine, loperamide
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Lotronex

Products Affected

- LOTRONEX

PA Criteria	Criteria Details
Covered Uses	severe diarrhea-predominant irritable bowel syndrome (IBS)
Exclusion Criteria	
Required Medical Information	Patient is female, and has a documented diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) including one or more of the following: frequent and severe abdominal pain/discomfort, frequent urgency or fecal incontinence or disability or restriction of daily activities due to IBS, AND patient has chronic IBS symptoms generally lasting 6 months or longer, AND anatomic or biochemical abnormalities of the gastrointestinal tract have been excluded
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each diphenoxylate/atropine and loperamide
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Lovastatin

Products Affected

- *lovastatin*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lovaza

Products Affected

- LOVAZA

QL Criteria	4 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lovenox

Products Affected

- LOVENOX

QL Criteria	2 syringes Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Low-Ogestrel

Products Affected

- *low-ogestrel*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lumigan

Products Affected

- LUMIGAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lumigan

Products Affected

- LUMIGAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Lumizyme

Products Affected

- LUMIZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Lunesta

Products Affected

- LUNESTA

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lutera

Products Affected

- *lutera*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lynparza

Products Affected

- LYNPARZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	480 EA Per 30 Days
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lysteda

Products Affected

- LYSTEDA

QL Criteria	30 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Lyza

Products Affected

- LYZA

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Makena

Products Affected

- MAKENA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/hydroxyprogesterone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Maprotiline HCl

Products Affected

- *maprotiline hcl*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Marinol

Products Affected

- MARINOL

PA Criteria	Criteria Details
Covered Uses	Anorexia associated with weight loss in patients with AIDS, Chemotherapy-induced nausea and vomiting
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Anorexia associated with weight loss in patients with AIDS, or Chemotherapy-induced nausea and vomiting
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
QL Criteria	2 CAPS Per 1 DAYS
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Marlissa

Products Affected

- *marlissa*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Matzim LA

Products Affected

- *matzim la oral tablet extended release 24 hr**
240 mg

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Matzim LA

Products Affected

- *matzim la oral tablet extended release 24 hr**
300 mg, 180 mg, 360 mg

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Maxalt

Products Affected

- MAXALT

QL Criteria	12 tablets Per 30 DAYs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Maxalt-MLT

Products Affected

- MAXALT-MLT

QL Criteria	12 tablets Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Maxima Blood Glucose Test

Products Affected

- MAXIMA BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

MedroxyPROGESTERone Acetate

Products Affected

- *medroxyprogesterone acetate intramuscular**

QL Criteria	1 syringe Per 90 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Meijer Blood Glucose

Products Affected

- MEIJER BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Meijer Blood Glucose Test

Products Affected

- *meijer blood glucose test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Meijer Premium Blood Glucose

Products Affected

- MEIJER PREMIUM BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Meijer TRUEtest Test

Products Affected

- MEIJER TRUETEST TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Meijer TRUEtrack Test

Products Affected

- MEIJER TRUETRACK TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Memantine HCl

Products Affected

- *memantine hcl oral tablet 5 (28)-10 (21) mg*

QL Criteria	1.75 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Memantine HCl

Products Affected

- *memantine hcl oral tablet 5 mg, 10 mg*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Menopur

Products Affected

- MENOPUR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Menostar

Products Affected

- MENOSTAR

QL Criteria	1 box (4 patches) Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mesalamine

Products Affected

- *mesalamine oral*

QL Criteria	6 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metadate CD

Products Affected

- METADATE CD ORAL CAPSULE
EXTENDED RELEASE* 20 MG

QL Criteria	3 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Metadate CD

Products Affected

- METADATE CD ORAL CAPSULE
EXTENDED RELEASE* 40 MG, 10 MG, 60
MG

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metadate CD

Products Affected

- METADATE CD ORAL CAPSULE
EXTENDED RELEASE* 30 MG

QL Criteria	2 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Metadate ER

Products Affected

- METADATE ER ORAL TABLET
EXTENDEDRELEASE* 20 MG

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metaxalone

Products Affected

- *metaxalone oral tablet 400 mg*

QL Criteria	56 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methadone HCl

Products Affected

- *methadone hcl oral solution 5 mg/5ml*
- *methadone hcl oral concentrate*

QL Criteria	60 mg Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methadone HCl

Products Affected

- *methadone hcl oral tablet*

QL Criteria	6 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methadone HCl

Products Affected

- *methadone hcl oral solution 10 mg/5ml*

QL Criteria	30 mg Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methadose

Products Affected

- *methadose oral tablet soluble*

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methamphetamine HCl

Products Affected

- *methamphetamine hcl*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of ADHD or Narcolepsy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylin

Products Affected

- METHYLIN ORAL SOLUTION 10 MG/5ML

QL Criteria	30 soln Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methylin

Products Affected

- METHYLIN ORAL SOLUTION 5 MG/5ML

QL Criteria	60 ML Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylin

Products Affected

- METHYLIN ORAL TABLET CHEWABLE

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methylphenidate HCl

Products Affected

- *methylphenidate hcl oral solution 5 mg/5ml*

QL Criteria	60 milliliters Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl

Products Affected

- *methylphenidate hcl oral tablet*

QL Criteria	6 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methylphenidate HCl

Products Affected

- *methylphenidate hcl oral solution 10 mg/5ml*

QL Criteria	30 milliliters Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER

Products Affected

- *methylphenidate hcl er oral tablet
extendedrelease* 20 mg, 10 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methylphenidate HCl ER

Products Affected

- *methylphenidate hcl er oral tablet
extendedrelease* 54 mg, 18 mg, 27 mg*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER

Products Affected

- *methylphenidate hcl er oral tablet extended release 24 hr* 36 mg*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methylphenidate HCl ER

Products Affected

- *methylphenidate hcl er oral tablet
extendedrelease* 36 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER (CD)

Products Affected

- *methylphenidate hcl er (cd)*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Methylphenidate HCl ER (LA)

Products Affected

- *methylphenidate hcl er (la) oral capsule
extended release 24 hour 20 mg, 40 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER (LA)

Products Affected

- *methylphenidate hcl er (la) oral capsule
extended release 24 hour 30 mg*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Metoprolol Succinate ER

Products Affected

- *metoprolol succinate er oral tablet extended release 24 hr* 100 mg, 50 mg*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metoprolol Succinate ER

Products Affected

- *metoprolol succinate er oral tablet extended release 24 hr* 200 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Metoprolol Succinate ER

Products Affected

- *metoprolol succinate er oral tablet extended release 24 hr* 25 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mevacor

Products Affected

- MEVACOR ORAL TABLET 40 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Miacalcin

Products Affected

- MIACALCIN NASAL

QL Criteria	1 bottle Per 30 Days
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Micardis

Products Affected

- MICARDIS

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Micardis HCT

Products Affected

- MICARDIS HCT

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Microdot Test

Products Affected

- MICRODOT TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Microgestin 1.5/30

Products Affected

- *microgestin 1.5/30*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Microgestin 1/20

Products Affected

- *microgestin 1/20*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Microgestin FE 1.5/30

Products Affected

- *microgestin fe 1.5/30*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Microgestin FE 1/20

Products Affected

- *microgestin fe 1/20*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mimvey

Products Affected

- *mimvey*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Minivelle

Products Affected

- MINIVELLE

QL Criteria	8 patches Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Mirapex ER

Products Affected

- MIRAPEX ER

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mircera

Products Affected

- MIRCERA INJECTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mirtazapine

Products Affected

- *mirtazapine oral*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mitigare

Products Affected

- MITIGARE

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Modafinil

Products Affected

- *modafinil oral tablet 200 mg*

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Modafinil

Products Affected

- *modafinil oral tablet 100 mg*

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Modicon (28)

Products Affected

- MODICON (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mondoxyne NL

Products Affected

- MONDOXYNE NL ORAL CAPSULE 75 MG

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Monoclote-P

Products Affected

- MONOCLATE-P

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Monodox

Products Affected

- MONODOX ORAL CAPSULE 75 MG

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mono-Linyah

Products Affected

- *mono-linyah*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

MonoNessa

Products Affected

- *mononessa*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mononine

Products Affected

- MONONINE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Monovisc

Products Affected

- MONOVISC

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Montelukast Sodium

Products Affected

- *montelukast sodium oral*

QL Criteria	1 pack Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Montelukast Sodium

Products Affected

- *montelukast sodium oral*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Morphine Sulfate ER

Products Affected

- *morphine sulfate er oral tablet extended release* 100 mg, 60 mg, 30 mg*
- *morphine sulfate er oral capsule extended release 24 hour*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Morphine Sulfate ER

Products Affected

- *morphine sulfate er oral tablet
extendedrelease* 15 mg, 200 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Morphine Sulfate ER Beads

Products Affected

- *morphine sulfate er beads*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

MS Contin

Products Affected

- MS CONTIN ORAL TABLET
EXTENDEDRELEASE* 60 MG, 100 MG, 15
MG, 30 MG

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Multaq

Products Affected

- MULTAQ

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Myalept

Products Affected

- MYALEPT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ENDO/Myalept.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	0.5 VIAL Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

MyGlucoHealth Test

Products Affected

- MYGLUCOHEALTH TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Myorisan

Products Affected

- *myorisan oral capsule 10 mg, 20 mg, 40 mg*

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Myozyme

Products Affected

- MYOZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Myrbetriq

Products Affected

- MYRBETRIQ

ST Criteria	Documented trial of 1 preferred generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Myzilra

Products Affected

- *myzilra*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Naglazyme

Products Affected

- NAGLAZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Namenda

Products Affected

- NAMENDA

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Namenda Titration Pak

Products Affected

- NAMENDA TITRATION PAK

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Namenda XR

Products Affected

- NAMENDA XR

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Namzarin

Products Affected

- NAMZARIC ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 28-10 MG, 14-10 MG

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Naratriptan HCl

Products Affected

- *naratriptan hcl*

QL Criteria	9 tablets Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Narcan

Products Affected

- NARCAN

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Natazia

Products Affected

- NATAZIA

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Natesto

Products Affected

- NATESTO

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Natpara

Products Affected

- NATPARA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 ctg Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 0.5/35 (28)

Products Affected

- *necon 0.5/35 (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 1/35 (28)

Products Affected

- *necon 1/35 (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 1/50 (28)

Products Affected

- *necon 1/50 (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 10/11 (28)

Products Affected

- *necon 10/11 (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nesina

Products Affected

- NESINA

ST Criteria	A documented step through 1 month each of Januvia, Janumet, or Janumet XR; Tradjenta or Jentadueto; and generic alogliptin, alogliptin/pioglitazone, or alogliptin/metformin
QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nesina

Products Affected

- NESINA

ST Criteria	A documented step through one month each of Januvia, Janumet, or Janumet XR, and either Onglyza or Kombiglyze XR
QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: July 15, 2016 Quantity Limits: August 25, 2015

Nesina

Products Affected

- NESINA

ST Criteria	Trial and failure of 1 month each of (a) Januvia, Janumet, or Janumet XR, and (b) Onglyza or Kombiglyze XR
QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Neupro

Products Affected

- NEUPRO

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Neurontin

Products Affected

- NEURONTIN ORAL TABLET

QL Criteria	6 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Neurontin

Products Affected

- NEURONTIN ORAL CAPSULE

QL Criteria	6 cap Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Neutek 2Tek Glucose/Pressure

Products Affected

- NEUTEK 2TEK GLUCOSE/PRESSURE

QL Criteria	1 meter Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Neutek 2Tek Test

Products Affected

- NEUTEK 2TEK TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nevirapine ER

Products Affected

- *nevirapine er oral tablet extended release 24 hr* 400 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nevirapine ER

Products Affected

- *nevirapine er oral tablet extended release 24 hr* 100 mg*

QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NexAVAR

Products Affected

- NEXAVAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

NexGen Test

Products Affected

- NEXGEN TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NexIUM

Products Affected

- NEXIUM ORAL CAPSULE DELAYED
RELEASE 40 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

NexIUM

Products Affected

- NEXIUM ORAL PACKET

QL Criteria	1 pack Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NexIUM 24HR

Products Affected

- NEXIUM 24HR ORAL TABLET DELAYED RELEASE

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nexplanon

Products Affected

- NEXPLANON

QL Criteria	1 implant Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Next Choice One Dose

Products Affected

- *next choice one dose*

QL Criteria	1 tablet Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicoderm CQ

Products Affected

- NICODERM CQ

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicorelief

Products Affected

- *nicorelief mouth/throat gum*

QL Criteria	24 EA Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicorette

Products Affected

- NICORETTE MOUTH/THROAT GUM

QL Criteria	24 EA Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotine

Products Affected

- *nicotine transdermal patch 24 hr*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotine Step 1

Products Affected

- *nicotine step 1*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotine Step 2

Products Affected

- *nicotine step 2*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotine Step 3

Products Affected

- *nicotine step 3*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotrol

Products Affected

- NICOTROL

QL Criteria	3 boxes-504 ctrtg Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nicotrol NS

Products Affected

- NICOTROL NS

QL Criteria	4 bottles Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nifediac CC

Products Affected

- *nifediac cc oral tablet extended release 24 hr**
60 mg

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nifediac CC

Products Affected

- *nifediac cc oral tablet extended release 24 hr**
30 mg

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nifedical XL

Products Affected

- *nifedical xl oral tablet extended release 24 hr**
30 mg

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nifedical XL

Products Affected

- *nifedical xl oral tablet extended release 24 hr**
60 mg

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NIFEdipine ER

Products Affected

- *nifedipine er oral tablet extended release 24 hr* 30 mg, 90 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

NIFEdipine ER

Products Affected

- *nifedipine er oral tablet extended release 24 hr* 60 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NIFEdipine ER Osmotic Release

Products Affected

- *nifedipine er osmotic release oral tablet*
extended release 24 hr 90 mg, 30 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

NIFEdipine ER Osmotic Release

Products Affected

- *nifedipine er osmotic release oral tablet*
extended release 24 hr 60 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nikki

Products Affected

- NIKKI

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ninlaro

Products Affected

- NINLARO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 capsules Per 28 days
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nisoldipine ER

Products Affected

- *nisoldipine er oral tablet extended release 24 hr* 17 mg, 34 mg, 25.5 mg, 40 mg, 8.5 mg, 20 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nisoldipine ER

Products Affected

- *nisoldipine er oral tablet extended release 24 hr* 30 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nitroglycerin

Products Affected

- *nitroglycerin translingual solution*

QL Criteria	12 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nora-BE

Products Affected

- *nora-be*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norditropin FlexPro

Products Affected

- NORDITROPIN FLEXPPO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Norethindrone

Products Affected

- *norethindrone oral*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norgestimate-Eth Estradiol

Products Affected

- *norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Norgestim-Eth Estrad Triphasic

Products Affected

- *norgestim-eth estrad triphasic oral tablet*
0.18/0.215/0.25 mg-35 mcg

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norinyl 1+35 (28)

Products Affected

- NORINYL 1+35 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norinyl 1+50 (28)

Products Affected

- NORINYL 1+50 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norlyroc

Products Affected

- NORLYROC

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nor-QD

Products Affected

- NOR-QD

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Northera

Products Affected

- NORTHERA ORAL CAPSULE 200 MG, 300 MG

QL Criteria	6 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Northera

Products Affected

- NORTHERA ORAL CAPSULE 100 MG

QL Criteria	3 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 0.5/35 (28)

Products Affected

- *nortrel 0.5/35 (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 1/35 (21)

Products Affected

- *nortrel 1/35 (21)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 1/35 (28)

Products Affected

- *nortrel 1/35 (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 7/7/7

Products Affected

- *nortrel 7/7/7*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nova Max Blood Glucose System

Products Affected

- NOVA MAX BLOOD GLUCOSE SYSTEM
DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nova Max Glucose Test

Products Affected

- NOVA MAX GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Novarel

Products Affected

- *novarel*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Novoeight

Products Affected

- NOVOEIGHT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NovoLIN 70/30

Products Affected

- NOVOLIN 70/30

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

NovoLIN N

Products Affected

- NOVOLIN N

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

NovoLIN R

Products Affected

- NOVOLIN R

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

NovoLOG

Products Affected

- NOVOLOG

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

NovoLOG FlexPen

Products Affected

- NOVOLOG FLEXPEN SUBCUTANEOUS*

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

NovoLOG Mix 70/30

Products Affected

- NOVOLOG MIX 70/30

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

NovoLOG Mix 70/30 FlexPen

Products Affected

- NOVOLOG MIX 70/30 FLEXPEN
SUBCUTANEOUS*

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

NovoLOG PenFill

Products Affected

- NOVOLOG PENFILL SUBCUTANEOUS*

ST Criteria	A documented step through one month of one preferred alternative rapid-acting insulin (Humulin or Humalog)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

NovoSeven RT

Products Affected

- NOVOSEVEN RT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Noxafil

Products Affected

- NOXAFIL ORAL TABLET DELAYED RELEASE

QL Criteria	93 TBEC Per 30 DAYSs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nucala

Products Affected

- NUCALA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/RESP/Interleukin%20Antagonist.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 injection Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Nucynta

Products Affected

- NUCYNTA

ST Criteria	Documented step through TWO of the following: MORPHINE, OXYCODONE, HYDROMORPHONE
QL Criteria	6 tablets Per 1 day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nucynta ER

Products Affected

- NUCYNTA ER

PA Criteria	Criteria Details
Covered Uses	(1)Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment, (2)Diabetic peripheral neuropathy
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic Pain or Diabetic peripheral neuropathy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of 2 preferred alternatives. FOR PAIN, qualified alternatives include Butrans, Hysingla ER, and Oxycontin. FOR DIABETIC PERIPHERAL NEUROPATHY, qualified alternatives include Cymbalta and Lyrica.
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Nuedexta

Products Affected

- NUEDEXTA

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nuplazid

Products Affected

- NUPLAZID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/Nuplazid.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nutropin AQ NuSpin 10

Products Affected

- NUTROPIN AQ NUSPIN 10

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nutropin AQ NuSpin 20

Products Affected

- NUTROPIN AQ NUSPIN 20

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Nutropin AQ NuSpin 5

Products Affected

- NUTROPIN AQ NUSPIN 5

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NuvaRing

Products Affected

- NUVARING

QL Criteria	1 ring Per 28 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nuvigil

Products Affected

- NUVIGIL

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Nuwiq

Products Affected

- NUWIQ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Nymalize

Products Affected

- NYMALIZE

QL Criteria	135.2 ml Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ocaliva

Products Affected

- OCALIVA ORAL TABLET 5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/Primary_Biliary_Cholangitis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Ocella

Products Affected

- *ocella*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Octagam

Products Affected

- OCTAGAM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Odefsey

Products Affected

- ODEFSEY

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Odomzo

Products Affected

- ODOMZO

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ofev

Products Affected

- OFEV

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Idiopathic_Pulmonary_Fibrosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ogestrel

Products Affected

- *ogestrel*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

OLANZapine

Products Affected

- *olanzapine oral tablet 10 mg, 15 mg, 5 mg, 7.5 mg, 20 mg*
- *olanzapine oral tablet dispersible*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OLANZapine

Products Affected

- *olanzapine oral tablet 2.5 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

OLANZapine-FLUOxetine HCl

Products Affected

- *olanzapine-fluoxetine hcl*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oleptro

Products Affected

- OLEPTRO

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Olysio

Products Affected

- OLYSIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
QL Criteria	1 CAPS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Olysio

Products Affected

- OLYSIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
QL Criteria	1 CAPS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Olysio

Products Affected

- OLYSIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	1 CAPS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 31, 2016 Quantity Limits: August 25, 2015

Omega-3-acid Ethyl Esters

Products Affected

- *omega-3-acid ethyl esters*

QL Criteria	4 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Omeprazole-Sodium Bicarbonate

Products Affected

- *omeprazole-sodium bicarbonate oral packet*

QL Criteria	1 packet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Omeprazole-Sodium Bicarbonate

Products Affected

- *omeprazole-sodium bicarbonate oral packet*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer- reviewed medical literature for use of a higher dose.
QL Criteria	1 packet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Omnaris

Products Affected

- OMNARIS

ST Criteria	Documented trial of 2 weeks each of 1 of the following: trial of Flonase OR Nasalide OR Nasacort 24HR OTC AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

On Call Express Blood Glucose

Products Affected

- ON CALL EXPRESS BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

On Call Plus Blood Glucose

Products Affected

- ON CALL PLUS BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

On Call Vivid Blood Glucose

Products Affected

- ON CALL VIVID BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ondansetron

Products Affected

- *ondansetron*

QL Criteria	12 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ondansetron HCl

Products Affected

- *ondansetron hcl oral tablet 4 mg, 24 mg*

QL Criteria	12 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ondansetron HCl

Products Affected

- *ondansetron hcl oral tablet 8 mg*

QL Criteria	60 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ondansetron HCl

Products Affected

- *ondansetron hcl oral solution*

QL Criteria	1 bottle Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OneTouch Test

Products Affected

- ONETOUCH TEST

QL Criteria	300 strips Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

OneTouch Ultra 2

Products Affected

- ONETOUCH ULTRA 2

QL Criteria	1 KIT Per 365 DAYSS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OneTouch Ultra Blue

Products Affected

- ONETOUCH ULTRA BLUE

QL Criteria	300 strips Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

OneTouch Ultra Mini

Products Affected

- ONETOUCH ULTRA MINI

QL Criteria	1 KIT Per 365 DAYSS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OneTouch Verio

Products Affected

- ONETOUCH VERIO IN VITRO STRIP

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

OneTouch Verio IQ System

Products Affected

- ONETOUCH VERIO IQ SYSTEM

QL Criteria	1 KIT Per 365 DAYSS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Onfi

Products Affected

- ONFI ORAL TABLET 10 MG, 20 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Onglyza

Products Affected

- ONGLYZA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Onsolis

Products Affected

- ONSOLIS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: July 15, 2016 Quantity Limits: August 25, 2015
----------------------	--

Onsolis

Products Affected

- ONSOLIS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Onsolis

Products Affected

- ONSOLIS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	A documented step through one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Onzetra Xsail

Products Affected

- ONZETRA XSAIL

ST Criteria	A documented step through sumatriptan nasal spray
QL Criteria	1 kit Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Opana ER

Products Affected

- OPANA ER ORAL TABLET EXTENDED
RELEASE 12 HR* 30 MG, 20 MG, 5 MG, 10
MG, 40 MG

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Opana ER

Products Affected

- OPANA ER ORAL

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each of two preferred alternatives which include Butrans, Hysingla ER, and Oxycontin
QL Criteria	4 tablets Per 1 day
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Opana ER

Products Affected

- OPANA ER ORAL

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each of two preferred alternatives which include Butrans, Hysingla ER, and Oxycontin
QL Criteria	4 tablets Per 1 DAYS
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Opsumit

Products Affected

- OPSUMIT

QL Criteria	1 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

OptumRx Blood Glucose Test

Products Affected

- OPTUMRX BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oracea

Products Affected

- ORACEA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Oramorph SR

Products Affected

- ORAMORPH SR ORAL TABLET
EXTENDEDRELEASE*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oravig

Products Affected

- ORAVIG

QL Criteria	14 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Orencia

Products Affected

- ORENCIA INTRAVENOUS*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Orencia

Products Affected

- ORENCIA SUBCUTANEOUS*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Orencia ClickJect

Products Affected

- ORENCIA CLICKJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Orencia ClickJect

Products Affected

- ORENCIA CLICKJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Orencia ClickJect

Products Affected

- ORENCIA CLICKJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/viscosupplements.html
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Orenitram

Products Affected

- ORENITRAM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Orkambi

Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Orsythia

Products Affected

- *orsythia*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho Diaphragm All-Flex

Products Affected

- ORTHO DIAPHRAGM ALL-FLEX
VAGINAL DIAPHRAGM 70 MM

QL Criteria	1 device Per 365 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho Micronor

Products Affected

- ORTHO MICRONOR

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ortho Tri-Cyclen (28)

Products Affected

- ORTHO TRI-CYCLEN (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho Tri-Cyclen Lo

Products Affected

- ORTHO TRI-CYCLEN LO

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Cept (28)

Products Affected

- ORTHO-CEPT (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Cyclen (28)

Products Affected

- ORTHO-CYCLEN (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Novum 1/35 (28)

Products Affected

- ORTHO-NOVUM 1/35 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Novum 7/7/7 (28)

Products Affected

- ORTHO-NOVUM 7/7/7 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OrthoVisc

Products Affected

- ORTHOVISC INTRA-ARTICULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oseni

Products Affected

- OSENI

ST Criteria	A documented step through one month each of Invokana/Invokamet and either Januvia/Janumet or Onglyza/Kombiglyze
QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Osphena

Products Affected

- OSPHENA

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Otezla

Products Affected

- OTEZLA ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Otezla

Products Affected

- OTEZLA ORAL 10 & 20 & 30 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ovidrel

Products Affected

- OVIDREL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Oxtellar XR

Products Affected

- OXTELLAR XR ORAL TABLET
EXTENDED RELEASE 24 HR* 150 MG, 300
MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oxtellar XR

Products Affected

- OXTELLAR XR ORAL TABLET
EXTENDED RELEASE 24 HR* 600 MG

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Oxybutynin Chloride

Products Affected

- *oxybutynin chloride oral tablet*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OxyCODONE HCl ER

Products Affected

- *oxycodone hcl er oral 10 mg, 20 mg, 40 mg, 80 mg*

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each of two preferred alternatives which include Butrans, Hysingla ER, and Oxycontin
QL Criteria	4 tablets Per 1 Day
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Oxycodone-Ibuprofen

Products Affected

- *oxycodone-ibuprofen*

QL Criteria	28 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OxyCONTIN

Products Affected

- OXYCONTIN ORAL

QL Criteria	4 tablets Per 1 Day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Oxymorphone HCl ER

Products Affected

- *oxymorphone hcl er*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paliperidone ER

Products Affected

- *paliperidone er oral tablet extended release 24 hr* 9 mg*

QL Criteria	1 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Paliperidone ER

Products Affected

- *paliperidone er oral tablet extended release 24 hr* 1.5 mg, 6 mg, 3 mg*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pancreaze

Products Affected

- PANCREAZE

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Paragard Intrauterine Copper

Products Affected

- PARAGARD INTRAUTERINE COPPER

QL Criteria	1 IUD Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paricalcitol

Products Affected

- *paricalcitol oral*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PARoxetine HCl

Products Affected

- *paroxetine hcl oral tablet 20 mg, 10 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PARoxetine HCl

Products Affected

- *paroxetine hcl oral tablet 40 mg, 30 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

PARoxetine HCl ER

Products Affected

- *paroxetine hcl er oral tablet extended release*
24 hr* 25 mg

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PARoxetine HCl ER

Products Affected

- *paroxetine hcl er oral tablet extended release*
24 hr 37.5 mg, 12.5 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Paxil

Products Affected

- PAXIL ORAL TABLET 10 MG, 20 MG

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paxil

Products Affected

- PAXIL ORAL TABLET 30 MG, 40 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Paxil

Products Affected

- PAXIL ORAL SUSPENSION

QL Criteria	30 ml Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paxil CR

Products Affected

- PAXIL CR ORAL TABLET EXTENDED
RELEASE 24 HR* 25 MG

QL Criteria	3 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Paxil CR

Products Affected

- PAXIL CR ORAL TABLET EXTENDED
RELEASE 24 HR* 12.5 MG

QL Criteria	6 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paxil CR

Products Affected

- PAXIL CR ORAL TABLET EXTENDED
RELEASE 24 HR* 37.5 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

PEG 3350/Electrolytes

Products Affected

- *peg 3350/electrolytes*

QL Criteria	4 liters Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PEG-3350/Electrolytes

Products Affected

- *peg-3350/electrolytes*

QL Criteria	4 liters Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pegasy

Products Affected

- PEGASYS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pegasis ProClick

Products Affected

- PEGASYS PROCLICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PegIntron

Products Affected

- PEGINTRON

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Peg-Intron

Products Affected

- PEG-INTRON

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Peg-Intron Redipen

Products Affected

- PEG-INTRON REDIPEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Peg-Intron Redipen Pak 4

Products Affected

- PEG-INTRON REDIPEN PAK 4

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Pennsaid

Products Affected

- PENNSAID TRANSDERMAL SOLUTION 2
%

ST Criteria	Documented Trial of 1 month of Voltaren Gel
QL Criteria	4 ml Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pentasa

Products Affected

- PENTASA ORAL CAPSULE EXTENDED RELEASE* 500 MG

QL Criteria	8 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Pentasa

Products Affected

- PENTASA ORAL CAPSULE EXTENDED RELEASE* 250 MG

QL Criteria	16 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Perforomist

Products Affected

- PERFOROMIST

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Serevent
QL Criteria	4 milliliters Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Perforomist

Products Affected

- PERFOROMIST

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Trial of one month of Serevent
QL Criteria	4 milliliters Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pertzye

Products Affected

- PERTZYE

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pexeva

Products Affected

- PEXEVA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Philith

Products Affected

- *philith*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Picato

Products Affected

- PICATO EXTERNAL GEL 0.015 %

QL Criteria	3 unit dose tubes Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Picato

Products Affected

- PICATO EXTERNAL GEL 0.05 %

QL Criteria	2 unit dose tubes Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pioglitazone HCl

Products Affected

- *pioglitazone hcl*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pioglitazone HCl-Glimepiride

Products Affected

- *pioglitazone hcl-glimepiride*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Pioglitazone HCl-Metformin HCl

Products Affected

- *pioglitazone hcl-metformin hcl*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plan B One-Step

Products Affected

- PLAN B ONE-STEP

QL Criteria	1 tablet Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plavix

Products Affected

- PLAVIX

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plegridy

Products Affected

- PLEGRIDY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 inj Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Plegridy Starter Pack

Products Affected

- PLEGRIDY STARTER PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 inj Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PocketChem EZ Test

Products Affected

- POCKETCHEM EZ TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Pomalyst

Products Affected

- POMALYST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Portia-28

Products Affected

- *portia-28*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Potiga

Products Affected

- POTIGA ORAL TABLET 300 MG, 200 MG, 400 MG

QL Criteria	3 tablets Per 1 day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Potiga

Products Affected

- POTIGA ORAL TABLET 50 MG

QL Criteria	6 tablets Per 1 day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Pradaxa

Products Affected

- PRADAXA

ST Criteria	Documented step through ELIQUIS and XARELTO
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Praluent

Products Affected

- PRALUENT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCSK9.html
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Praluent

Products Affected

- PRALUENT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Praluent

Products Affected

- PRALUENT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Pramipexole Dihydrochloride ER

Products Affected

- *pramipexole dihydrochloride er*

QL Criteria	1 TAB Per 1 DAILY
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pramipexole Dihydrochloride ER

Products Affected

- *pramipexole dihydrochloride er*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

PrandiMet

Products Affected

- PRANDIMET

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pravachol

Products Affected

- PRAVACHOL ORAL TABLET 40 MG, 20 MG, 80 MG

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Pravastatin Sodium

Products Affected

- *pravastatin sodium*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Precision PCx

Products Affected

- PRECISION PCX

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Precision PCX Plus Test

Products Affected

- PRECISION PCX PLUS TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Precision Point of Care Test

Products Affected

- PRECISION POINT OF CARE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Precision QID Test

Products Affected

- PRECISION QID TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Precision Sof-Tact Test

Products Affected

- PRECISION SOF-TACT TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Precision Xtra

Products Affected

- PRECISION XTRA DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Precision Xtra Blood Glucose

Products Affected

- PRECISION XTRA BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Precision Xtra Monitor

Products Affected

- PRECISION XTRA MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prefest

Products Affected

- PREFEST

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pregnyl

Products Affected

- *pregnyl*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Premarin

Products Affected

- PREMARIN ORAL

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Premphase

Products Affected

- PREMPHASE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prempro

Products Affected

- PREMPRO

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prestige Smart System Test

Products Affected

- *prestige smart system test*

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prestige Test

Products Affected

- PRESTIGE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Prevacid

Products Affected

- PREVACID ORAL CAPSULE DELAYED
RELEASE 30 MG

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prevacid

Products Affected

- PREVACID ORAL CAPSULE DELAYED
RELEASE 15 MG

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Prevacid 24HR

Products Affected

- PREVACID 24HR

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prevacid SoluTab

Products Affected

- PREVACID SOLUTAB

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer- reviewed medical literature for use of a higher dose.
ST Criteria	Documented step through 2 generic PPI or OTC (i.e. omeprazole, pantoprazole, esomeprazole, lansoprazole, Prevacid 24H, Nexium)
QL Criteria	2 tablets Per 1 Day
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prevacid SoluTab

Products Affected

- PREVACID SOLUTAB

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer-reviewed medical literature for use of a higher dose.
ST Criteria	A documented step through 2 generic RX or OTC proton pump inhibitors (i.e. esomeprazole mag, lansoprazole, omeprazole, pantoprazole, rabeprazole)
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Previfem

Products Affected

- *previfem*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prezista

Products Affected

- PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prezista

Products Affected

- PREZISTA ORAL TABLET 800 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Prezista

Products Affected

- PREZISTA ORAL SUSPENSION

QL Criteria	12 milliliters Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PriLOSEC

Products Affected

- PRILOSEC ORAL PACKET

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Treatment and maintenance of GERD and its complications (e.g. esophageal strictures, Barrett's Esophagus, erosive esophagitis, ulcers), Peptic ulcer disease, GI bleeds, Treatment of gastroduodenal ulcers, Pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome), Preventative needs (i.e. chronic oral steroid use, post transplant, NSAID use, chemotherapy or radiation therapy, etc), Helicobacter pylori eradication, additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required. In addition, for approval of Aciphex Sprinkle and Prevacid Solutab the following criteria must also be met: inability to swallow tablets/capsules, and a trial/failure or intolerance to either Nexium granules, Prilosec (capsules may be opened and sprinkled on 1 tablespoon of applesauce), or Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), or the member is an infant (1 month to 1 year of age) and has a documented contraindication or intolerance or allergy or failure of an adequate trial of one month of Nexium granules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet ANY of the following criteria: Member has a diagnosis of a pathological hypersecretory condition (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasia type 1 (MEN-1), or member is being treated for Barrett's esophagus, or member is being treated for eradication of H. pylori (triple therapy only, 30-day duration), or member has refractory gastroesophageal reflux disease (GERD) (defined as continued symptoms despite PPI therapy) and has had at least 4 weeks of once daily PPI therapy taken 30-60 min before a meal (any meal) and is experiencing acid breakthrough, or member's physician provides documentation (controlled clinical trial) from the peer-reviewed medical literature for use of a higher dose.</p>
Notes/References	
Revision Date	<p>Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

PriLOSEC OTC

Products Affected

- PRILOSEC OTC

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Pristiq

Products Affected

- PRISTIQ

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Procardia XL

Products Affected

- PROCARDIA XL ORAL TABLET
EXTENDED RELEASE 24 HR* 30 MG

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Procardia XL

Products Affected

- PROCARDIA XL ORAL TABLET
EXTENDED RELEASE 24 HR* 90 MG, 60
MG

QL Criteria	2 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ProCentra

Products Affected

- PROCENTRA

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of ADHD or Narcolepsy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	40 milliliters Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Procrit

Products Affected

- PROCIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html
QL Criteria	8 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 75 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
QL Criteria	25 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	8 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 75 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	25 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
QL Criteria	8 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 75 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html
QL Criteria	25 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Prodigy AutoCode Blood Glucose

Products Affected

- PRODIGY AUTOCODE BLOOD GLUCOSE
IN VITRO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Prodigy AutoCode Blood Glucose

Products Affected

- PRODIGY AUTOCODE BLOOD GLUCOSE KIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prodigy AutoCode Blood Glucose

Products Affected

- PRODIGY AUTOCODE BLOOD GLUCOSE DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Prodigy No Coding Blood Gluc

Products Affected

- PRODIGY NO CODING BLOOD GLUC

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Profilnine

Products Affected

- PROFILNINE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Profilnine SD

Products Affected

- PROFILNINE SD

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Progesterone Micronized

Products Affected

- *progesterone micronized oral*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Prolia

Products Affected

- PROLIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Promacta

Products Affected

- PROMACTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/promacta.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Promacta

Products Affected

- PROMACTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/promacta.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prometrium

Products Affected

- PROMETRIUM

QL Criteria	2 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Propafenone HCl ER

Products Affected

- *propafenone hcl er*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Protopic

Products Affected

- PROTOPIC

PA Criteria	Criteria Details
Covered Uses	Atopic dermatitis, Vitiligo
Exclusion Criteria	
Required Medical Information	FOR PROTOPIC 0.1%: A documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or an adolescent 16 years of age or older with either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas. FOR PROTOPIC 0.03%: A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required) or a documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or child 2 years of age or older and either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 26, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Protopic

Products Affected

- PROTOPIC

PA Criteria	Criteria Details
Covered Uses	Atopic dermatitis, Vitiligo
Exclusion Criteria	
Required Medical Information	FOR PROTOPIC 0.1%: A documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or an adolescent 16 years of age or older with either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas. FOR PROTOPIC 0.03%: A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required) or a documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or child 2 years of age or older and either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through 2 weeks (14 days) of one preferred alternative topical corticosteroid (triamcinolone acetonide, fluocinonide cream, augmented betamethasone gel, betamethasone dipropionate, hydrocortisone valerate, or fluticasone propionate ointment)
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 26, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015
----------------------	---

Proventil HFA

Products Affected

- PROVENTIL HFA

ST Criteria	Documented step through one week each of VENTOLIN HFA AND PROAIR
Notes/ References	Annual Review: 03/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Provigil

Products Affected

- PROVIGIL

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Provigil

Products Affected

- PROVIGIL

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	2 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

PROzac

Products Affected

- PROZAC ORAL CAPSULE 40 MG

QL Criteria	2 cap Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PROzac

Products Affected

- PROZAC ORAL CAPSULE 20 MG

QL Criteria	4 cap Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PROzac

Products Affected

- PROZAC ORAL CAPSULE 10 MG

QL Criteria	1 cap Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PROzac Weekly

Products Affected

- PROZAC WEEKLY

QL Criteria	0.15 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

PTS Panels Glucose Test

Products Affected

- PTS PANELS GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pulmicort

Products Affected

- PULMICORT

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	For ages 5-8 documented inability to use metered dose inhalers
Age Restrictions	Less than 8 years of age
Prescriber Restrictions	
Coverage Duration	Up to the age of 8
Other Criteria	No prior authorization required for children 1-4 years of age. Medical Exception for Pulmicort Respules: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Pulmicort Flexhaler

Products Affected

- PULMICORT FLEXHALER

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
ST Criteria	Documented step through one month of ASMANEX AND QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pulmozyme

Products Affected

- PULMOZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 ampules Per 1 day
Notes/References	
Revision Date	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Purixan

Products Affected

- PURIXAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3.5 ML Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Qbrelis

Products Affected

- QBRELIS

PA Criteria	Criteria Details
Covered Uses	Hypertension, Heart Failure, Myocardial Infarction
Exclusion Criteria	
Required Medical Information	A documented diagnosis of hypertension (Approved only for ages 6 and older), Heart failure, or Myocardial Infarction AND must have a documented inability to swallow tablets/capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Qnasl

Products Affected

- QNASL

ST Criteria	A documented step through 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Quartette

Products Affected

- QUARTETTE

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Quasense

Products Affected

- *quasense*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Qudexy XR

Products Affected

- QUDEXY XR ORAL 200 MG, 150 MG

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Qudexy XR

Products Affected

- QUDEXY XR ORAL 100 MG, 25 MG, 50 MG

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 200 mg*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 50 mg, 100 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 400 mg, 300 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 25 mg*

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QuickTek Test

Products Affected

- QUICKTEK TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

QuilliChew ER

Products Affected

- QUILLICHEW ER ORAL 20 MG, 40 MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QuilliChew ER

Products Affected

- QUILLICHEW ER ORAL 30 MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Quillivant XR

Products Affected

- QUILLIVANT XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	12 milliliters Per 1 day
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QuiNINE Sulfate

Products Affected

- *quinine sulfate oral*

QL Criteria	42 capsule Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Quintet AC Blood Glucose Test

Products Affected

- QUINTET AC BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Quintet Blood Glucose Test

Products Affected

- QUINTET BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RA Blood Glucose Monitor

Products Affected

- *ra blood glucose monitor*

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RA Nicotine

Products Affected

- *ra nicotine transdermal*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RA TRUEtest Test

Products Affected

- RA TRUETEST TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RABEprazole Sodium

Products Affected

- *rabeprazole sodium*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ranexa

Products Affected

- RANEXA

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ravicti

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	20 bottles Per 30 months
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rayos

Products Affected

- RAYOS

ST Criteria	Documented step through PREDNISONE
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Razadyne

Products Affected

- RAZADYNE ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rebetol

Products Affected

- REBETOL ORAL SOLUTION

QL Criteria	5 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Reclipsen

Products Affected

- *reclipsen*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Recombinate

Products Affected

- RECOMBINATE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rectiv

Products Affected

- RECTIV

QL Criteria	1 tube Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RefuAH Plus Blood Glucose Test

Products Affected

- REFUAH PLUS BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Relenza Diskhaler

Products Affected

- RELENZA DISKHALER

QL Criteria	40 disks Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ReliOn Prime Monitor

Products Affected

- RELION PRIME MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Relistor

Products Affected

- RELISTOR SUBCUTANEOUS* SOLUTION
8 MG/0.4ML

PA Criteria	Criteria Details
Covered Uses	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
Exclusion Criteria	
Required Medical Information	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	0.4 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Relistor

Products Affected

- RELISTOR SUBCUTANEOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
Exclusion Criteria	
Required Medical Information	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	0.2 ml Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Relistor

Products Affected

- RELISTOR SUBCUTANEOUS* SOLUTION
12 MG/0.6ML

PA Criteria	Criteria Details
Covered Uses	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
Exclusion Criteria	
Required Medical Information	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	0.6 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Relpax

Products Affected

- RELPAX

QL Criteria	6 tablets Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Remeron

Products Affected

- REMERON

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Remeron SolTab

Products Affected

- REMERON SOLTAB

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Remodulin

Products Affected

- REMODULIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Repaglinide-Metformin HCl

Products Affected

- *repaglinide-metformin hcl*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Repatha

Products Affected

- REPATHA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCSK9.html
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Repatha

Products Affected

- REPATHA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

Repatha

Products Affected

- REPATHA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Repatha Pushtronex System

Products Affected

- REPATHA PUSHTRONEX SYSTEM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 syringe Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Repatha SureClick

Products Affected

- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Repatha SureClick

Products Affected

- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Repatha SureClick

Products Affected

- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/PCSK9.html
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Repronex

Products Affected

- REPRONEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/infertility.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Requip XL

Products Affected

- REQUIP XL

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rescula

Products Affected

- RESCULA

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rescula

Products Affected

- RESCULA

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Restoril

Products Affected

- RESTORIL ORAL CAPSULE 22.5 MG, 7.5 MG

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Retin-A

Products Affected

- RETIN-A

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Retin-A Micro

Products Affected

- RETIN-A MICRO

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Retin-A Micro Pump

Products Affected

- RETIN-A MICRO PUMP

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revatio

Products Affected

- REVATIO ORAL SUSPENSION
RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Revatio

Products Affected

- REVATIO ORAL SUSPENSION
RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Revatio

Products Affected

- REVATIO ORAL SUSPENSION
RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Revatio

Products Affected

- REVATIO ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revatio

Products Affected

- REVATIO INTRAVENOUS*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Revatio

Products Affected

- REVATIO ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CV/pulmonaryhypertensionagents.html
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revatio

Products Affected

- REVATIO ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Reveal Blood Glucose Test

Products Affected

- REVEAL BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Revlimid

Products Affected

- REVLIMID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rexulti

Products Affected

- REXULTI

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder, Schizophrenia
Exclusion Criteria	
Required Medical Information	Documented diagnosis of major depressive disorder or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	FOR MAJOR DEPRESSIVE DISORDER: Trial of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine). FOR SCHIZOPHRENIA: Trial of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine) and Latuda.
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Reyataz

Products Affected

- REYATAZ ORAL CAPSULE 150 MG, 300 MG

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Reyataz

Products Affected

- REYATAZ ORAL CAPSULE 200 MG

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RiaSTAP

Products Affected

- RIASTAP

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rightest GS100 Blood Glucose

Products Affected

- RIGHTEST GS100 BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rightest GS300 Blood Glucose

Products Affected

- RIGHTEST GS300 BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rightest GS550 Blood Glucose

Products Affected

- RIGHTEST GS550 BLOOD GLUCOSE

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rilutek

Products Affected

- RILUTEK

PA Criteria	Criteria Details
Covered Uses	amyotrophic lateral sclerosis (ALS)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of amyotrophic lateral sclerosis (ALS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Riluzole

Products Affected

- *riluzole*

PA Criteria	Criteria Details
Covered Uses	amyotrophic lateral sclerosis (ALS)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of amyotrophic lateral sclerosis (ALS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Risedronate Sodium

Products Affected

- *risedronate sodium oral tablet 150 mg*

ST Criteria	A documented step through alendronate 70mg
QL Criteria	1 tablet Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Risedronate Sodium

Products Affected

- *risedronate sodium oral tablet 5 mg, 30 mg*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Risedronate Sodium

Products Affected

- *risedronate sodium oral tablet 35 mg*
- *risedronate sodium oral tablet delayed release*

QL Criteria	4 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Risedronate Sodium

Products Affected

- *risedronate sodium oral tablet 150 mg*

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	1 tablet Per 1 month
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RisperDAL

Products Affected

- RISPERDAL ORAL TABLET 3 MG, 0.25 MG, 0.5 MG, 1 MG, 2 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL

Products Affected

- RISPERDAL ORAL TABLET 4 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	4 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RisperDAL

Products Affected

- RISPERDAL ORAL SOLUTION

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL M-TAB

Products Affected

- RISPERDAL M-TAB ORAL TABLET
DISPERSIBLE 0.5 MG, 1 MG, 2 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RisperDAL M-TAB

Products Affected

- RISPERDAL M-TAB ORAL TABLET
DISPERSIBLE 4 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL M-TAB

Products Affected

- RISPERDAL M-TAB ORAL TABLET
DISPERSIBLE 3 MG

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperidONE

Products Affected

- *risperidone oral tablet 2 mg, 0.25 mg, 0.5 mg, 1 mg*
- *risperidone oral tablet dispersible 0.5 mg, 1 mg, 2 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperidONE

Products Affected

- *risperidone oral tablet dispersible 4 mg*
- *risperidone oral tablet 4 mg*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RisperiDONE

Products Affected

- *risperidone oral tablet 3 mg*
- *risperidone oral tablet dispersible 3 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE M-TAB

Products Affected

- RISPERIDONE M-TAB ORAL TABLET
DISPERSIBLE 1 MG, 0.5 MG, 2 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

RisperiDONE M-TAB

Products Affected

- RISPERIDONE M-TAB ORAL TABLET
DISPERSIBLE 3 MG

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE M-TAB

Products Affected

- RISPERIDONE M-TAB ORAL TABLET
DISPERSIBLE 4 MG

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ritalin

Products Affected

- RITALIN

QL Criteria	6 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ritalin LA

Products Affected

- RITALIN LA ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 10 MG, 30 MG

QL Criteria	2 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ritalin LA

Products Affected

- RITALIN LA ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 60 MG

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ritalin LA

Products Affected

- RITALIN LA ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 40 MG, 20 MG

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rivastigmine

Products Affected

- *rivastigmine*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rivastigmine Tartrate

Products Affected

- *rivastigmine tartrate*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rixubis

Products Affected

- RIXUBIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rizatriptan Benzoate

Products Affected

- *rizatriptan benzoate*

QL Criteria	9 tablets Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ROPINIRole HCl ER

Products Affected

- *ropinirole hcl er oral tablet extended release*
24 hr* 2 mg, 6 mg, 8 mg, 4 mg

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ROPINIRole HCl ER

Products Affected

- *ropinirole hcl er oral tablet extended release*
24 hr 12 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rosuvastatin Calcium

Products Affected

- *rosuvastatin calcium*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rozerem

Products Affected

- ROZEREM

ST Criteria	Documentation of a trial and failure with Ambien IR (zolpidem tartrate) or Sonata (zalelpon)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rozerem

Products Affected

- ROZEREM

ST Criteria	A documented step through zolpidem, zaleplon, or eszopiclone
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Ruconest

Products Affected

- RUCONEST

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/hereditary_angi_oedema.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Rythmol SR

Products Affected

- RYTHMOL SR

QL Criteria	2 CP12 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sabril

Products Affected

- SABRIL

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sabril

Products Affected

- SABRIL

QL Criteria	6 packets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Safyral

Products Affected

- SAFYRAL

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Saizen

Products Affected

- SAIZEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Samsca

Products Affected

- SAMSCA ORAL TABLET 15 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/samsca.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Samsca

Products Affected

- SAMSCA ORAL TABLET 30 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/samsca.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sanctura

Products Affected

- SANCTURA

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sanctura XR

Products Affected

- SANCTURA XR

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sancuso

Products Affected

- SANCUSO

QL Criteria	1 patch Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Saphris

Products Affected

- SAPHRIS

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Savaysa

Products Affected

- SAVAYSA

ST Criteria	Documented Trial of Eliquis AND Xarelto
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Savella

Products Affected

- SAVELLA

QL Criteria	2 tablets Per 1 day
Notes/ References	Annual Review: 03/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Savella Titration Pack

Products Affected

- SAVELLA TITRATION PACK

QL Criteria	2 tablets Per 1 day
Notes/ References	Annual Review: 03/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Seebri Neohaler

Products Affected

- SEEBRI NEOHALER

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Trial of 1 month each of Spiriva and Incruse Ellipta
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Selzentry

Products Affected

- SELZENTRY ORAL TABLET 150 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sensipar

Products Affected

- SENSIPAR

PA Criteria	Criteria Details
Covered Uses	Documented diagnosis of hyperparathyroidism & parathyroid carcinoma or other FDA approved indication
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Serevent Diskus

Products Affected

- SEREVENT DISKUS

QL Criteria	2 blisters Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

SEROquel

Products Affected

- SEROQUEL ORAL TABLET 200 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	4 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel

Products Affected

- SEROQUEL ORAL TABLET 25 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	6 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

SEROquel

Products Affected

- SEROQUEL ORAL TABLET 300 MG, 400 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel

Products Affected

- SEROQUEL ORAL TABLET 50 MG, 100 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	3 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel XR

Products Affected

- SEROQUEL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 50 MG, 300
MG, 400 MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder, Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder, Bipolar Disorder or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	FOR MAJOR DEPRESSIVE DISORDER: Trial of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine). FOR SCHIZOPHRENIA: Trial of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine) and Latuda.
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel XR

Products Affected

- SEROQUEL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 150 MG, 200
MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder, Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder, Bipolar Disorder or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	FOR MAJOR DEPRESSIVE DISORDER: Trial of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine). FOR SCHIZOPHRENIA: Trial of one atypical generic antipsychotic (i.e. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine) and Latuda.
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Serostim

Products Affected

- SEROSTIM SUBCUTANEOUS* SOLUTION
RECONSTITUTED 5 MG, 4 MG, 6 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sertraline HCl

Products Affected

- *sertraline hcl oral tablet 100 mg*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sertraline HCl

Products Affected

- *sertraline hcl oral tablet 25 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sertraline HCl

Products Affected

- *sertraline hcl oral concentrate*

QL Criteria	10 ml Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sertraline HCl

Products Affected

- *sertraline hcl oral tablet 50 mg*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sharobel

Products Affected

- SHAROBEL

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Signifor

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ENDO/Signifor.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 SOLN Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Signifor LAR

Products Affected

- SIGNIFOR LAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ENDO/Signifor.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 EA Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sildenafil Citrate

Products Affected

- *sildenafil citrate oral*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Simcor

Products Affected

- SIMCOR ORAL TABLET EXTENDED
RELEASE 24 HR* 1000-20 MG, 500-20 MG,
750-20 MG

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Simcor

Products Affected

- SIMCOR ORAL TABLET EXTENDED
RELEASE 24 HR* 1000-40 MG, 500-40 MG

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Simponi

Products Affected

- SIMPONI SUBCUTANEOUS*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 syringe Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Simponi Aria

Products Affected

- SIMPONI ARIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 vial Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Simvastatin

Products Affected

- *simvastatin oral*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Singular

Products Affected

- SINGULAIR

QL Criteria	1 PACK Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Singular

Products Affected

- SINGULAIR

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sirturo

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Covered Uses	Multi-drug resistant tuberculosis
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 years or greater
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
QL Criteria	188 EA Per 365 Days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Skyla

Products Affected

- SKYLA

QL Criteria	1 IUD Per 365 DAYs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

SM Nicotine

Products Affected

- *sm nicotine transdermal*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Smart Sense Value Test

Products Affected

- SMART SENSE VALUE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Smartest Blood Glucose Test

Products Affected

- SMARTEST BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Smartest Eject

Products Affected

- SMARTEST EJECT

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Smartest Protege

Products Affected

- SMARTEST PROTEGE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sodium Phenylbutyrate

Products Affected

- *sodium phenylbutyrate oral powder 3 gm/tsp*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Solaraze

Products Affected

- SOLARAZE

QL Criteria	200 gm Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Solia

Products Affected

- *solia*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Soliris

Products Affected

- SOLIRIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/soliris.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Solus V2 Test

Products Affected

- SOLUS V2 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Somavert

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sonata

Products Affected

- SONATA ORAL CAPSULE 5 MG

QL Criteria	3 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sonata

Products Affected

- SONATA ORAL CAPSULE 10 MG

QL Criteria	2 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Soolantra

Products Affected

- SOOLANTRA

ST Criteria	A documented trial of one month each of any of the preferred topical generic alternatives, metronidazole OR sulfacetamide sodium with sulfu
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Soriatane

Products Affected

- SORIATANE ORAL CAPSULE 10 MG, 17.5 MG, 25 MG

QL Criteria	2 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sovaldi

Products Affected

- SOVALDI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Spiriva HandiHaler

Products Affected

- SPIRIVA HANDIHALER

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Spiriva Respimat

Products Affected

- SPIRIVA RESPIMAT

QL Criteria	1 inhaler Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sporanox

Products Affected

- SPORANOX ORAL CAPSULE

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sporanox Pulsepak

Products Affected

- SPORANOX PULSEPAK

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sprintec 28

Products Affected

- *sprintec 28*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Spritam

Products Affected

- SPRITAM

ST Criteria	Documented trial and failure of immediate release levitiracetam tablets
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sprix

Products Affected

- SPRIX

QL Criteria	5 UD sprays Per 30 DAYs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 80 MG, 70 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 140 MG, 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 80 MG, 50 MG, 70 MG, 20 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 20 MG, 50 MG, 80 MG, 70 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 140 MG, 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Sronyx

Products Affected

- *sronyx*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Stelara

Products Affected

- STELARA SUBCUTANEOUS*

QL Criteria	1 syringe Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Stiolto Respimat

Products Affected

- STIOLTO RESPIMAT

QL Criteria	1 inhaler Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Stivarga

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Strattera

Products Affected

- STRATTERA

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Strensiq

Products Affected

- STRENSIQ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Striant

Products Affected

- STRIANT

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Stribild

Products Affected

- STRIBILD

PA Criteria	Criteria Details
Covered Uses	A documented diagnosis of human immunodeficiency virus (HIV), and a documented viral load assay AND CD4 count indicating that the patient is stable on Stribild (stable or increase in CD4 counts AND viral load less than 50 copies/ml) (FOR renewals/continuations ONLY). For treatment naïve patients only, a documented resistance test within the past 3 months demonstrating virologic susceptibility to all of the following components of Stribild: elvitegravir, emtricitabine, and tenofovir AND A documented contraindication or intolerance or allergy or failure of an adequate trial of one month of one of the preferred regimens: 1) Triumeq (dolutegravir/abacavir/lamivudine) OR 2) Tivicay (dolutegravir) plus Truvada (tenofovir disoproxil fumarate/emtricitabine) OR 3) Isentress (Raltegravir) plus Truvada (tenofovir disoproxil fumarate/emtricitabine) OR 4) Prezista (Darunavir) plus Norvir (ritonavir) plus Truvada (tenofovir disoproxil fumarate/emtricitabine).
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 Years
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 27, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Striverdi Respimat

Products Affected

- STRIVERDI RESPIMAT

QL Criteria	1 inhaler Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Suboxone

Products Affected

- SUBOXONE SUBLINGUAL FILM 2-0.5 MG, 4-1 MG, 8-2 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	3 films Per 1 day
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Suboxone

Products Affected

- SUBOXONE SUBLINGUAL FILM 12-3 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	2 films Per 1 day
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Suboxone

Products Affected

- SUBOXONE SUBLINGUAL TABLET
SUBLINGUAL

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Subsys

Products Affected

- SUBSYS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	A documented step through one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)
QL Criteria	8 sprays Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Subsys

Products Affected

- SUBSYS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	A documented step through one week each of fentanyl transmucosal lozenge and two other short acting opioids (i.e., morphine, hydrocodone, oxycodone, hydromorphone)
QL Criteria	8 sprays Per 1 DAYS

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Subsys

Products Affected

- SUBSYS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	8 sprays Per 1 DAYS

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: July 15, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Subsys

Products Affected

- SUBSYS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	8 sprays Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Subsys

Products Affected

- SUBSYS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	8 sprays Per 1 DAYS

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Subsys

Products Affected

- SUBSYS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))
ST Criteria	Documented trial or intolerance to two (2) immediate-release opioids (morphine, hydrocodone, oxycodone, or hydromorphone) AND fentanyl citrate lozenge
QL Criteria	8 sprays Per 1 Day

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: July 15, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sular

Products Affected

- SULAR ORAL TABLET EXTENDED
RELEASE 24 HR* 8.5 MG, 17 MG, 34 MG

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SulfaSALazine

Products Affected

- *sulfasalazine oral*

QL Criteria	8 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sulfazine

Products Affected

- *sulfazine*

QL Criteria	8 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sulfazine EC

Products Affected

- SULFAZINE EC

QL Criteria	8 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

SUMAtriptan

Products Affected

- *sumatriptan nasal*

QL Criteria	3 nasal sprays Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SUMAtriptan Succinate

Products Affected

- *sumatriptan succinate subcutaneous* 4 mg/0.5ml, 6 mg/0.5ml*
- *sumatriptan succinate subcutaneous* solution 4 mg/0.5ml*

QL Criteria	2 boxes (4 doses) Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

SUMAtriptan Succinate

Products Affected

- *sumatriptan succinate oral*

QL Criteria	9 tablets Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SUMAtriptan Succinate

Products Affected

- *sumatriptan succinate subcutaneous* solution*
6 mg/0.5ml

QL Criteria	5 vials Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

SUMatriptan Succinate Refill

Products Affected

- *sumatriptan succinate refill subcutaneous**

QL Criteria	2 boxes (4 doses) Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sumavel DosePro

Products Affected

- SUMAVEL DOSEPRO SUBCUTANEOUS* 4
MG/0.5ML

QL Criteria	6 injections Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Supartz

Products Affected

- SUPARTZ INTRA-ARTICULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Supreme Test

Products Affected

- SUPREME TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sure Edge Glucose Monitor

Products Affected

- SURE EDGE GLUCOSE MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sure Edge Test

Products Affected

- SURE EDGE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

SureChek Blood Glucose Monitor

Products Affected

- SURECHEK BLOOD GLUCOSE MONITOR
DEVICE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SureChek Blood Glucose Test

Products Affected

- SURECHEK BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sure-Test EasyPlus Mini Meter

Products Affected

- SURE-TEST EASYPLUS MINI METER

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sure-Test EasyPlus Mini Test

Products Affected

- SURE-TEST EASYPLUS MINI TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Sutent

Products Affected

- SUTENT

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Syeda

Products Affected

- *syeda*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sylatron

Products Affected

- SYLATRON SUBCUTANEOUS* KIT 200 MCG, 4 X 200 MCG, 4 X 300 MCG, 300 MCG, 600 MCG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Symbicort

Products Affected

- SYMBICORT

QL Criteria	1 inhaler Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Symbyax

Products Affected

- SYMBYAX ORAL CAPSULE 6-25 MG, 6-50 MG, 12-50 MG, 12-25 MG

QL Criteria	1 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Symlin

Products Affected

- SYMLIN

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes, Type 2 Diabetes
Exclusion Criteria	Poor compliance with current insulin regimen, poor compliance with prescribed self-blood glucose monitoring, an A1C greater than 9%, recurrent severe hypoglycemia requiring assistance during the previous 6 months, presence of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, need for medications that stimulate GI motility, patient is less than 18 years old, concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
Required Medical Information	A documented diagnosis of type I or type II diabetes and concurrent use of a rapid or short-acting insulin i.e., Humalog or regular insulin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 Months (initial)
Other Criteria	12 month extended approval if patient has demonstrated expected reduction in HbA1c since starting therapy.
Notes/References	Annual Review: 05/2016
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

SymlinPen 120

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS*

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes, Type 2 Diabetes
Exclusion Criteria	Poor compliance with current insulin regimen, poor compliance with prescribed self-blood glucose monitoring, an A1C greater than 9%, recurrent severe hypoglycemia requiring assistance during the previous 6 months, presence of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, need for medications that stimulate GI motility, patient is less than 18 years old, concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
Required Medical Information	A documented diagnosis of type I or type II diabetes and concurrent use of a rapid or short-acting insulin i.e., Humalog or regular insulin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 Months (initial)
Other Criteria	12 month extended approval if patient has demonstrated expected reduction in HbA1c since starting therapy.
Notes/References	Annual Review: 05/2016
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SymlinPen 60

Products Affected

- SYMLINPEN 60 SUBCUTANEOUS*

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes, Type 2 Diabetes
Exclusion Criteria	Poor compliance with current insulin regimen, poor compliance with prescribed self-blood glucose monitoring, an A1C greater than 9%, recurrent severe hypoglycemia requiring assistance during the previous 6 months, presence of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, need for medications that stimulate GI motility, patient is less than 18 years old, concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
Required Medical Information	A documented diagnosis of type I or type II diabetes and concurrent use of a rapid or short-acting insulin i.e., Humalog or regular insulin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 Months (initial)
Other Criteria	12 month extended approval if patient has demonstrated expected reduction in HbA1c since starting therapy.
Notes/References	Annual Review: 05/2016
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Synagis

Products Affected

- SYNAGIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/Synagis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Synjardy

Products Affected

- SYNJARDY

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Synribo

Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Synribo

Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Synribo

Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Synvisc

Products Affected

- SYNVISC INTRA-ARTICULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Synvisc One

Products Affected

- SYNVISC ONE INTRA-ARTICULAR*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Taclonex

Products Affected

- TACLONEX EXTERNAL OINTMENT

ST Criteria	Documented trial and failure of 1 medium to high potency steroid indicated for patients condition.
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tacrolimus

Products Affected

- *tacrolimus external*

PA Criteria	Criteria Details
Covered Uses	Atopic dermatitis, Vitiligo
Exclusion Criteria	
Required Medical Information	FOR PROTOPIC 0.1%: A documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or an adolescent 16 years of age or older with either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas. FOR PROTOPIC 0.03%: A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required) or a documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or child 2 years of age or older and either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through 2 weeks (14 days) of one preferred alternative topical corticosteroid (triamcinolone acetonide, fluocinonide cream, augmented betamethasone gel, betamethasone dipropionate, hydrocortisone valerate, or fluticasone propionate ointment)
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 26, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015
----------------------	---

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tacrolimus

Products Affected

- *tacrolimus external*

PA Criteria	Criteria Details
Covered Uses	Atopic dermatitis, Vitiligo
Exclusion Criteria	
Required Medical Information	FOR PROTOPIC 0.1%: A documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or an adolescent 16 years of age or older with either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas. FOR PROTOPIC 0.03%: A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required) or a documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or child 2 years of age or older and either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition
Notes/References	

Revision Date	Prior Authorization: April 26, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tafinlar

Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tagrisso

Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Take Action

Products Affected

- *take action*

QL Criteria	1 tablet Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Taltz

Products Affected

- TALTZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tamiflu

Products Affected

- TAMIFLU ORAL CAPSULE

QL Criteria	20 capsules Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tamiflu

Products Affected

- TAMIFLU ORAL SUSPENSION
RECONSTITUTED 6 MG/ML

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tanzeum

Products Affected

- TANZEUM

ST Criteria	Trial and failure of 1 month each of Victoza and Trulicity
QL Criteria	4 pens Per 1 month
Notes/ References	Annual Review: 02/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tarceva

Products Affected

- TARCEVA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tasigna

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ANEOPL/Antineoplastics.html
QL Criteria	4 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Tasigna

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
QL Criteria	4 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Tasigna

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	4 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Tazorac

Products Affected

- TAZORAC EXTERNAL GEL 0.05 %
- TAZORAC EXTERNAL CREAM 0.1 %

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris, plaque psoriasis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Acne Vulgaris or plaque psoriasis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tazorac

Products Affected

- TAZORAC EXTERNAL CREAM 0.05 %
- TAZORAC EXTERNAL GEL 0.1 %

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris, plaque psoriasis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Acne Vulgaris or plaque psoriasis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through RETIN-A
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tazorac

Products Affected

- TAZORAC EXTERNAL GEL 0.1 %
- TAZORAC EXTERNAL CREAM 0.05 %

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris, plaque psoriasis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Acne Vulgaris or plaque psoriasis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through Epiduo
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Taztia XT

Products Affected

- *taztia xt oral capsule extended release 24 hour*
240 mg

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Taztia XT

Products Affected

- *taztia xt oral capsule extended release 24 hour*
360 mg, 300 mg, 120 mg, 180 mg

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tecfidera

Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Tecfidera

Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Tecfidera

Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tecfidera

Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
QL Criteria	2 CPDR Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Tecfidera

Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 CPDR Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

Tecfidera

Products Affected

- TECFIDERA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
QL Criteria	2 CPDR Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Technivie

Products Affected

- TECHNIVIE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Technivie

Products Affected

- TECHNIVIE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Technivie

Products Affected

- TECHNIVIE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 31, 2016 Quantity Limits: August 25, 2015

Tekamlo

Products Affected

- TEKAMLO

ST Criteria	Documented step thru 2 preferred ACE-I or ARB . Formulary Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations include: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril),Univasc (moexipril). Formulary Angiotensin Receptor Blocker (ARB) & ARB combinations include: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tekturna

Products Affected

- TEKTURNA

ST Criteria	Documented step thru 2 preferred ACE-I or ARB . Formulary Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations include: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril),Univasc (moexipril). Formulary Angiotensin Receptor Blocker (ARB) & ARB combinations include: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tekturna HCT

Products Affected

- TEKTURNA HCT

ST Criteria	Documented step thru 2 preferred ACE-I or ARB . Formulary Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations include: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril),Univasc (moexipril). Formulary Angiotensin Receptor Blocker (ARB) & ARB combinations include: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Telcare Blood Glucose Test

Products Affected

- TELCARE BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Telmisartan

Products Affected

- *telmisartan*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Telmisartan-Amlodipine

Products Affected

- *telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg*

ST Criteria	Documented step through AMLODIPINE in combination with TWO of the following (brand or generic if available): ATACAND, AVAPRO, COZAAR, MICARDIS
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Telmisartan-Amlodipine

Products Affected

- *telmisartan-amlodipine oral tablet 80-10 mg, 80-5 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Telmisartan-HCTZ

Products Affected

- *telmisartan-hctz*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Temazepam

Products Affected

- *temazepam oral capsule 22.5 mg, 7.5 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Temozolomide

Products Affected

- *temozolomide*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Testim

Products Affected

- TESTIM

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
QL Criteria	10 grams Per 1 fill
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Testosterone

Products Affected

- *testosterone transdermal gel 12.5 mg/act (1%), 25 mg/2.5gm (1%), 10 mg/act (2%), 50 mg/5gm (1%)*

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	10 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Testosterone Cypionate

Products Affected

- *testosterone cypionate intramuscular* solution*
100 mg/ml

QL Criteria	10 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Testosterone Cypionate

Products Affected

- *testosterone cypionate intramuscular* solution*
200 mg/ml

QL Criteria	10 ml Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Testosterone Cypionate

Products Affected

- *testosterone cypionate intramuscular* solution*
250 mg/ml

QL Criteria	4 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tetrabenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg*

QL Criteria	8 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tetrabenazine

Products Affected

- *tetrabenazine oral tablet 25 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Teveten HCT

Products Affected

- TEVETEN HCT ORAL TABLET 600-25 MG

ST Criteria	Documented step through TWO of the following: ATACAND HCT*, AVALIDE*, HYZAAR*, MICARDIS HCT*
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Teveten HCT

Products Affected

- TEVETEN HCT ORAL TABLET 600-25 MG

ST Criteria	A documented step through one month each of any two preferred alternatives from the following: candesartan/hctz, eprosartan/hctz, irbesartan/hctz, losartan/hctz, telmisartan/hctz, or valsartan/hctz
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Teveten HCT

Products Affected

- TEVETEN HCT ORAL TABLET 600-12.5 MG

ST Criteria	A documented step through one month each of any two preferred alternatives from the following: candesartan/hctz, eprosartan/hctz, irbesartan/hctz, losartan/hctz, telmisartan/hctz, or valsartan/hctz
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Tev-Tropin

Products Affected

- TEV-TROPIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

TGT Blood Glucose Monitoring

Products Affected

- TGT BLOOD GLUCOSE MONITORING

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TGT Nicotine Step One

Products Affected

- *tgt nicotine step one*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TGT Nicotine Step Three

Products Affected

- *tgt nicotine step three*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TGT Nicotine Step Two

Products Affected

- *tgt nicotine step two*

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Thrive

Products Affected

- *thrive mouth/throat gum 2 mg*

QL Criteria	24 EA Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TiaGABine HCl

Products Affected

- *tia gabine hcl oral tablet 2 mg*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

TiaGABine HCl

Products Affected

- *tia gabine hcl oral tablet 4 mg*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tiazac

Products Affected

- TIAZAC ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 120 MG, 180 MG, 360
MG, 300 MG, 420 MG

QL Criteria	1 CP24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tiazac

Products Affected

- TIAZAC ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 240 MG

QL Criteria	2 CP24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tilia Fe

Products Affected

- *tilia fe*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tirosint

Products Affected

- TIROSINT

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tivicay

Products Affected

- TIVICAY

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tivicay

Products Affected

- TIVICAY

QL Criteria	2 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tivorbex

Products Affected

- TIVORBEX

QL Criteria	3 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tobi

Products Affected

- TOBI

QL Criteria	56 ML Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tobi Podhaler

Products Affected

- TOBI PODHALER

QL Criteria	1 CAPS Per 28 DAYs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tobramycin

Products Affected

- *tobramycin inhalation*

QL Criteria	10 ml Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tolterodine Tartrate ER

Products Affected

- *tolterodine tartrate er*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Topamax Sprinkle

Products Affected

- TOPAMAX SPRINKLE

QL Criteria	4 CPSP Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Topicort Spray

Products Affected

- TOPICORT SPRAY

QL Criteria	100 ML Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Topiramate

Products Affected

- *topiramate oral capsule sprinkle*

QL Criteria	4 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Toprol XL

Products Affected

- TOPROL XL ORAL TABLET EXTENDED
RELEASE 24 HR* 200 MG

QL Criteria	2 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Toprol XL

Products Affected

- TOPROL XL ORAL TABLET EXTENDED
RELEASE 24 HR* 100 MG, 50 MG

QL Criteria	1.5 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Toprol XL

Products Affected

- TOPROL XL ORAL TABLET EXTENDED
RELEASE 24 HR* 25 MG

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Toujeo SoloStar

Products Affected

- TOUJEO SOLOSTAR

ST Criteria	A documented step through one month each of Levemir and Tresiba
Notes/ References	Annual Review: 03/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Toviaz

Products Affected

- TOVIAZ

ST Criteria	Documented trial of 2 preferred alternatives: Vesicare OR Myrbetriq AND one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Toviaz

Products Affected

- TOVIAZ

ST Criteria	A documented step through Vesicare and Myrbetriq and one generic (i.e. trospium, trospium ER, tolterodine, Tolterodine ER, oxybutynin, oxybutynin XL)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Tradjenta

Products Affected

- TRADJENTA

QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

TraMADol HCl ER

Products Affected

- *tramadol hcl er oral capsule extended release*
24 hour 100 mg, 200 mg, 300 mg

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TraMADol HCl ER

Products Affected

- *tramadol hcl er oral tablet extended release 24 hr**

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

TraMADol HCl ER (Biphasic)

Products Affected

- *tramadol hcl er (biphasic)*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tramadol-Acetaminophen

Products Affected

- *tramadol-acetaminophen*

QL Criteria	8 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tranexamic Acid

Products Affected

- *tranexamic acid oral*

QL Criteria	30 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Travoprost

Products Affected

- *travoprost*

ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tretinoin

Products Affected

- *tretinoin external cream*
- *tretinoin external gel 0.025 %*

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	50 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tretinoin

Products Affected

- *tretinoin external gel 0.01 %*

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tretinoin Microsphere

Products Affected

- *tretinoin microsphere*

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tretinoin Microsphere Pump

Products Affected

- *tretinoin microsphere pump*

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tretin-X

Products Affected

- TRETIN-X EXTERNAL KIT 0.05 %
CREAM, 0.025 % CREAM, 0.1 % CREAM

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through Epiduo
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Tretin-X

Products Affected

- TRETIN-X EXTERNAL KIT 0.05 %
CREAM, 0.025 % CREAM, 0.1 % CREAM

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through RETIN-A
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tretin-X

Products Affected

- TRETIN-X EXTERNAL CREAM 0.0375 %

ST Criteria	A documented step through Epiduo
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Tretin-X

Products Affected

- TRETIN-X EXTERNAL CREAM 0.075 %

PA Criteria	Criteria Details
Covered Uses	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
Exclusion Criteria	
Required Medical Information	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
Age Restrictions	Prior authorization only applies for members greater than 35 years of age
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Tretten

Products Affected

- TRETEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tribenzor

Products Affected

- TRIBENZOR

ST Criteria	Documented step through AMLODIPINE in combination with TWO of the following: ATACAND HCT, AVALIDE, HYZAAR, MICARDIS HCT
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tricor

Products Affected

- TRICOR

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Triglide

Products Affected

- TRIGLIDE ORAL TABLET 160 MG

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tri-Legest Fe

Products Affected

- *tri-legest fe*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Linyah

Products Affected

- *tri-linyah*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trilipix

Products Affected

- TRILIPIX

QL Criteria	1 CPDR Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TriNessa (28)

Products Affected

- *trinessa (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Norinyl (28)

Products Affected

- TRI-NORINYL (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trintellix

Products Affected

- TRINTELLIX

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass: Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam Step Therapy is required
ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	1 tablet Per 1 Day
Notes/References	

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Tri-Previfem

Products Affected

- *tri-previfem*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Sprintec

Products Affected

- *tri-sprintec*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Triumeq

Products Affected

- TRIUMEQ

QL Criteria	1 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Trivora (28)

Products Affected

- *trivora (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trokendi XR

Products Affected

- TROKENDI XR

QL Criteria	1 CP24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Trospium Chloride

Products Affected

- *trospium chloride*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trospium Chloride ER

Products Affected

- *trospium chloride er*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

True Metrix Blood Glucose Test

Products Affected

- TRUE METRIX BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TRUE2go Blood Glucose Monitor

Products Affected

- TRUE2GO BLOOD GLUCOSE MONITOR

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

TRUEresult Blood Glucose

Products Affected

- TRUERESULT BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TRUEtest Test

Products Affected

- TRUETEST TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

TrueTrack Blood Glucose

Products Affected

- TRUETRACK BLOOD GLUCOSE KIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TrueTrack Smart System

Products Affected

- TRUETRACK SMART SYSTEM

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYSS
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

TrueTrack Test

Products Affected

- TRUETRACK TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trulicity

Products Affected

- TRULICITY

QL Criteria	4 injections Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tudorza Pressair

Products Affected

- TUDORZA PRESSAIR INHALATION
AEROSOL POWDER, BREATH
ACTIVATED 400 MCG/ACT

ST Criteria	Trial of 1 month each of Spiriva and Incruse Ellipta
QL Criteria	1 inhaler Per 30 fills
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TussiCaps

Products Affected

- TUSSICAPS

QL Criteria	20 capsules Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Twynsta

Products Affected

- TWYNSTA

ST Criteria	Documented step through AMLODIPINE in combination with TWO of the following (brand or generic if available): ATACAND, AVAPRO, COZAAR, MICARDIS
QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tybost

Products Affected

- TYBOST

QL Criteria	1 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tykerb

Products Affected

- TYKERB

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tysabri

Products Affected

- TYSABRI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Tysabri

Products Affected

- TYSABRI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tysabri

Products Affected

- TYSABRI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 10, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Tyvaso

Products Affected

- TYVASO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 SOLN Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tyvaso Refill

Products Affected

- TYVASO REFILL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Tyvaso Starter

Products Affected

- TYVASO STARTER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tyzeka

Products Affected

- TYZEKA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Uceris

Products Affected

- UCERIS ORAL

ST Criteria	A documented trial of Asacol HD, Delzicol, Lialda or Pentasa
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Uceris

Products Affected

- UCERIS

PA Criteria	Criteria Details
Covered Uses	Active mild to moderate ulcerative colitis
Exclusion Criteria	
Required Medical Information	A documented diagnosis of ACTIVE mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge, requiring induction of remission.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 canisters Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Ulesfia

Products Affected

- ULESFIA

QL Criteria	3 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Uloric

Products Affected

- ULORIC

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ultima Test

Products Affected

- ULTIMA TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ultracet

Products Affected

- ULTRACET

QL Criteria	8 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ultram ER

Products Affected

- ULTRAM ER ORAL TABLET EXTENDED
RELEASE 24 HR* 300 MG, 100 MG

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ultram ER

Products Affected

- ULTRAM ER ORAL TABLET EXTENDED
RELEASE 24 HR* 200 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

UltraTRAK Active

Products Affected

- ULTRATRAK ACTIVE

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

UltraTRAK PRO

Products Affected

- ULTRATRAK PRO

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

UltraTRAK PRO Test

Products Affected

- ULTRATRAK PRO TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

UltraTRAK Ultimate Monitor

Products Affected

- ULTRATRAK ULTIMATE MONITOR

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

UltraTRAK Ultimate Test

Products Affected

- ULTRATRAK ULTIMATE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ultresa

Products Affected

- ULTRESA

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Unistrip1 Generic

Products Affected

- UNISTRIP1 GENERIC

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Uptravi

Products Affected

- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 800 MCG, 1600 MCG, 400 MCG, 600 MCG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Uptravi

Products Affected

- UPTRAVI ORAL
- UPTRAVI ORAL TABLET 200 MCG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Utibron Neohaler

Products Affected

- UTIBRON NEOHALER

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Valchlor

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 GM Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Valcyte

Products Affected

- VALCYTE ORAL TABLET

QL Criteria	102 EA Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ValGANciclovir HCl

Products Affected

- *valganciclovir hcl oral tablet*

QL Criteria	102 TABS Per 30 DAYSs
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Valsartan

Products Affected

- *valsartan*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Valsartan-Hydrochlorothiazide

Products Affected

- *valsartan-hydrochlorothiazide*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Varubi

Products Affected

- VARUBI

QL Criteria	4 tablets Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vascepa

Products Affected

- VASCEPA

QL Criteria	4 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vecamyl

Products Affected

- VECAMYL

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of trial and failure with four antihypertensive drugs from at least three different therapeutic subclasses, and documentation of moderately severe to severe hypertension (blood pressure greater than or equal to 160/100 mmHg) or documentation of malignant hypertension without complications (blood pressure greater or equal to 180/120 mmHg) with retinal hemorrhages, exudates, or papilledema
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Examples of antihypertensive drugs listed by therapeutic subclasses:DIURETICS: HydroDiuril, Microzide (hydrochlorothiazide), Hygroton (chlorthalidone), Diuril (chlorthiazide), Lasix (furosemide), Midamor (amiloride), Dyazide, Maxzide (triamterene-hydrochlorothiazide). BETA BLOCKERS: Tenormin (atenolol), Toprol XL (metoprolol succinate), Lopressor (metoprolol tartrate), Zebeta (bisoprolol), Coreg (carvedilol), Inderal LA (propranolol). CALCIUM CHANNEL BLOCKERS: Adalat CC, Procardia XL (nifedipine), Calan, Isoptin, Verelan (verapamil), Cardizem, Cartia (diltiazem), Norvasc (amlodipine), Sular (nisoldipine), Plendil (felodipine). ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEI) & ACEI COMBINATIONS: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril),Univasc (moexipril). ANGIOTENSION RECEPTOR BLOCKER (ARB) & ARB COMBINATIONS: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
QL Criteria	10 tabs Per 1 DAYS

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Notes/ References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Veletri

Products Affected

- VELETRI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Velivet

Products Affected

- *velivet*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Veltassa

Products Affected

- VELTASSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Veltassa.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 packet Per 1 day
Notes/References	
Revision Date	Prior Authorization: February 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Veltin

Products Affected

- VELTIN

ST Criteria	A documented step through Epiduo
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Venclexta

Products Affected

- VENCLEXTA ORAL TABLET 50 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Venclexta.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Venclexta

Products Affected

- VENCLEXTA ORAL TABLET 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Venclexta.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venclexta

Products Affected

- VENCLEXTA ORAL TABLET 10 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Venclexta.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	40 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Venclexta Starting Pack

Products Affected

- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Venclexta.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 pack Per 28 days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 37.5 mg*

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 75 mg*

QL Criteria	5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 25 mg, 100 mg*

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 50 mg*

QL Criteria	6 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 150 mg*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral tablet extended release*
24 hr 150 mg*

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral tablet extended release*
24 hr* 225 mg, 37.5 mg, 75 mg

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 75 mg, 37.5 mg*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ventavis

Products Affected

- VENTAVIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Veramyst

Products Affected

- VERAMYST

ST Criteria	A documented step through 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Verapamil HCl ER

Products Affected

- *verapamil hcl er oral capsule extended release*
24 hour 200 mg

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Verapamil HCl ER

Products Affected

- *verapamil hcl er oral capsule extended release*
24 hour 300 mg, 100 mg

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Versacloz

Products Affected

- VERSACLOZ

ST Criteria	Documented step through Clozaril tablets
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

VESIcare

Products Affected

- VESICARE

ST Criteria	Documented trial of 1 preferred generic (i.e. tiroprium, tiroprium ER, tolterodine, Tolterodine ER, oxybutynin)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vestura

Products Affected

- *vestura*

QL Criteria	1.5 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viberzi

Products Affected

- VIBERZI

PA Criteria	Criteria Details
Covered Uses	Diarrhea-predominant irritable bowel syndrome (IBS)
Exclusion Criteria	No known or suspected history of any of the following: diagnosis of pancreatitis, diagnosis of alcoholism, member drinks more than 3 alcoholic beverages/day, severe (Child-Pugh C) hepatic impairment, or anatomic or biochemical abnormalities of the gastrointestinal tract (e.g., biliary duct obstruction, sphincter of Oddi dysfunction, or severe constipation)
Required Medical Information	
Age Restrictions	A documented diagnosis of diarrhea-predominant irritable bowel syndrome (IBS)
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Victory AGM-4000 Test

Products Affected

- VICTORY AGM-4000 TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Victory Blood Glucose System

Products Affected

- VICTORY BLOOD GLUCOSE SYSTEM

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Victoza

Products Affected

- VICTOZA SUBCUTANEOUS*

QL Criteria	1 box-2 or 3 pens Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Victrelis

Products Affected

- VICTRELIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	10 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 31, 2016 Quantity Limits: August 25, 2015

Victrelis

Products Affected

- VICTRELIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
QL Criteria	10 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Victrelis

Products Affected

- VICTRELIS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
QL Criteria	10 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Viekira Pak

Products Affected

- VIEKIRA PAK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Viekira Pak

Products Affected

- VIEKIRA PAK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 31, 2016 Quantity Limits: August 25, 2015

Viekira Pak

Products Affected

- VIEKIRA PAK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Viekira XR

Products Affected

- VIEKIRA XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viekira XR

Products Affected

- VIEKIRA XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 31, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Viekira XR

Products Affected

- VIEKIRA XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/GI/hepatitis_c.html
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Viibryd

Products Affected

- VIIBRYD ORAL TABLET

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Viibryd

Products Affected

- VIIBRYD ORAL TABLET

QL Criteria	1 tablet Per 1 day
Notes/ References	Annual Review: 05/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vimizim

Products Affected

- VIMIZIM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vimovo

Products Affected

- VIMOVO

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vimpat

Products Affected

- VIMPAT ORAL SOLUTION

QL Criteria	40 ML Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vimpat

Products Affected

- VIMPAT ORAL TABLET

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viokace

Products Affected

- VIOKACE

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Viorele

Products Affected

- *viorele*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viramune XR

Products Affected

- VIRAMUNE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 100 MG

QL Criteria	3 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Viramune XR

Products Affected

- VIRAMUNE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 400 MG

QL Criteria	1 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viread

Products Affected

- VIREAD ORAL TABLET

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vistogard

Products Affected

- VISTOGARD

QL Criteria	20 packs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vivelle

Products Affected

- VIVELLE

QL Criteria	8 patches Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vivelle-Dot

Products Affected

- VIVELLE-DOT

QL Criteria	8 patches Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vivlodex

Products Affected

- VIVLODEX

ST Criteria	Trial of one month each of two generic non steroidal anti-inflammatory drugs
QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vocal Point Blood Glucose Test

Products Affected

- VOCAL POINT BLOOD GLUCOSE TEST

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vogelxo

Products Affected

- VOGELXO TRANSDERMAL GEL 50 MG/5GM (1%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
QL Criteria	10 grams Per 1 DAYS
Notes/References	Annual Review: 02/2016

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Vogelxo Pump

Products Affected

- VOGELXO PUMP

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through one month of Androgel 1.62%
QL Criteria	10 grams Per 1 DAYS
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

Voltaren

Products Affected

- VOLTAREN TRANSDERMAL

QL Criteria	5 tubes-500 grams Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vonvendi

Products Affected

- VONVENDI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Votrient

Products Affected

- VOTRIENT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vpriv

Products Affected

- VPRIV

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vraylar

Products Affected

- VRAYLAR ORAL

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vraylar

Products Affected

- VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vraylar

Products Affected

- VRAYLAR ORAL CAPSULE 3 MG

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	2 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vraylar

Products Affected

- VRAYLAR ORAL CAPSULE 1.5 MG

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	4 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vytorin

Products Affected

- VYTORIN

ST Criteria	A documented step through one generic statin medication (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin) and Zetia
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Vytorin

Products Affected

- VYTORIN

ST Criteria	Documented step through ZOCOR 80MG
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Vytorin

Products Affected

- VYTORIN

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vyvanse

Products Affected

- VYVANSE

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

WaveSense KeyNote Pro Meter

Products Affected

- WAVESENSE KEYNOTE PRO METER

QL Criteria	1 meter Per 1 year
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

WaveSense Presto

Products Affected

- WAVESENSE PRESTO

QL Criteria	300 strips Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Wellbutrin

Products Affected

- WELLBUTRIN

QL Criteria	6 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wellbutrin SR

Products Affected

- WELLBUTRIN SR

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Wellbutrin XL

Products Affected

- WELLBUTRIN XL

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wera

Products Affected

- *wera*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Wide-Seal Diaphragm 60

Products Affected

- WIDE-SEAL DIAPHRAGM 60

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wide-Seal Diaphragm 65

Products Affected

- WIDE-SEAL DIAPHRAGM 65

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wide-Seal Diaphragm 70

Products Affected

- WIDE-SEAL DIAPHRAGM 70

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wide-Seal Diaphragm 75

Products Affected

- WIDE-SEAL DIAPHRAGM 75

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Wide-Seal Diaphragm 80

Products Affected

- WIDE-SEAL DIAPHRAGM 80

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wide-Seal Diaphragm 85

Products Affected

- WIDE-SEAL DIAPHRAGM 85

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Wide-Seal Diaphragm 90

Products Affected

- WIDE-SEAL DIAPHRAGM 90

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wide-Seal Diaphragm 95

Products Affected

- WIDE-SEAL DIAPHRAGM 95

QL Criteria	1 diaphragm Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wilate

Products Affected

- WILATE INTRAVENOUS* SOLUTION RECONSTITUTED 1000-1000 UNIT, 500-500 UNIT
- WILATE INTRAVENOUS* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wymzya Fe

Products Affected

- *wymzya fe*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xalatan

Products Affected

- XALATAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Xalatan

Products Affected

- XALATAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xalkori

Products Affected

- XALKORI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xanax XR

Products Affected

- XANAX XR

QL Criteria	2 TB24 Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xartemis XR

Products Affected

- XARTEMIS XR

ST Criteria	Documented step through TWO of the following: MORPHINE, OXYCODONE, HYDROMORPHONE
QL Criteria	4 tablets Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xeljanz

Products Affected

- XELJANZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Xeljanz XR

Products Affected

- XELJANZ XR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xenazine

Products Affected

- XENAZINE ORAL TABLET 12.5 MG

QL Criteria	8 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xenazine

Products Affected

- XENAZINE ORAL TABLET 25 MG

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xeomin

Products Affected

- XEOMIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xgeva

Products Affected

- XGEVA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xifaxan

Products Affected

- XIFAXAN ORAL TABLET 550 MG

QL Criteria	3 tablets Per 1 Day
Notes/ References	Annual Review: 04/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xifaxan

Products Affected

- XIFAXAN ORAL TABLET 200 MG

QL Criteria	9 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xigduo XR

Products Affected

- XIGDUO XR ORAL TABLET EXTENDED
RELEASE 24 HR* 10-1000 MG, 10-500 MG,
5-500 MG

QL Criteria	1 TAB Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xigduo XR

Products Affected

- XIGDUO XR ORAL TABLET EXTENDED
RELEASE 24 HR* 5-1000 MG

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xiidra

Products Affected

- XIIDRA

PA Criteria	Criteria Details
Covered Uses	Treatment of the signs and symptoms of dry eye disease (DED)
Exclusion Criteria	
Required Medical Information	A documented diagnosis of dry eye disease (DED)
Age Restrictions	Not covered if less than 17 years old. Dry eye disease does not routinely occur in children. Safety and efficacy in pediatric patients below the age of 17 years has not been studied.
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	A documented step through Restasis
QL Criteria	2 vials Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xolair

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xopenex HFA

Products Affected

- XOPENEX HFA

ST Criteria	Documented step through one week each of VENTOLIN HFA AND PROAIR
QL Criteria	2 inhalers Per 1 fill
Notes/ References	Annual Review: 03/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xtampza ER

Products Affected

- XTAMPZA ER

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each of two preferred alternatives which include Butrans, Hysingla ER, and Oxycontin
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xtandi

Products Affected

- XTANDI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xulane

Products Affected

- XULANE

QL Criteria	1 box (3 patches) Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xuriden

Products Affected

- XURIDEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 packets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Xyntha

Products Affected

- XYNTHA INTRAVENOUS* KIT 1000 UNIT, 500 UNIT, 2000 UNIT, 250 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xyntha Solofuse

Products Affected

- XYNTHA SOLOFUSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Xyrem

Products Affected

- XYREM

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Cataplexy associated with narcolepsy
Exclusion Criteria	
Required Medical Information	FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN ASSOCIATION WITH NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of narcolepsy, such as MSLT, clinical progress notes, and documentation of failure of an adequate trial of at least two of the immediate release stimulants (Dexedrine, Ritalin, Adderall), and documentation of failure of an adequate trial of Nuvigil. FOR THE TREATMENT OF CATAPLEXY IN ASSOCIATION WITH NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of narcolepsy, such as MSLT, clinical progress notes, and documentation of failure of an adequate trial of at least two of the immediate release stimulants (Dexedrine, Ritalin, Adderall), and documentation of failure of an adequate trial of an antidepressant.
Age Restrictions	
Prescriber Restrictions	Sleep specialist, pulmonologist, neurologist, or psychiatrist
Coverage Duration	3 months, extended approval based on therapeutic response
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xyzal

Products Affected

- XYZAL ORAL TABLET

QL Criteria	1 TABS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Yasmin 28

Products Affected

- YASMIN 28

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

YAZ

Products Affected

- YAZ

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Yervoy

Products Affected

- YERVOY

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/ANEOPL/yervoy.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zaleplon

Products Affected

- *zaleplon*

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zarah

Products Affected

- *zarah*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zavesca

Products Affected

- ZAVESCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
QL Criteria	3 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Zavesca

Products Affected

- ZAVESCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/lysosomal_storage.html
QL Criteria	3 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Zavesca

Products Affected

- ZAVESCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html
QL Criteria	3 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Zecuity

Products Affected

- ZECUITY

QL Criteria	4 patches Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zegerid OTC

Products Affected

- ZEGERID OTC

QL Criteria	1 capsule Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zelapar

Products Affected

- ZELAPAR

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zelboraf

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zembrace SymTouch

Products Affected

- ZEMBRACE SYMTOUCH

ST Criteria	Documented trial and failure of generic Imitrex injection
QL Criteria	8 syringes Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zemplar

Products Affected

- ZEMPLAR ORAL

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zenatane

Products Affected

- *zenatane oral capsule 20 mg, 10 mg, 40 mg*

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
QL Criteria	2 capsules Per 1 DAYS
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zenchant

Products Affected

- *zenchant*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zenchant FE

Products Affected

- *zenchant fe*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zepatier

Products Affected

- ZEPATIER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnnonmedicare/data/2016/GI/hepatitis_c.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Zetia

Products Affected

- ZETIA

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zetonna

Products Affected

- ZETONNA

ST Criteria	A documented step through 2 weeks of flunisolide or mometasone and either OTC Nasacort 24HR or Flonase OTC
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ziana

Products Affected

- ZIANA

ST Criteria	A documented step through Epiduo
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

Zinbryta

Products Affected

- ZINBRYTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 injection Per 30 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zioptan

Products Affected

- ZIOPTAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zioptan

Products Affected

- ZIOPTAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma, ocular hypertension
Exclusion Criteria	
Required Medical Information	Documented diagnosis of glaucoma or ocular hypertension
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	A documented step through one week of latanoprost and one week of Travatan Z
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: May 28, 2016 Step Therapy: September 27, 2016 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Ziprasidone HCl

Products Affected

- *ziprasidone hcl*

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zocor

Products Affected

- ZOCOR

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zofran

Products Affected

- ZOFRAN ORAL TABLET 8 MG

QL Criteria	60 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zohydro ER

Products Affected

- ZOHYDRO ER

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	A documented step through one month each of two preferred alternatives which include Butrans, Hysingla ER, and Oxycontin
QL Criteria	2 capsules Per 1 Day
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Zolinza

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZOLMitriptan

Products Affected

- *zolmitriptan oral tablet dispersible 5 mg*
- *zolmitriptan oral tablet 5 mg*

QL Criteria	30 tablet Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ZOLMitriptan

Products Affected

- *zolmitriptan oral tablet 2.5 mg*

QL Criteria	3 tablets Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZOLMitriptan

Products Affected

- *zolmitriptan oral tablet dispersible 2.5 mg*

QL Criteria	6 tablets Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zoloft

Products Affected

- ZOLOFT ORAL TABLET 25 MG

QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zoloft

Products Affected

- ZOLOFT ORAL TABLET 100 MG

QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zoloft

Products Affected

- ZOLOFT ORAL TABLET 50 MG

QL Criteria	1.5 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zolpidem Tartrate

Products Affected

- *zolpidem tartrate oral*

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zolpidem Tartrate

Products Affected

- *zolpidem tartrate sublingual*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zolpidem Tartrate ER

Products Affected

- *zolpidem tartrate er*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zomacton

Products Affected

- ZOMACTON

ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Zometa

Products Affected

- ZOMETA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zomig

Products Affected

- ZOMIG NASAL SOLUTION 5 MG

QL Criteria	1 box (6 doses) Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zomig

Products Affected

- ZOMIG ORAL

QL Criteria	3 tablets Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zomig ZMT

Products Affected

- ZOMIG ZMT

QL Criteria	3 tablets Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zontivity

Products Affected

- ZONTIVITY

QL Criteria	1 tablet Per 1 Day
Notes/ References	Annual Review: 06/2016
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zorbtive

Products Affected

- ZORBTIVE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2017/ENDO/growthhormone.html
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 21, 2016 Quantity Limits: August 25, 2015

Zorbtive

Products Affected

- ZORBTIVE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Zorbtive

Products Affected

- ZORBTIVE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	pending
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: September 16, 2016 Quantity Limits: August 25, 2015

Zorvolex

Products Affected

- ZORVOLEX

QL Criteria	3 CAPS Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zovia 1/35E (28)

Products Affected

- *zovia 1/35e (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zovia 1/50E (28)

Products Affected

- *zovia 1/50e (28)*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zubsolv

Products Affected

- ZUBSOLV

PA Criteria	Criteria Details
Covered Uses	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
ST Criteria	A documented step through one month each of the preferred alternatives, buprenorphine-naloxone sublingual tablet and Suboxone SL film
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 04/2016
Revision Date	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

Zurampic

Products Affected

- ZURAMPIC

ST Criteria	A documented step through allopurinol or febuxostat
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zyban

Products Affected

- ZYBAN

QL Criteria	2 tablet Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zydelig

Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zykadia

Products Affected

- ZYKADIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	5 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

ZyPREXA

Products Affected

- ZYPREXA ORAL TABLET 7.5 MG, 5 MG, 15 MG, 20 MG, 10 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZyPREXA

Products Affected

- ZYPREXA ORAL TABLET 2.5 MG

ST Criteria	A documented step through one generic medication such as aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, or clozapine and Latuda
QL Criteria	2 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ZyPREXA Zydys

Products Affected

- ZYPREXA ZYDIS

ST Criteria	A documented step through aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone er, clozapine, or Latuda
QL Criteria	1 tabs Per 1 DAYS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zytiga

Products Affected

- ZYTIGA

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

Zyvox

Products Affected

- ZYVOX ORAL SUSPENSION
RECONSTITUTED

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zyvox

Products Affected

- ZYVOX ORAL TABLET

QL Criteria	28 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Index

ABILIFY DISCMELT	4	ADALAT CC ORAL TABLET EXTENDED	
ABILIFY ORAL SOLUTION	1	RELEASE 24 HR* 90 MG, 30 MG	55
ABILIFY ORAL TABLET	2	ADCIRCA	56
ABILIFY ORAL TABLET	3	ADCIRCA	57
ABSORICA	5	ADCIRCA	58
ABSTRAL	6	ADDERALL	59
ABSTRAL	8	ADDERALL XR	60
ABSTRAL	10	<i>adefovir dipivoxil</i>	61
<i>acamprosate calcium</i>	12	ADEMPAS	62
ACCU-CHEK ACTIVE	13	ADEMPAS	63
ACCU-CHEK ADVANTAGE TEST	14	ADEMPAS	64
ACCU-CHEK AVIVA IN VITRO STRIP	15	ADOXA ORAL CAPSULE	65
ACCU-CHEK AVIVA PLUS	16	ADOXA ORAL TABLET 50 MG	65
ACCU-CHEK AVIVA PLUS IN VITRO	17	ADRENACLICK INJECTION	66
ACCU-CHEK COMFORT CURVE IN VITRO		ADVAIR DISKUS INHALATION AEROSOL	
STRIP	18	POWDER, BREATH ACTIVATED 100-50	
ACCU-CHEK COMPACT	19	MCG/DOSE, 250-50 MCG/DOSE	67
ACCU-CHEK COMPACT PLUS	20	ADVAIR DISKUS INHALATION AEROSOL	
ACCU-CHEK COMPACT PLUS CARE	21	POWDER, BREATH ACTIVATED 500-50	
ACCU-CHEK COMPACT TEST DRUM	22	MCG/DOSE	68
ACCU-CHEK MULTICLIX LANCET DEV	23	ADVAIR HFA	69
ACCU-CHEK NANO SMARTVIEW	24	ADVANCE INTUITION METER	70
ACCU-CHEK SMARTVIEW	25	ADVANCE INTUITION TEST	71
ACCU-CHEK VOICEMATE	26	ADVANCE MICRO-DRAW TEST	72
ACCUTREND GLUCOSE	27	ADVATE	73
ACIPHEX	28	ADVICOR ORAL TABLET EXTENDED	
ACIPHEX	30	RELEASE 24 HR* 1000-20 MG	76
ACIPHEX SPRINKLE	32	ADVICOR ORAL TABLET EXTENDED	
ACIPHEX SPRINKLE	34	RELEASE 24 HR* 1000-40 MG, 500-20 MG	74
<i>acitretin</i>	36	ADVICOR ORAL TABLET EXTENDED	
ACTEMRA INTRAVENOUS*	37	RELEASE 24 HR* 750-20 MG	75
ACTEMRA SUBCUTANEOUS*	38	ADVOCATE BLOOD GLUCOSE MONITOR	
ACTIQ	39	77
ACTIQ	41	ADVOCATE DUO DEVICE	78
ACTIVELLA	43	ADVOCATE REDI-CODE DEVICE	80
ACTONEL ORAL TABLET 150 MG	45	ADVOCATE REDI-CODE IN VITRO	79
ACTONEL ORAL TABLET 150 MG	49	ADVOCATE REDI-CODE+	81
ACTONEL ORAL TABLET 30 MG, 5 MG	46	ADVOCATE REDI-CODE+ TEST	82
ACTONEL ORAL TABLET 35 MG	44	ADVOCATE TEST	83
ACTONEL ORAL TABLET 35 MG	47	<i>adynovate</i>	84
ACTONEL ORAL TABLET 5 MG, 30 MG	48	ADZENYS XR-ODT	85
ACTOPLUS MET	50	AEROSPAN	86
ACTOPLUS MET XR	51	<i>afeditab cr oral tablet extended release 24 hr* 30</i>	
ACTOS	52	<i>mg</i>	87
ACURA BLOOD GLUCOSE TEST	53	<i>afeditab cr oral tablet extended release 24 hr* 60</i>	
ADALAT CC ORAL TABLET EXTENDED		<i>mg</i>	88
RELEASE 24 HR* 60 MG	54	AFINITOR	89
		AFINITOR DISPERZ	90

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
 Updated 10/2016
 Next expected update 11/2016

AFREZZA	91	ANDRODERM TRANSDERMAL PATCH 24 HR	
AFREZZA	92	2 MG/24HR, 4 MG/24HR	139
AFSTYLA	93	ANDRODERM TRANSDERMAL PATCH 24 HR	
AGAMATRIX AMP TEST	94	5 MG/24HR, 2.5 MG/24HR	140
AGAMATRIX JAZZ TEST	95	ANDROGEL PUMP TRANSDERMAL GEL 12.5	
AGAMATRIX KEYNOTE TEST	96	MG/ACT (1%)	147
AGAMATRIX PRESTO	97	ANDROGEL PUMP TRANSDERMAL GEL	
AGAMATRIX PRESTO PRO METER	98	20.25 MG/ACT (1.62%)	149
AGAMATRIX PRESTO TEST	99	ANDROGEL TRANSDERMAL GEL 20.25	
AKYNZEO	100	MG/1.25GM (1.62%)	141
ALDARA	101	ANDROGEL TRANSDERMAL GEL 25	
ALDURAZYME	102	MG/2.5GM (1%)	142
ALECENSA	103	ANDROGEL TRANSDERMAL GEL 40.5	
<i>alendronate sodium oral tablet 35 mg</i>	104	MG/2.5GM (1.62%)	144
<i>alendronate sodium oral tablet 5 mg, 40 mg, 10 mg</i>		ANDROGEL TRANSDERMAL GEL 50	
.....	105	MG/5GM (1%)	145
<i>alfuzosin hcl er</i>	106	ANGELIQ	150
<i>almotriptan malate</i>	107	ANORO ELLIPTA	151
<i>alogliptin benzoate</i>	108	ANTARA ORAL CAPSULE 30 MG, 90 MG ..	152
<i>alogliptin-metformin hcl</i>	109	ANZEMET ORAL	153
<i>alogliptin-pioglitazone</i>	110	<i>apap-caff-dihydrocodeine oral capsule</i>	154
ALORA	111	APIDRA	155
<i>alosectron hcl</i>	112	APIDRA SOLOSTAR SUBCUTANEOUS* ..	156
<i>alosectron hcl</i>	113	APLENZIN	157
ALPHANATE/VWF COMPLEX/HUMAN	114	<i>apri</i>	158
ALPHANINE SD	115	APRISO	159
<i>alprazolam er</i>	116	APTENSIO XR	160
<i>alprazolam xr</i>	117	APTIOM ORAL TABLET 400 MG, 800 MG ..	161
ALPROLIX	118	APTIOM ORAL TABLET 600 MG, 200 MG ..	162
<i>altavera</i>	119	<i>aranelle</i>	163
ALTOPREV	120	ARANESP (ALBUMIN FREE) INJECTION ..	164
ALVESCO	121	ARANESP (ALBUMIN FREE) INJECTION	
<i>alyacen 1/35</i>	122	SOLUTION 10 MCG/0.4ML, 60 MCG/ML, 25	
<i>alyacen 7/7/7</i>	123	MCG/ML, 300 MCG/ML, 40 MCG/ML, 100	
AMBIEN CR	126	MCG/ML, 200 MCG/ML, 150 MCG/0.75ML ..	164
AMBIEN ORAL TABLET 10 MG	124	ARAVA	165
AMBIEN ORAL TABLET 5 MG	125	ARCALYST	166
AMERGE	127	ARCAPTA NEOHALER	167
<i>amethia</i>	128	ARCAPTA NEOHALER	168
<i>amethia lo</i>	129	ARICEPT	169
<i>amethyst</i>	130	ARICEPT ODT	170
AMITIZA	131	<i>aripiprazole oral solution</i>	172
<i>amlodipine besylate-valsartan</i>	132	<i>aripiprazole oral tablet</i>	171
<i>amlodipine-valsartan-hctz</i>	133	<i>aripiprazole oral tablet dispersible</i>	171
<i>amnestem</i>	134	ARIXTRA	173
<i>amphetamine-dextroamphet er</i>	135	<i>armodafinil oral tablet 150 mg, 200 mg, 250 mg</i>	
<i>amphetamine-dextroamphetamine</i>	136	174
AMPYRA	137	<i>armodafinil oral tablet 50 mg</i>	175
AMTURNIDE	138	ARNUITY ELLIPTA	176
		ASACOL HD	177

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

ASCENSIA AUTODISC TEST	178	AVONEX PREFILLED INTRAMUSCULAR*	219
ASSURE 3 TEST	179	AXERT	220
ASSURE 4 METER	180	AXIRON	221
ASSURE 4 TEST	181	AZILECT	222
ASSURE II	182	AZOR	223
ASSURE II CHECK	183	AZULFIDINE	224
ASSURE PLATINUM	184	AZULFIDINE EN-TABS	225
ASSURE PLATINUM METER	185	<i>azurette</i>	226
ASSURE PRISM MULTI TEST	186	<i>balsalazide disodium</i>	227
ASSURE PRO BLOOD GLUCOSE METER ...	187	<i>balziva</i>	228
ASSURE PRO TEST	188	BANZEL ORAL TABLET	229
ASTAGRAF XL ORAL CAPSULE EXTENDED		BARACLUDE ORAL TABLET	230
RELEASE 24 HOUR 0.5 MG	189	BAYER BREEZE 2 TEST	231
ASTAGRAF XL ORAL CAPSULE EXTENDED		BAYER CONTOUR LINK MONITOR	232
RELEASE 24 HOUR 1 MG	190	BAYER CONTOUR MONITOR DEVICE	233
AT LAST TEST	191	BAYER CONTOUR MONITOR KIT	234
ATACAND HCT ORAL TABLET 16-12.5 MG		BAYER CONTOUR NEXT EZ	235
.....	195	BAYER CONTOUR NEXT LINK	236
ATACAND HCT ORAL TABLET 32-12.5 MG,		BAYER CONTOUR NEXT MONITOR	237
32-25 MG	194	BAYER CONTOUR NEXT TEST	238
ATACAND ORAL TABLET 16 MG, 8 MG, 4		BAYER CONTOUR NEXT USB MONITOR	
MG	193	239
ATACAND ORAL TABLET 32 MG	192	BAYER CONTOUR TEST	240
ATELVIA	196	BAYER CONTOUR USB	241
<i>atorvastatin calcium oral</i>	197	BEBULIN	242
ATRIPLA	198	BEBULIN VH	243
AUBAGIO	199	BECONASE AQ	244
AUBAGIO	200	BELBUCA	245
AUBAGIO	201	BELSOMRA	246
AUVI-Q INJECTION	202	BELSOMRA	247
AVALIDE ORAL TABLET 150-12.5 MG	204	BENEFIX	248
AVALIDE ORAL TABLET 300-12.5 MG	203	BENICAR	249
AVANDAMET ORAL TABLET 2-1000 MG		BENICAR HCT	250
.....	205	BENICAR HCT	251
AVANDIA	206	BENLYSTA	252
AVAPRO	207	BERINERT	253
<i>aviane</i>	208	BETASERON SUBCUTANEOUS* KIT	254
AVINZA	209	BETASERON SUBCUTANEOUS* KIT	255
<i>avita external cream</i>	210	BETASERON SUBCUTANEOUS* KIT	256
<i>avita external gel</i>	211	BETHKIS	257
AVODART	212	BEVESPI AEROSPHERE	258
AVONEX	213	BEVESPI AEROSPHERE	259
AVONEX	214	BEYAZ	260
AVONEX	215	BG STAR TEST	261
AVONEX PEN INTRAMUSCULAR*	216	<i>bicalutamide</i>	262
AVONEX PREFILLED INTRAMUSCULAR*		<i>bimatoprost ophthalmic</i>	263
.....	217	BIOSCANNER GLUCOSE TEST	264
AVONEX PREFILLED INTRAMUSCULAR*		<i>bl test</i>	265
.....	218	<i>blood glucose test</i>	266

BONIVA ORAL TABLET 150 MG	267	<i>calcipotriene-betameth diprop</i>	315
BOSULIF	268	<i>calcitonin (salmon)</i>	316
BOSULIF	269	<i>calcitrene</i>	317
BOSULIF	270	<i>camila</i>	318
BOTOX	271	<i>camrese</i>	319
BRAVELLE	272	<i>camrese lo</i>	320
BREEZE 2 BLOOD GLUCOSE SYSTEM	273	CANASA	321
BREO ELLIPTA	274	<i>candesartan cilexetil oral tablet 16 mg, 8 mg, 4 mg</i>	322
BREO ELLIPTA	275		323
BREVICON (28)	276	<i>candesartan cilexetil-hctz</i>	323
<i>briellyn</i>	277	CAPRELSA ORAL TABLET 100 MG	325
BRILINTA	278	CAPRELSA ORAL TABLET 300 MG	324
BRINTELLIX	279	CARBAGLU	326
BRISDELLE	281	CARDIZEM CD	327
BRIVIACT ORAL SOLUTION	283	CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 120 MG	329
BRIVIACT ORAL TABLET	282	CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 180 MG, 300 MG	328
BROVANA	284	CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 240 MG	330
BROVANA	285	CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 360 MG	331
<i>budesonide inhalation</i>	286	CARDURA XL	332
BUNAVAIL BUCCAL FILM 2.1-0.3 MG	287	CARESENS N GLUCOSE SYSTEM	333
BUNAVAIL BUCCAL FILM 6.3-1 MG, 4.2-0.7 MG	289	CARESENS N GLUCOSE TEST	334
BUPHENYL ORAL POWDER 3 GM/TSP	291	<i>cartia xt oral capsule extended release 24 hour</i>	120
BUPHENYL ORAL TABLET	291	<i>mg, 300 mg, 180 mg</i>	335
<i>buprenorphine hcl sublingual tablet sublingual 2 mg</i>	294	<i>cartia xt oral capsule extended release 24 hour</i>	240
<i>buprenorphine hcl sublingual tablet sublingual 8 mg</i>	292	<i>mg</i>	336
<i>buprenorphine hcl-naloxone hcl</i>	296	CASODEX	337
<i>buproban</i>	298	<i>caziant</i>	338
<i>bupropion hcl er (smoking det)</i>	300	<i>cefixime</i>	339
<i>bupropion hcl er (sr)</i>	301	CELEBREX	340
<i>bupropion hcl er (xl)</i>	302	<i>celecoxib oral</i>	341
<i>bupropion hcl oral</i>	299	CELEXA ORAL TABLET	342
<i>butorphanol tartrate nasal</i>	303	CENESTIN ORAL TABLET 0.9 MG, 0.45 MG, 0.625 MG, 0.3 MG	343
BUTRANS	304	CENESTIN ORAL TABLET 1.25 MG	344
BYDUREON SUBCUTANEOUS* 2 MG	306	CERDELGA	345
BYDUREON SUBCUTANEOUS* SUSPENSION RECONSTITUTED	305	CEREZYME INTRAVENOUS* SOLUTION RECONSTITUTED 400 UNIT	346
BYETTA 10 MCG PEN SUBCUTANEOUS*	307	CESAMET	347
BYETTA 5 MCG PEN SUBCUTANEOUS*	308	<i>cesia</i>	348
BYSTOLIC ORAL TABLET 2.5 MG, 5 MG, 10 MG	309	CETROTIDE SUBCUTANEOUS* KIT 0.25 MG	349
BYSTOLIC ORAL TABLET 20 MG	310	<i>cevimeline hcl</i>	350
BYVALSON	311	CHANTIX	351
CABOMETYX	312	CHANTIX CONTINUING MONTH PAK	352
CADUET	313	CHANTIX STARTING MONTH PAK	353
<i>calcipotriene external cream</i>	314	<i>chateal</i>	354
<i>calcipotriene external ointment</i>	314		

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

CHENODAL	355	COMETRIQ (100 MG DAILY DOSE)	399
CHOICE DM FORA G20 TEST STRIPS	356	COMETRIQ (140 MG DAILY DOSE)	400
CHOLBAM	357	COMETRIQ (60 MG DAILY DOSE)	401
<i>chorionic gonadotropin intramuscular*</i>	358	COMPLERA	402
CIALIS ORAL TABLET 5 MG, 2.5 MG	359	CONCERTA ORAL TABLET	
CIMZIA PREFILLED	361	EXTENDEDRELEASE* 27 MG, 54 MG, 18 MG	
CIMZIA STARTER KIT	362		403
CIMZIA SUBCUTANEOUS* KIT 2 X 200 MG		CONCERTA ORAL TABLET	
	360	EXTENDEDRELEASE* 36 MG	404
CINQAIR	363	CONTROL AST	405
CINRYZE	364	CONTROL TEST	406
<i>citalopram hydrobromide oral tablet 10 mg, 20 mg</i>		CONZIP	407
	365	COOL BLOOD GLUCOSE TEST STRIPS	408
<i>citalopram hydrobromide oral tablet 40 mg</i>	366	COPAXONE SUBCUTANEOUS* 20 MG/ML	
<i>claravis</i>	367		409
CLARINEX ORAL TABLET	368	COPAXONE SUBCUTANEOUS* 20 MG/ML	
CLARINEX-D 12 HOUR	369		410
CLEVER CHEK AUTO-CODE	370	COPAXONE SUBCUTANEOUS* 20 MG/ML	
CLEVER CHEK AUTO-CODE SYSTEM	371		411
CLEVER CHEK AUTO-CODE TEST	372	CORDRAN EXTERNAL TAPE	412
CLEVER CHEK AUTO-CODE VOICE	374	COREG CR	413
CLEVER CHEK AUTO-CODE VOICE IN		CORIFACT	414
VITRO	373	CORLANOR	415
CLEVER CHEK TEST	375	COSENTYX	416
CLEVER CHOICE AUTO-CODE SYSTEM	376	COSENTYX SENSOREADY PEN	
CLEVER CHOICE AUTO-CODE TEST	377	SUBCUTANEOUS* 150 MG/ML	417
CLEVER CHOICE MICRO SYSTEM	378	COTELLIC	418
CLEVER CHOICE MICRO TEST	379	COZAAR ORAL TABLET 50 MG, 25 MG	419
CLEVER CHOICE MINI SYSTEM	380	CRESTOR	420
CLIMARA	381	CRESTOR	421
CLIMARA PRO	382	<i>cryselle-28</i>	422
<i>clonidine hcl er</i>	383	CVS ADVANCED GLUCOSE TEST	423
<i>clopidogrel bisulfate</i>	384	<i>cvs blood glucose test</i>	424
<i>clozapine oral tablet 100 mg</i>	385	<i>cvs nicotine polacrilex mouth/throat lozenge 4 mg</i>	
<i>clozapine oral tablet 200 mg</i>	389		426
<i>clozapine oral tablet 25 mg, 50 mg</i>	386	<i>cvs nicotine transdermal patch 24 hr 14 mg/24hr, 7</i>	
<i>clozapine oral tablet dispersible 100 mg</i>	385	<i>mg/24hr</i>	425
<i>clozapine oral tablet dispersible 12.5 mg</i>	387	<i>cvs nts step 1</i>	427
<i>clozapine oral tablet dispersible 150 mg</i>	388	<i>cyclafem 1/35</i>	428
<i>clozapine oral tablet dispersible 200 mg</i>	390	<i>cyclafem 7/7/7</i>	429
<i>clozapine oral tablet dispersible 25 mg</i>	386	CYCLESSA	430
CLOZARIL ORAL TABLET 100 MG	392	CYCLOSET	431
CLOZARIL ORAL TABLET 25 MG	391	CYMBALTA ORAL CAPSULE DELAYED	
COAGADEX	393	RELEASE PARTICLES 20 MG	432
COLAZAL	394	CYMBALTA ORAL CAPSULE DELAYED	
<i>colchicine oral tablet</i>	395	RELEASE PARTICLES 30 MG	434
COLCRYS	396	CYMBALTA ORAL CAPSULE DELAYED	
COLYTE WITH FLAVOR PACKS ORAL		RELEASE PARTICLES 60 MG	433
SOLUTION RECONSTITUTED 227.1 GM	397	CYSTAGON	435
COMBIPATCH	398	CYSTARAN	436

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

DAKLINZA	437	<i>diltiazem hcl er beads oral capsule extended</i>	
DAKLINZA	438	<i>release 24 hour 240 mg</i>	485
DAKLINZA	439	<i>diltiazem hcl er beads oral capsule extended</i>	
DAKLINZA	440	<i>release 24 hour 360 mg, 120 mg, 420 mg, 180 mg,</i>	
DAKLINZA	441	<i>300 mg</i>	484
DAKLINZA	442	<i>diltiazem hcl er coated beads oral capsule</i>	
DALIRESP	443	<i>extended release 24 hour 180 mg, 120 mg, 360 mg,</i>	
<i>darifenacin hydrobromide er</i>	444	<i>300 mg</i>	487
<i>dasetta 1/35</i>	445	<i>diltiazem hcl er coated beads oral capsule</i>	
<i>dasetta 7/7/7</i>	446	<i>extended release 24 hour 240 mg</i>	486
<i>daysee</i>	447	<i>diltiazem hcl er oral capsule extended release 12</i>	
DAYTRANA	448	<i>hour 120 mg</i>	482
DEBLITANE	449	<i>diltiazem hcl er oral capsule extended release 24</i>	
DELZICOL	450	<i>hour 120 mg, 180 mg</i>	482
DEPO-PROVERA INTRAMUSCULAR*		<i>diltiazem hcl er oral capsule extended release 24</i>	
SUSPENSION 150 MG/ML	451	<i>hour 240 mg</i>	483
DEPO-SUBQ PROVERA 104	452	<i>dilt-xr oral capsule extended release 24 hour 120</i>	
DESCOVY	453	<i>mg, 180 mg</i>	488
<i>desloratadine</i>	454	<i>dilt-xr oral capsule extended release 24 hour 240</i>	
DESOGEN	455	<i>mg</i>	489
DESOXYN	456	DIOVAN	490
<i>desvenlafaxine er</i>	457	DIOVAN HCT	491
<i>desvenlafaxine fumarate er</i>	458	DIPENTUM	492
DETROL LA	459	DITROPAN XL	493
DEXEDRINE ORAL CAPSULE EXTENDED		DOLOPHINE	494
RELEASE 24 HOUR	461	<i>donepezil hcl oral tablet 10 mg</i>	495
<i>dexedrine oral tablet</i>	460	<i>donepezil hcl oral tablet 5 mg, 23 mg</i>	496
DEXILANT	462	<i>donepezil hcl oral tablet dispersible</i>	496
DEXILANT	464	DORYX MPC	497
<i>dexmethylphenidate hcl</i>	466	DOVONEX EXTERNAL CREAM	498
<i>dexmethylphenidate hcl er oral capsule extended</i>		<i>doxycycline</i>	499
<i>release 24 hour 10 mg, 15 mg, 5 mg, 30 mg, 40 mg</i>		<i>doxycycline monohydrate oral capsule 75 mg, 150</i>	
.....	467	<i>mg</i>	500
<i>dextroamphetamine sulfate er</i>	470	<i>doxycycline monohydrate oral tablet 50 mg</i>	500
<i>dextroamphetamine sulfate oral solution</i>	469	<i>dronabinol</i>	501
<i>dextroamphetamine sulfate oral tablet</i>	468	<i>drospirenone-ethinyl estradiol oral tablet 3-0.03</i>	
<i>diatrue plus test</i>	471	<i>mg</i>	502
<i>diazepam gel</i>	472	DUAVEE	503
DICLEGIS	473	DUETACT	504
<i>diclofenac sodium transdermal gel 1 %</i>	474	DUEXIS	505
<i>diclofenac sodium transdermal gel 3 %</i>	476	DULERA	506
<i>diclofenac sodium transdermal solution</i>	475	<i>duloxetine hcl oral capsule delayed release</i>	
DIFFERIN EXTERNAL GEL	477	<i>particles 40 mg, 30 mg</i>	507
DIFFERIN EXTERNAL LOTION	477	<i>duloxetine hcl oral capsule delayed release</i>	
DIFICID	478	<i>particles 60 mg, 20 mg</i>	508
<i>dihydroergotamine mesylate nasal</i>	479	DUO-CARE TEST	509
<i>diltiazem cd oral capsule extended release 24 hour</i>		DURAGESIC-100	510
<i>120 mg, 180 mg</i>	480	DURAGESIC-12	511
<i>diltiazem cd oral capsule extended release 24 hour</i>		DURAGESIC-25	512
<i>240 mg</i>	481	DURAGESIC-50	513

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

DURAGESIC-75.....	514	ELOCTATE.....	559
<i>dutasteride</i>	515	EMBEDA.....	560
DYANAVEL XR.....	516	EMBRACE BLOOD GLUCOSE MONITOR.....	561
DYSPORT.....	517	EMBRACE BLOOD GLUCOSE TEST.....	562
<i>easy plus blood glucose test</i>	518	EMBRACE EVO BLOOD GLUCOSE TEST.....	563
<i>easy plus ii glucose system</i>	519	EMBRACE PRO GLUCOSE TEST.....	564
<i>easy plus ii glucose test</i>	520	EMEND ORAL CAPSULE 40 MG, 125 MG, 80	
EASY STEP GLUCOSE MONITOR DEVICE		MG.....	565
.....	521	EMEND ORAL CAPSULE 80 & 125 MG.....	566
EASY STEP TEST.....	522	EMLA.....	567
<i>easy talk blood glucose system device</i>	523	<i>emoquette</i>	569
<i>easy talk blood glucose test</i>	524	EMSAM.....	570
EASY TOUCH HEALTHPRO TEST.....	525	EMTRIVA ORAL CAPSULE.....	571
EASY TOUCH TEST.....	526	ENABLEX.....	572
<i>easy trak blood glucose test</i>	527	ENABLEX.....	573
EASYGLUCO IN VITRO.....	528	ENABLEX.....	574
EASYGLUCO PLUS IN VITRO.....	529	ENABLEX.....	575
EASYMAX 15 TEST.....	530	ENBREL SUBCUTANEOUS* 25 MG/0.5ML	
EASYMAX L BLOOD GLUCOSE DEVICE.....	531	576
EASYMAX N BLOOD GLUCOSE DEVICE.....	532	ENBREL SUBCUTANEOUS* 50 MG/ML.....	577
EASYMAX NG BLOOD GLUCOSE DEVICE		ENBREL SUBCUTANEOUS* KIT.....	577
.....	533	ENBREL SUBCUTANEOUS* SOLUTION	
EASYMAX TEST.....	534	RECONSTITUTED.....	578
EASYMAX V BLOOD GLUCOSE DEVICE.....	535	ENBREL SURECLICK SUBCUTANEOUS*	
EASYMAX V2 BLOOD GLUCOSE DEVICE		579
.....	536	ENJUVIA ORAL TABLET 0.3 MG, 0.9 MG, 0.45	
<i>easyplus blood glucose test</i>	537	MG, 0.625 MG.....	580
EASYPRO BLOOD GLUCOSE TEST.....	538	ENJUVIA ORAL TABLET 1.25 MG.....	581
EASYPRO PLUS IN VITRO.....	539	<i>enoxaparin sodium</i>	582
ECLIPSE TEST.....	540	<i>enpresse-28</i>	583
EDARBI.....	541	<i>entecavir</i>	584
EDARBYCLOR.....	542	<i>entecavir</i>	585
EDURANT.....	543	ENTRESTO.....	586
EFFEXOR XR ORAL CAPSULE EXTENDED		ENTYVIO.....	587
RELEASE 24 HOUR 150 MG.....	544	ENVISION AUTOCODE TEST.....	588
EFFEXOR XR ORAL CAPSULE EXTENDED		EPCLUSA.....	589
RELEASE 24 HOUR 37.5 MG, 75 MG.....	545	EPIDUO.....	590
EFFIENT.....	546	EPIDUO FORTE.....	591
ELAPRASE.....	547	<i>epinephrine injection 0.3 mg/0.3ml, 0.15</i>	
ELELYSO.....	548	<i>mg/0.15ml</i>	592
ELELYSO.....	549	EPOGEN INJECTION SOLUTION 20000	
ELELYSO.....	550	UNIT/ML, 4000 UNIT/ML, 2000 UNIT/ML,	
<i>element compact test</i>	551	10000 UNIT/ML, 3000 UNIT/ML.....	593
ELEMENT PLUS.....	552	<i>eprosartan mesylate</i>	594
ELEMENT PLUS TEST.....	553	<i>eq nicotine transdermal</i>	595
ELEMENT TEST.....	554	<i>eq nicotine</i>	596
ELESTRIN.....	555	EQL TRUETEST TEST.....	597
ELIDEL.....	556	ERIVEDGE.....	598
<i>elinest</i>	557	<i>errin</i>	599
ELLA.....	558	ESBRIET.....	600

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

<i>escitalopram oxalate oral solution</i>	602	FANAPT	646
<i>escitalopram oxalate oral tablet 10 mg</i>	603	FANAPT TITRATION PACK	647
<i>escitalopram oxalate oral tablet 20 mg, 5 mg</i>	601	FARXIGA	648
<i>esomeprazole magnesium oral capsule delayed</i>		FARYDAK	649
<i>release 40 mg</i>	604	FAZACLO ORAL TABLET DISPERSIBLE 100	
ESTRADERM	605	MG	651
<i>estradiol transdermal patch biweekly</i>	606	FAZACLO ORAL TABLET DISPERSIBLE 12.5	
<i>estradiol transdermal patch weekly 0.05 mg/24hr</i>		MG	654
.....	607	FAZACLO ORAL TABLET DISPERSIBLE 150	
<i>estradiol transdermal patch weekly 0.06 mg/24hr,</i>		MG	652
<i>0.1 mg/24hr, 0.075 mg/24hr, 0.0375 mg/24hr,</i>		FAZACLO ORAL TABLET DISPERSIBLE 200	
<i>0.025 mg/24hr</i>	608	MG	653
<i>estradiol-norethindrone acet</i>	609	FAZACLO ORAL TABLET DISPERSIBLE 25	
ESTROGEL	610	MG	650
ESTROSTEP FE	611	<i>felodipine er</i>	655
<i>eszopiclone</i>	612	FEMCON FE	656
EUFLEXXA INTRA-ARTICULAR*	613	FEMHRT LOW DOSE	657
EVAMIST	614	FEMRING	658
EVEKEO	615	<i>fenofibrate micronized</i>	661
EVENCARE + BLOOD GLUCOSE TEST	616	<i>fenofibrate oral capsule</i>	660
EVENCARE BLOOD GLUCOSE TEST	617	<i>fenofibrate oral tablet 54 mg, 145 mg, 160 mg, 48</i>	
EVENCARE G2 MONITOR	618	<i>mg</i>	659
EVENCARE G2 TEST	619	<i>fenofibric acid oral tablet</i>	662
EVENCARE G3 MONITOR	620	FENOGLIDE	663
EVENCARE G3 TEST	621	<i>fentanyl</i>	664
EVENCARE MINI GLUCOSE TEST	622	<i>fentanyl citrate buccal</i>	665
EVOLUTION AUTOCODE	623	<i>fentanyl citrate buccal</i>	667
EVOLUTION AUTOCODE IN VITRO	624	<i>fentanyl citrate buccal</i>	669
EVOXAC	625	FENTORA	671
EXALGO ORAL 16 MG	627	FENTORA	673
EXALGO ORAL 32 MG, 8 MG, 12 MG	626	FENTORA	675
EXELON ORAL CAPSULE	628	FENTORA	677
EXELON TRANSDERMAL	628	FERRIPROX	678
EXFORGE	629	FETZIMA	679
EXJADE	630	FETZIMA	681
EXTAVIA SUBCUTANEOUS* KIT	631	FETZIMA TITRATION	683
EXTAVIA SUBCUTANEOUS* KIT	632	FETZIMA TITRATION	685
EXTAVIA SUBCUTANEOUS* KIT	633	FIBRICOR	687
EZ SMART BLOOD GLUCOSE TEST	634	FIFTY50 GLUCOSE TEST 2.0	688
EZ SMART MONITORING SYSTEM	635	FIRAZYR	689
EZ SMART PLUS GLUCOSE TEST	636	FLEBOGAMMA DIF	690
EZ SMART PLUS MONITORING SYS	637	FLECTOR	691
FABIOR	638	FLOLAN	692
FABRAZYME	639	FLONASE ALLERGY RELIEF	693
FALESSA ORAL KIT 20-1-0.1 MCG-MG	640	FLOVENT DISKUS	694
<i>falmina</i>	641	<i>fluocinonide external cream</i>	695
<i>famciclovir oral tablet 125 mg, 250 mg</i>	642	<i>fluoxetine hcl oral capsule delayed release</i>	697
<i>famciclovir oral tablet 500 mg</i>	643	<i>fluoxetine hcl oral tablet 20 mg</i>	698
FAMVIR ORAL TABLET 250 MG, 125 MG	645	<i>fluoxetine hcl oral tablet 60 mg</i>	696
FAMVIR ORAL TABLET 500 MG	644	<i>fluvastatin sodium</i>	699

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

<i>fluvoxamine maleate er</i>	702	FORTESTA.....	745
<i>fluvoxamine maleate oral tablet 100 mg</i>	701	<i>fortical</i>	746
<i>fluvoxamine maleate oral tablet 25 mg, 50 mg</i>	700	FORTISCARE TEST.....	747
FOCALIN.....	703	FOSAMAX ORAL TABLET 70 MG.....	748
FOCALIN XR.....	704	FOSAMAX PLUS D.....	749
FOLLISTIM AQ.....	705	FRAGMIN.....	750
<i>fondaparinux sodium</i>	706	FREESTYLE FLASH SYSTEM.....	751
FORA D10 2-IN-1 MONITOR.....	707	FREESTYLE FREEDOM LITE.....	752
FORA D10 BLOOD GLUCOSE TEST.....	708	FREESTYLE INSULINX SYSTEM.....	753
FORA D15C BLOOD GLUCOSE TEST.....	709	FREESTYLE INSULINX TEST.....	754
FORA D15G 2-IN-1 MONITOR.....	710	FREESTYLE LITE.....	755
FORA D15G BLOOD GLUCOSE TEST.....	711	FREESTYLE LITE TEST.....	756
FORA D15Z BLOOD GLUCOSE TEST.....	712	FREESTYLE PRECISION NEO TEST.....	757
FORA D20 2-IN-1 MONITOR.....	713	FREESTYLE SYSTEM.....	758
FORA D20 BLOOD GLUCOSE TEST.....	714	FREESTYLE TEST.....	759
FORA D40/G31 BLOOD GLUCOSE.....	715	FROVA.....	760
FORA G20 BLOOD GLUCOSE TEST.....	716	<i>frovatriptan succinate</i>	761
FORA G30A BLOOD GLUCOSE SYSTEM.....	717	FULYZAQ.....	762
FORA G30A BLOOD GLUCOSE TEST.....	718	FYCOMPA ORAL TABLET.....	763
FORA G71A BLOOD GLUCOSE TEST.....	719	<i>gabapentin oral capsule</i>	764
FORA G90 BLOOD GLUCOSE TEST.....	720	<i>gabapentin oral solution 250 mg/5ml</i>	765
FORA GD20 BLOOD GLUCOSE SYSTEM.....	721	<i>gabapentin oral tablet</i>	766
FORA GD20 TEST.....	722	GABITRIL ORAL TABLET 16 MG.....	769
FORA GD50 BLOOD GLUCOSE TEST.....	723	GABITRIL ORAL TABLET 2 MG.....	768
FORA TEST N' GO GLUCOSE TEST.....	724	GABITRIL ORAL TABLET 4 MG, 12 MG.....	767
FORA TN'G/TN'G VOICE.....	725	<i>galantamine hydrobromide oral tablet</i>	770
FORA V10 BLOOD GLUCOSE SYSTEM.....	726	GAMMAGARD S/D LESS IGA.....	771
FORA V10 BLOOD GLUCOSE TEST.....	727	<i>ganirelix acetate</i>	772
FORA V12 BLOOD GLUCOSE SYSTEM.....	728	GATTEX.....	773
FORA V12 BLOOD GLUCOSE TEST.....	729	<i>gavilyte-c</i>	774
FORA V20 BLOOD GLUCOSE SYSTEM.....	730	<i>gavilyte-g</i>	775
FORA V20 BLOOD GLUCOSE TEST.....	731	<i>ge100 blood glucose test</i>	776
FORA V22 BLOOD GLUCOSE TEST.....	732	GELNIQUE.....	777
FORA V30A BLOOD GLUCOSE SYSTEM.....	733	GEL-ONE INTRA-ARTICULAR*.....	778
DEVICE.....	733	GELSYN-3.....	779
FORA V30A BLOOD GLUCOSE TEST.....	734	GENERESS FE.....	780
FORACARE GD40 MONITOR.....	735	GENOTROPIN.....	781
FORACARE GD40 TEST.....	736	GENOTROPIN MINIQUICK.....	782
FORACARE PREMIUM V10.....	737	GENSTRIP 50.....	783
FORACARE PREMIUM V10 TEST.....	738	GENVOYA.....	784
FORACARE TEST N GO TEST.....	739	GEODON ORAL.....	785
FORADIL AEROLIZER.....	740	<i>ght test</i>	786
FORFIVO XL.....	741	<i>gianvi</i>	787
FORTAMET ORAL TABLET EXTENDED.....	743	GIAZO.....	788
RELEASE 24 HR* 1000 MG.....	743	GIAZO.....	789
FORTAMET ORAL TABLET EXTENDED.....	742	<i>gildagia</i>	790
RELEASE 24 HR* 500 MG.....	742	<i>gildess 1.5/30</i>	791
FORTEO SUBCUTANEOUS* SOLUTION 600.....	744	<i>gildess 1/20</i>	792
MCG/2.4ML.....	744	<i>gildess fe 1.5/30</i>	793
		<i>gildess fe 1/20</i>	794

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

GILENYA	795	HEPSERA	837
GILOTRIF	796	HETLIOZ	838
GLEEVEC ORAL TABLET 100 MG	797	<i>hm nicotine</i>	839
GLEEVEC ORAL TABLET 100 MG	798	<i>hm nicotine polacrilex mouth/throat lozenge 2 mg</i>	840
GLEEVEC ORAL TABLET 100 MG	802		
GLEEVEC ORAL TABLET 400 MG	799	HORIZANT ORAL TABLET	
GLEEVEC ORAL TABLET 400 MG	800	EXTENDEDRELEASE* 300 MG	841
GLEEVEC ORAL TABLET 400 MG	801	HORIZANT ORAL TABLET	
GLUCAGEN DIAGNOSTIC	803	EXTENDEDRELEASE* 600 MG	842
GLUCAGEN HYPOKIT	804	HUMATE-P INTRAVENOUS* SOLUTION	
GLUCO PERFECT 3 TEST	805	RECONSTITUTED 500-1200 UNIT, 1000-2400	
GLUCOCARD 01 BLOOD GLUCOSE DEVICE	806	UNIT, 250-600 UNIT	843
		HUMATROPE	844
GLUCOCARD 01 SENSOR PLUS	807	HUMIRA PEDIATRIC CROHNS START	
GLUCOCARD 01 TEST	808	SUBCUTANEOUS* 40 MG/0.8ML	848
GLUCOCARD EXPRESSION TEST	809	HUMIRA PEN SUBCUTANEOUS*	849
GLUCOCARD SHINE TEST	810	HUMIRA PEN-CROHNS STARTER	
GLUCOCARD VITAL TEST	811	SUBCUTANEOUS*	850
GLUCOCARD X-SENSOR	812	HUMIRA PEN-PSORIASIS STARTER	
GLUCOCOM BLOOD GLUCOSE MONITOR	813	SUBCUTANEOUS*	851
		HUMIRA SUBCUTANEOUS* 10 MG/0.2ML	847
GLUCOCOM TEST	814		
GLUCOLAB TEST	815	HUMIRA SUBCUTANEOUS* 20 MG/0.4ML	845
GLUCONAVII BLOOD GLUCOSE TEST	816		
GLUMETZA ORAL TABLET EXTENDED		HUMIRA SUBCUTANEOUS* 40 MG/0.8ML	846
RELEASE 24 HR* 1000 MG	817		
GLUMETZA ORAL TABLET EXTENDED		HUMULIN 70/30	852
RELEASE 24 HR* 500 MG	818	HUMULIN N	853
GLYXAMBI	819	HYALGAN	854
GLYXAMBI	820	HYCAMTIN ORAL	855
GMATE BLOOD GLUCOSE TEST	821	<i>hydrocod polst-cpm polst er oral liquid</i>	
GONAL-F	822	<i>extendedrelease*</i>	856
GONAL-F RFF	823	<i>hydromorphone hcl er oral 16 mg</i>	858
GONAL-F RFF PEN	824	<i>hydromorphone hcl er oral 8 mg, 32 mg, 12 mg</i>	857
GONAL-F RFF REDIJECT	825		
GRALISE ORAL TABLET 300 MG	827	HYMOVIS	859
GRALISE ORAL TABLET 600 MG	826	HYMOVIS	860
GRALISE STARTER	828	HYMOVIS	861
<i>granisetron hcl oral</i>	829	HYQVIA	862
<i>guanfacine hcl er</i>	830	HYSINGLA ER	863
<i>guanfacine hcl er</i>	831	<i>ibandronate sodium oral</i>	864
HARVONI	832	IBRANCE	865
<i>heather</i>	833	ICLUSIG ORAL TABLET 15 MG	866
HELIXATE FS	834	ICLUSIG ORAL TABLET 15 MG	869
HEMANGEOL	835	ICLUSIG ORAL TABLET 15 MG	871
HEMOFIL M INTRAVENOUS* SOLUTION		ICLUSIG ORAL TABLET 45 MG	867
RECONSTITUTED 401-800 UNIT, 220-400		ICLUSIG ORAL TABLET 45 MG	868
UNIT, 250 UNIT, 1000 UNIT, 1700 UNIT,		ICLUSIG ORAL TABLET 45 MG	870
1501-2000 UNIT, 801-1500 UNIT, 500 UNIT		IDELVION	872
	836	ILARIS	873

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

<i>imatinib mesylate oral tablet 100 mg</i>	875	JANUMET XR ORAL TABLET EXTENDED	
<i>imatinib mesylate oral tablet 400 mg</i>	874	RELEASE 24 HR* 50-500 MG, 100-1000 MG	
IMBRUVICA	876		914
<i>imiquimod external</i>	877	JANUVIA	916
IMITREX NASAL SOLUTION 20 MG/ACT ..	879	JARDIANCE	917
IMITREX NASAL SOLUTION 5 MG/ACT	880	JENTADUETO	918
IMITREX ORAL	878	JENTADUETO XR ORAL TABLET EXTENDED	
IMPAVIDO	881	RELEASE 24 HR* 2.5-1000 MG	919
IMPLANON	882	JENTADUETO XR ORAL TABLET EXTENDED	
IN TOUCH BLOOD GLUCOSE TEST	883	RELEASE 24 HR* 5-1000 MG	920
INCRELEX	884	<i>jinteli</i>	921
INDERAL XL ORAL CAPSULE EXTENDED		<i>jolessa</i>	922
RELEASE 24 HOUR 80 MG	885	<i>jolivette</i>	923
INFINITY BLOOD GLUCOSE TEST	886	JUBLIA	924
INLYTA	887	<i>junel 1.5/30</i>	925
INNOPRAN XL ORAL CAPSULE EXTENDED		<i>junel 1/20</i>	926
RELEASE 24 HOUR 120 MG	889	<i>junel fe 1.5/30</i>	927
INNOPRAN XL ORAL CAPSULE EXTENDED		<i>junel fe 1/20</i>	928
RELEASE 24 HOUR 80 MG	888	JUXTAPID ORAL CAPSULE 10 MG	930
INTELENCE ORAL TABLET 200 MG	891	JUXTAPID ORAL CAPSULE 20 MG, 40 MG, 30	
INTELENCE ORAL TABLET 25 MG, 100 MG		MG, 5 MG, 60 MG	929
.....	890	KADIAN ORAL CAPSULE EXTENDED	
INTERMEZZO	892	RELEASE 24 HOUR 130 MG, 150 MG, 50 MG,	
INTRON A	893	80 MG, 100 MG, 20 MG, 60 MG, 200 MG, 30	
<i>introvale</i>	894	MG, 40 MG, 70 MG	931
INTUNIV	895	KALBITOR	932
INTUNIV	896	KALYDECO	933
INVEGA ORAL TABLET EXTENDED		KALYDECO	934
RELEASE 24 HR* 1.5 MG, 9 MG, 3 MG	897	KANUMA	935
INVEGA ORAL TABLET EXTENDED		KAPVAY ORAL TABLET EXTENDED	
RELEASE 24 HR* 6 MG	898	RELEASE 12 HR*	936
INVOKAMET	899	<i>kariva</i>	937
INVOKANA	900	KAZANO	938
<i>ipratropium bromide nasal</i>	901	<i>kelnor 1/35</i>	939
IPRIVASK	902	KEPPRA XR ORAL TABLET EXTENDED	
<i>irbesartan</i>	903	RELEASE 24 HR* 500 MG	941
<i>irbesartan-hydrochlorothiazide</i>	904	KEPPRA XR ORAL TABLET EXTENDED	
IRENKA	905	RELEASE 24 HR* 750 MG	940
IRESSA	906	KERYDIN	942
ISENTRESS ORAL TABLET	907	<i>ketoconazole oral</i>	943
ISENTRESS ORAL TABLET CHEWABLE	908	<i>ketorolac tromethamine ophthalmic</i>	944
<i>itraconazole oral</i>	909	<i>ketorolac tromethamine oral</i>	945
IXINITY INTRAVENOUS* SOLUTION		KEVEYIS	946
RECONSTITUTED 1500 UNIT	910	KHEDEZLA	947
JADENU	911	KINERET SUBCUTANEOUS*	948
JAKAFI	912	KOATE-DVI	949
JANUMET	913	KOGENATE FS	950
JANUMET XR ORAL TABLET EXTENDED		KOGENATE FS BIO-SET	951
RELEASE 24 HR* 50-1000 MG	915		

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HR* 2.5-1000 MG	953	LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT	987
KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HR* 5-1000 MG, 5-500 MG	952	LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT	989
KORLYM	954	LAZANDA NASAL SOLUTION 300 MCG/ACT	983
KOVALTRY	955	<i>leena</i>	991
KROGER BLOOD GLUCOSE KIT W/DEVICE	956	<i>leflunomide oral</i>	992
<i>kroger blood glucose test</i>	957	LEMTRADA	993
KROGER PREMIUM BLOOD GLUCOSE	958	LENVIMA 10 MG DAILY DOSE	994
<i>kroger test</i>	959	LENVIMA 14 MG DAILY DOSE	995
<i>kurvelo</i>	960	LENVIMA 18 MG DAILY DOSE	996
KUVAN	961	LENVIMA 20 MG DAILY DOSE	997
KYNAMRO SUBCUTANEOUS*	962	LENVIMA 24 MG DAILY DOSE	998
LAMICTAL ODT ORAL TABLET DISPERSIBLE 200 MG, 100 MG	963	LENVIMA 8 MG DAILY DOSE	999
LAMICTAL ODT ORAL TABLET DISPERSIBLE 25 MG	965	LESCOL	1000
LAMICTAL ODT ORAL TABLET DISPERSIBLE 50 MG	964	LESCOL XL	1001
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 200 MG	966	<i>lessina</i>	1002
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 25 MG, 100 MG, 50 MG	967	<i>leuprolide acetate injection</i>	1003
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 250 MG, 300 MG	968	<i>levetiracetam er oral tablet extended release 24 hr* 500 mg</i>	1004
LAMISIL ORAL PACKET 125 MG	970	<i>levetiracetam er oral tablet extended release 24 hr* 750 mg</i>	1005
LAMISIL ORAL PACKET 187.5 MG	969	<i>levocetirizine dihydrochloride oral tablet</i>	1006
<i>lamotrigine er oral tablet extended release 24 hr* 100 mg, 25 mg</i>	974	<i>levonest</i>	1007
<i>lamotrigine er oral tablet extended release 24 hr* 200 mg</i>	975	<i>levonorgest-eth estrad 91-day oral tablet 0.1-0.02 & 0.01 mg, 0.15-0.03 mg</i>	1008
<i>lamotrigine er oral tablet extended release 24 hr* 300 mg, 250 mg</i>	976	<i>levonorgestrel-ethinyl estrad oral tablet 0.15-30 mg-mcg</i>	1009
<i>lamotrigine er oral tablet extended release 24 hr* 50 mg</i>	977	<i>levora 0.15/30 (28)</i>	1010
<i>lamotrigine oral tablet dispersible 200 mg, 100 mg</i>	971	LEXAPRO ORAL TABLET 10 MG	1011
<i>lamotrigine oral tablet dispersible 25 mg</i>	972	LEXAPRO ORAL TABLET 20 MG, 5 MG ...	1012
<i>lamotrigine oral tablet dispersible 50 mg</i>	973	LIALDA	1013
<i>lansoprazole oral capsule delayed release</i>	978	<i>liberty blood glucose meter</i>	1014
LARIN FE 1.5/30	979	<i>liberty blood glucose monitor</i>	1015
LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG	980	LIBERTY NEXT GENERATION TEST	1016
LATUDA ORAL TABLET 60 MG	981	LIBERTY NXT GENERATION MONITOR	1017
LATUDA ORAL TABLET 80 MG	982	<i>liberty test</i>	1018
LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT	985	LIDEX	1019
		<i>lidocaine external ointment</i>	1021
		<i>lidocaine external patch 5 %</i>	1020
		<i>lidocaine pak</i>	1023
		<i>lidocaine-prilocaine external cream</i>	1024
		LIDODERM	1026
		<i>lindane external lotion</i>	1027
		<i>linezolid oral suspension reconstituted</i>	1028
		<i>linezolid oral tablet</i>	1029
		LINZESS	1030
		LIPITOR	1031

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

LIPOFEN.....	1032	MENOPUR.....	1079
LIPTRUZET.....	1033	MENOSTAR.....	1080
LIVALO.....	1034	<i>mesalamine oral</i>	1081
LO LOESTRIN FE.....	1035	METADATE CD ORAL CAPSULE EXTENDED	
LOESTRIN 1.5/30 (21).....	1036	RELEASE* 20 MG.....	1082
LOESTRIN 1/20 (21).....	1037	METADATE CD ORAL CAPSULE EXTENDED	
LOESTRIN FE 1.5/30.....	1038	RELEASE* 30 MG.....	1084
LOESTRIN FE 1/20.....	1039	METADATE CD ORAL CAPSULE EXTENDED	
LOFIBRA.....	1040	RELEASE* 40 MG, 10 MG, 60 MG.....	1083
LOFIBRA.....	1041	METADATE ER ORAL TABLET	
<i>lomedica 24 fe</i>	1042	EXTENDEDRELEASE* 20 MG.....	1085
LONSURF ORAL TABLET 15-6.14 MG.....	1043	<i>metaxalone oral tablet 400 mg</i>	1086
LONSURF ORAL TABLET 20-8.19 MG.....	1044	<i>methadone hcl oral concentrate</i>	1087
<i>loryna</i>	1045	<i>methadone hcl oral solution 10 mg/5ml</i>	1089
<i>losartan potassium oral tablet 25 mg, 50 mg</i>	1046	<i>methadone hcl oral solution 5 mg/5ml</i>	1087
LOSEASONIQUE.....	1047	<i>methadone hcl oral tablet</i>	1088
LOTRONEX.....	1048	<i>methadose oral tablet soluble</i>	1090
LOTRONEX.....	1049	<i>methamphetamine hcl</i>	1091
<i>lovastatin</i>	1050	METHYLIN ORAL SOLUTION 10 MG/5ML	
LOVAZA.....	1051	1092
LOVENOX.....	1052	METHYLIN ORAL SOLUTION 5 MG/5ML	
<i>low-ogestrel</i>	1053	1093
LUMIGAN.....	1054	METHYLIN ORAL TABLET CHEWABLE	
LUMIGAN.....	1055	1094
LUMIZYME.....	1056	<i>methylphenidate hcl er (cd)</i>	1102
LUNESTA.....	1057	<i>methylphenidate hcl er (la) oral capsule extended</i>	
<i>lutura</i>	1058	<i>release 24 hour 20 mg, 40 mg</i>	1103
LYNPARZA.....	1059	<i>methylphenidate hcl er (la) oral capsule extended</i>	
LYSTEDA.....	1060	<i>release 24 hour 30 mg</i>	1104
LYZA.....	1061	<i>methylphenidate hcl er oral tablet extended release</i>	
MAKENA.....	1062	<i>24 hr* 36 mg</i>	1100
<i>maprotiline hcl</i>	1063	<i>methylphenidate hcl er oral tablet</i>	
MARINOL.....	1064	<i>extendedrelease* 20 mg, 10 mg</i>	1098
<i>marlissa</i>	1065	<i>methylphenidate hcl er oral tablet</i>	
<i>matzim la oral tablet extended release 24 hr* 240</i>		<i>extendedrelease* 36 mg</i>	1101
<i>mg</i>	1066	<i>methylphenidate hcl er oral tablet</i>	
<i>matzim la oral tablet extended release 24 hr* 300</i>		<i>extendedrelease* 54 mg, 18 mg, 27 mg</i>	1099
<i>mg, 180 mg, 360 mg</i>	1067	<i>methylphenidate hcl oral solution 10 mg/5ml</i>	
MAXALT.....	1068	1097
MAXALT-MLT.....	1069	<i>methylphenidate hcl oral solution 5 mg/5ml</i>	1095
MAXIMA BLOOD GLUCOSE TEST.....	1070	<i>methylphenidate hcl oral tablet</i>	1096
<i>medroxyprogesterone acetate intramuscular*</i>		<i>metoprolol succinate er oral tablet extended</i>	
.....	1071	<i>release 24 hr* 100 mg, 50 mg</i>	1105
MEIJER BLOOD GLUCOSE.....	1072	<i>metoprolol succinate er oral tablet extended</i>	
<i>meijer blood glucose test</i>	1073	<i>release 24 hr* 200 mg</i>	1106
MEIJER PREMIUM BLOOD GLUCOSE.....	1074	<i>metoprolol succinate er oral tablet extended</i>	
MEIJER TRUETEST TEST.....	1075	<i>release 24 hr* 25 mg</i>	1107
MEIJER TRUETRACK TEST.....	1076	MEVACOR ORAL TABLET 40 MG.....	1108
<i>memantine hcl oral tablet 5 (28)-10 (21) mg</i>	1077	MIACALCIN NASAL.....	1109
<i>memantine hcl oral tablet 5 mg, 10 mg</i>	1078	MICARDIS.....	1110

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

MICARDIS HCT	1111	NATAZIA	1153
MICRODOT TEST	1112	NATESTO	1154
<i>microgestin 1.5/30</i>	1113	NATPARA	1155
<i>microgestin 1/20</i>	1114	<i>necon 0.5/35 (28)</i>	1156
<i>microgestin fe 1.5/30</i>	1115	<i>necon 1/35 (28)</i>	1157
<i>microgestin fe 1/20</i>	1116	<i>necon 1/50 (28)</i>	1158
<i>mimvey</i>	1117	<i>necon 10/11 (28)</i>	1159
MINIVELLE	1118	NESINA	1160
MIRAPEX ER	1119	NESINA	1161
MIRCERA INJECTION	1120	NESINA	1162
<i>mirtazapine oral</i>	1121	NEUPRO	1163
MITIGARE	1122	NEURONTIN ORAL CAPSULE	1165
<i>modafinil oral tablet 100 mg</i>	1124	NEURONTIN ORAL TABLET	1164
<i>modafinil oral tablet 200 mg</i>	1123	NEUTEK 2TEK GLUCOSE/PRESSURE	1166
MODICON (28)	1125	NEUTEK 2TEK TEST	1167
MONDOXYNE NL ORAL CAPSULE 75 MG		<i>nevirapine er oral tablet extended release 24 hr*</i>	
	1126	<i>100 mg</i>	1169
MONOCLATE-P	1127	<i>nevirapine er oral tablet extended release 24 hr*</i>	
MONODOX ORAL CAPSULE 75 MG	1128	<i>400 mg</i>	1168
<i>mono-lynyah</i>	1129	NEXAVAR	1170
<i>mononessa</i>	1130	NEXGEN TEST	1171
MONONINE	1131	NEXIUM 24HR ORAL TABLET DELAYED	
MONOVISC	1132	RELEASE	1174
<i>montelukast sodium oral</i>	1133	NEXIUM ORAL CAPSULE DELAYED	
<i>montelukast sodium oral</i>	1134	RELEASE 40 MG	1172
<i>morphine sulfate er beads</i>	1137	NEXIUM ORAL PACKET	1173
<i>morphine sulfate er oral capsule extended release</i>		NEXPLANON	1175
<i>24 hour</i>	1135	<i>next choice one dose</i>	1176
<i>morphine sulfate er oral tablet extended release*</i>		NICODERM CQ	1177
<i>100 mg, 60 mg, 30 mg</i>	1135	<i>nicorelief mouth/throat gum</i>	1178
<i>morphine sulfate er oral tablet extended release* 15</i>		NICORETTE MOUTH/THROAT GUM	1179
<i>mg, 200 mg</i>	1136	<i>nicotine step 1</i>	1181
MS CONTIN ORAL TABLET		<i>nicotine step 2</i>	1182
EXTENDEDRELEASE* 60 MG, 100 MG, 15		<i>nicotine step 3</i>	1183
MG, 30 MG	1138	<i>nicotine transdermal patch 24 hr</i>	1180
MULTAQ	1139	NICOTROL	1184
MYALEPT	1140	NICOTROL NS	1185
MYGLUCOHEALTH TEST	1141	<i>nifediac cc oral tablet extended release 24 hr* 30</i>	
<i>myorisan oral capsule 10 mg, 20 mg, 40 mg</i>	1142	<i>mg</i>	1187
MYOZYME	1143	<i>nifediac cc oral tablet extended release 24 hr* 60</i>	
MYRBETRIQ	1144	<i>mg</i>	1186
<i>myzilra</i>	1145	<i>nifedical xl oral tablet extended release 24 hr* 30</i>	
NAGLAZYME	1146	<i>mg</i>	1188
NAMENDA	1147	<i>nifedical xl oral tablet extended release 24 hr* 60</i>	
NAMENDA TITRATION PAK	1148	<i>mg</i>	1189
NAMENDA XR	1149	<i>nifedipine er oral tablet extended release 24 hr* 30</i>	
NAMZARIC ORAL CAPSULE EXTENDED		<i>mg, 90 mg</i>	1190
RELEASE 24 HOUR 28-10 MG, 14-10 MG	1150	<i>nifedipine er oral tablet extended release 24 hr* 60</i>	
<i>naratriptan hcl</i>	1151	<i>mg</i>	1191
NARCAN	1152		

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

<i>nifedipine er osmotic release oral tablet extended release 24 hr* 60 mg</i>	1193	NUCYNTA.....	1229
<i>nifedipine er osmotic release oral tablet extended release 24 hr* 90 mg, 30 mg</i>	1192	NUCYNTA ER.....	1230
NIKKI.....	1194	NUEDEXTA.....	1231
NINLARO.....	1195	NUPLAZID.....	1232
<i>nisoldipine er oral tablet extended release 24 hr* 17 mg, 34 mg, 25.5 mg, 40 mg, 8.5 mg, 20 mg</i>	1196	NUTROPIN AQ NUSPIN 10.....	1233
<i>nisoldipine er oral tablet extended release 24 hr* 30 mg</i>	1197	NUTROPIN AQ NUSPIN 20.....	1234
<i>nitroglycerin translingual solution</i>	1198	NUTROPIN AQ NUSPIN 5.....	1235
<i>nora-be</i>	1199	NUVARING.....	1236
NORDITROPIN FLEXPRO.....	1200	NUVIGIL.....	1237
<i>norethindrone oral</i>	1201	NUWIQ.....	1238
<i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i>	1202	NYMALIZE.....	1239
<i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-35 mcg</i>	1203	OCALIVA ORAL TABLET 5 MG.....	1240
NORINYL 1+35 (28).....	1204	<i>ocella</i>	1241
NORINYL 1+50 (28).....	1205	OCTAGAM.....	1242
NORLYROC.....	1206	ODEFSEY.....	1243
NOR-QD.....	1207	ODOMZO.....	1244
NORTHERA ORAL CAPSULE 100 MG.....	1209	OFEV.....	1245
NORTHERA ORAL CAPSULE 200 MG, 300 MG.....	1208	<i>ogestrel</i>	1246
<i>nortrel 0.5/35 (28)</i>	1210	<i>olanzapine oral tablet 10 mg, 15 mg, 5 mg, 7.5 mg, 20 mg</i>	1247
<i>nortrel 1/35 (21)</i>	1211	<i>olanzapine oral tablet 2.5 mg</i>	1248
<i>nortrel 1/35 (28)</i>	1212	<i>olanzapine oral tablet dispersible</i>	1247
<i>nortrel 7/7/7</i>	1213	<i>olanzapine-fluoxetine hcl</i>	1249
NOVA MAX BLOOD GLUCOSE SYSTEM DEVICE.....	1214	OLEPTRO.....	1250
NOVA MAX GLUCOSE TEST.....	1215	OLYSIO.....	1251
<i>novarel</i>	1216	OLYSIO.....	1252
NOVOEIGHT.....	1217	OLYSIO.....	1253
NOVOLIN 70/30.....	1218	<i>omega-3-acid ethyl esters</i>	1254
NOVOLIN N.....	1219	<i>omeprazole-sodium bicarbonate oral packet</i>	1255
NOVOLIN R.....	1220	<i>omeprazole-sodium bicarbonate oral packet</i>	1256
NOVOLOG.....	1221	OMNARIS.....	1258
NOVOLOG FLEXPEN SUBCUTANEOUS*.....	1222	ON CALL EXPRESS BLOOD GLUCOSE.....	1259
NOVOLOG MIX 70/30.....	1223	ON CALL PLUS BLOOD GLUCOSE.....	1260
NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS*.....	1224	ON CALL VIVID BLOOD GLUCOSE.....	1261
NOVOLOG PENFILL SUBCUTANEOUS*.....	1225	<i>ondansetron</i>	1262
NOVOSEVEN RT.....	1226	<i>ondansetron hcl oral solution</i>	1265
NOXAFIL ORAL TABLET DELAYED RELEASE.....	1227	<i>ondansetron hcl oral tablet 4 mg, 24 mg</i>	1263
NUCALA.....	1228	<i>ondansetron hcl oral tablet 8 mg</i>	1264
		ONETOUCH TEST.....	1266
		ONETOUCH ULTRA 2.....	1267
		ONETOUCH ULTRA BLUE.....	1268
		ONETOUCH ULTRA MINI.....	1269
		ONETOUCH VERIO IN VITRO STRIP.....	1270
		ONETOUCH VERIO IQ SYSTEM.....	1271
		ONFI ORAL TABLET 10 MG, 20 MG.....	1272
		ONGLYZA.....	1273
		ONSOLIS.....	1274
		ONSOLIS.....	1276
		ONSOLIS.....	1278
		ONZETRA XSAIL.....	1280

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

OPANA ER ORAL	1282	<i>paricalcitol oral</i>	1322
OPANA ER ORAL	1283	<i>paroxetine hcl er oral tablet extended release 24 hr* 25 mg</i>	1325
OPANA ER ORAL TABLET EXTENDED RELEASE 12 HR* 30 MG, 20 MG, 5 MG, 10 MG, 40 MG	1281	<i>paroxetine hcl er oral tablet extended release 24 hr* 37.5 mg, 12.5 mg</i>	1326
OPSUMIT	1284	<i>paroxetine hcl oral tablet 20 mg, 10 mg</i>	1323
OPTUMRX BLOOD GLUCOSE TEST	1285	<i>paroxetine hcl oral tablet 40 mg, 30 mg</i>	1324
ORACEA	1286	PAXIL CR ORAL TABLET EXTENDED RELEASE 24 HR* 12.5 MG	1331
ORAMORPH SR ORAL TABLET EXTENDEDRELEASE*	1287	PAXIL CR ORAL TABLET EXTENDED RELEASE 24 HR* 25 MG	1330
ORAVIG	1288	PAXIL CR ORAL TABLET EXTENDED RELEASE 24 HR* 37.5 MG	1332
ORENCIA CLICKJECT	1291	PAXIL ORAL SUSPENSION	1329
ORENCIA CLICKJECT	1292	PAXIL ORAL TABLET 10 MG, 20 MG	1327
ORENCIA CLICKJECT	1293	PAXIL ORAL TABLET 30 MG, 40 MG	1328
ORENCIA INTRAVENOUS*	1289	<i>peg 3350/electrolytes</i>	1333
ORENCIA SUBCUTANEOUS*	1290	<i>peg-3350/electrolytes</i>	1334
ORENITRAM	1294	PEGASYS	1335
ORKAMBI	1295	PEGASYS PROCLICK	1336
<i>orsythia</i>	1296	PEGINTRON	1337
ORTHO DIAPHRAGM ALL-FLEX VAGINAL DIAPHRAGM 70 MM	1297	PEG-INTRON	1338
ORTHO MICRONOR	1298	PEG-INTRON REDIPEN	1339
ORTHO TRI-CYCLEN (28)	1299	PEG-INTRON REDIPEN PAK 4	1340
ORTHO TRI-CYCLEN LO	1300	PENNSAID TRANSDERMAL SOLUTION 2 %	1341
ORTHO-CEPT (28)	1301	PENTASA ORAL CAPSULE EXTENDED RELEASE* 250 MG	1343
ORTHO-CYCLEN (28)	1302	PENTASA ORAL CAPSULE EXTENDED RELEASE* 500 MG	1342
ORTHO-NOVUM 1/35 (28)	1303	PERFOROMIST	1344
ORTHO-NOVUM 7/7/7 (28)	1304	PERFOROMIST	1345
ORTHOVISC INTRA-ARTICULAR*	1305	PERTZYE	1346
OSENI	1306	PEXEVA	1347
OSPHENA	1307	<i>philith</i>	1348
OTEZLA ORAL 10 & 20 & 30 MG	1309	PICATO EXTERNAL GEL 0.015 %	1349
OTEZLA ORAL TABLET	1308	PICATO EXTERNAL GEL 0.05 %	1350
OVIDREL	1310	<i>pioglitazone hcl</i>	1351
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR* 150 MG, 300 MG	1311	<i>pioglitazone hcl-glimepiride</i>	1352
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR* 600 MG	1312	<i>pioglitazone hcl-metformin hcl</i>	1353
<i>oxybutynin chloride oral tablet</i>	1313	PLAN B ONE-STEP	1354
<i>oxycodone hcl er oral 10 mg, 20 mg, 40 mg, 80 mg</i>	1314	PLAVIX	1355
<i>oxycodone-ibuprofen</i>	1315	PLEGRIDY	1356
OXYCONTIN ORAL	1316	PLEGRIDY STARTER PACK	1357
<i>oxymorphone hcl er</i>	1317	POCKETCHEM EZ TEST	1358
<i>paliperidone er oral tablet extended release 24 hr* 1.5 mg, 6 mg, 3 mg</i>	1319	POMALYST	1359
<i>paliperidone er oral tablet extended release 24 hr* 9 mg</i>	1318	<i>portia-28</i>	1360
PANCREAZE	1320	POTIGA ORAL TABLET 300 MG, 200 MG, 400 MG	1361
PARAGARD INTRAUTERINE COPPER	1321	POTIGA ORAL TABLET 50 MG	1362

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

PRADAXA	1363	PROCYSBI ORAL CAPSULE DELAYED	
PRALUENT	1364	RELEASE 25 MG	1410
PRALUENT	1365	PROCYSBI ORAL CAPSULE DELAYED	
PRALUENT	1366	RELEASE 75 MG	1407
<i>pramipexole dihydrochloride er</i>	1367	PROCYSBI ORAL CAPSULE DELAYED	
<i>pramipexole dihydrochloride er</i>	1368	RELEASE 75 MG	1409
PRANDIMET	1369	PROCYSBI ORAL CAPSULE DELAYED	
PRAVACHOL ORAL TABLET 40 MG, 20 MG,		RELEASE 75 MG	1411
80 MG	1370	PRODIGY AUTOCODE BLOOD GLUCOSE	
<i>pravastatin sodium</i>	1371	DEVICE	1414
PRECISION PCX	1372	PRODIGY AUTOCODE BLOOD GLUCOSE IN	
PRECISION PCX PLUS TEST	1373	VITRO	1412
PRECISION POINT OF CARE TEST	1374	PRODIGY AUTOCODE BLOOD GLUCOSE KIT	
PRECISION QID TEST	1375	1413
PRECISION SOF-TACT TEST	1376	PRODIGY NO CODING BLOOD GLUC	1415
PRECISION XTRA BLOOD GLUCOSE	1378	PROFILNINE	1416
PRECISION XTRA DEVICE	1377	PROFILNINE SD	1417
PRECISION XTRA MONITOR	1379	<i>progesterone micronized oral</i>	1418
PREFEST	1380	PROLIA	1419
<i>pregnyl</i>	1381	PROMACTA	1420
PREMARIN ORAL	1382	PROMACTA	1421
PREMPHASE	1383	PROMETRIUM	1422
PREMPRO	1384	<i>propafenone hcl er</i>	1423
<i>prestige smart system test</i>	1385	PROTOPIC	1424
PRESTIGE TEST	1386	PROTOPIC	1426
PREVACID 24HR	1389	PROVENTIL HFA	1428
PREVACID ORAL CAPSULE DELAYED		PROVIGIL	1429
RELEASE 15 MG	1388	PROVIGIL	1430
PREVACID ORAL CAPSULE DELAYED		PROZAC ORAL CAPSULE 10 MG	1433
RELEASE 30 MG	1387	PROZAC ORAL CAPSULE 20 MG	1432
PREVACID SOLUTAB	1390	PROZAC ORAL CAPSULE 40 MG	1431
PREVACID SOLUTAB	1392	PROZAC WEEKLY	1434
<i>previfem</i>	1394	PTS PANELS GLUCOSE TEST	1435
PREZISTA ORAL SUSPENSION	1397	PULMICORT	1436
PREZISTA ORAL TABLET 150 MG, 600 MG, 75		PULMICORT FLEXHALER	1437
MG	1395	PULMOZYME	1438
PREZISTA ORAL TABLET 800 MG	1396	PURIXAN	1439
PRILOSEC ORAL PACKET	1398	QBRELIS	1440
PRILOSEC OTC	1400	QNASL	1441
PRISTIQ	1401	QUARTETTE	1442
PROCARDIA XL ORAL TABLET EXTENDED		<i>quasense</i>	1443
RELEASE 24 HR* 30 MG	1402	QUDEXY XR ORAL 100 MG, 25 MG, 50 MG	
PROCARDIA XL ORAL TABLET EXTENDED		1445
RELEASE 24 HR* 90 MG, 60 MG	1403	QUDEXY XR ORAL 200 MG, 150 MG	1444
PROCENTRA	1404	<i>quetiapine fumarate oral tablet 200 mg</i>	1446
PROCRIT	1405	<i>quetiapine fumarate oral tablet 25 mg</i>	1449
PROCYSBI ORAL CAPSULE DELAYED		<i>quetiapine fumarate oral tablet 400 mg, 300 mg</i>	
RELEASE 25 MG	1406	1448
PROCYSBI ORAL CAPSULE DELAYED		<i>quetiapine fumarate oral tablet 50 mg, 100 mg</i>	
RELEASE 25 MG	1408	1447

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

QUICKTEK TEST.....	1450	REVATIO ORAL SUSPENSION	
QUILLICHEW ER ORAL 20 MG, 40 MG.....	1451	RECONSTITUTED.....	1495
QUILLICHEW ER ORAL 30 MG.....	1452	REVATIO ORAL SUSPENSION	
QUILLIVANT XR.....	1453	RECONSTITUTED.....	1496
<i>quinine sulfate oral</i>	1454	REVATIO ORAL SUSPENSION	
QUINTET AC BLOOD GLUCOSE TEST.....	1455	RECONSTITUTED.....	1497
QUINTET BLOOD GLUCOSE TEST.....	1456	REVATIO ORAL TABLET.....	1498
<i>ra blood glucose monitor</i>	1457	REVATIO ORAL TABLET.....	1500
<i>ra nicotine transdermal</i>	1458	REVATIO ORAL TABLET.....	1501
RA TRUETEST TEST.....	1459	REVEAL BLOOD GLUCOSE TEST.....	1502
<i>rabeprazole sodium</i>	1460	REVLIMID.....	1503
RANEXA.....	1461	REXULTI.....	1504
RAVICTI.....	1462	REYATAZ ORAL CAPSULE 150 MG, 300 MG	
RAYOS.....	1463	1505
RAZADYNE ORAL TABLET.....	1464	REYATAZ ORAL CAPSULE 200 MG.....	1506
REBETOL ORAL SOLUTION.....	1465	RIASTAP.....	1507
<i>reclipsen</i>	1466	RIGHTEST GS100 BLOOD GLUCOSE.....	1508
RECOMBINATE.....	1467	RIGHTEST GS300 BLOOD GLUCOSE.....	1509
RECTIV.....	1468	RIGHTEST GS550 BLOOD GLUCOSE.....	1510
REFUAH PLUS BLOOD GLUCOSE TEST.....	1469	RILUTEK.....	1511
RELENZA DISKHALER.....	1470	<i>riluzole</i>	1512
RELION PRIME MONITOR.....	1471	<i>risedronate sodium oral tablet 150 mg</i>	1513
RELISTOR SUBCUTANEOUS* KIT.....	1473	<i>risedronate sodium oral tablet 150 mg</i>	1516
RELISTOR SUBCUTANEOUS* SOLUTION 12		<i>risedronate sodium oral tablet 35 mg</i>	1515
MG/0.6ML.....	1474	<i>risedronate sodium oral tablet 5 mg, 30 mg</i>	1514
RELISTOR SUBCUTANEOUS* SOLUTION 8		<i>risedronate sodium oral tablet delayed release</i>	
MG/0.4ML.....	1472	1515
RELPAK.....	1475	RISPERDAL M-TAB ORAL TABLET	
REMERON.....	1476	DISPERSIBLE 0.5 MG, 1 MG, 2 MG.....	1520
REMERON SOLTAB.....	1477	RISPERDAL M-TAB ORAL TABLET	
REMODULIN.....	1478	DISPERSIBLE 3 MG.....	1522
<i>repaglinide-metformin hcl</i>	1479	RISPERDAL M-TAB ORAL TABLET	
REPATHA.....	1480	DISPERSIBLE 4 MG.....	1521
REPATHA.....	1481	RISPERDAL ORAL SOLUTION.....	1519
REPATHA.....	1482	RISPERDAL ORAL TABLET 3 MG, 0.25 MG,	
REPATHA PUSHTRONEX SYSTEM.....	1483	0.5 MG, 1 MG, 2 MG.....	1517
REPATHA SURECLICK.....	1484	RISPERDAL ORAL TABLET 4 MG.....	1518
REPATHA SURECLICK.....	1485	RISPERIDONE M-TAB ORAL TABLET	
REPATHA SURECLICK.....	1486	DISPERSIBLE 1 MG, 0.5 MG, 2 MG.....	1526
REPRONEX.....	1487	RISPERIDONE M-TAB ORAL TABLET	
REQUIP XL.....	1488	DISPERSIBLE 3 MG.....	1527
RESCULA.....	1489	RISPERIDONE M-TAB ORAL TABLET	
RESCULA.....	1490	DISPERSIBLE 4 MG.....	1528
RESTORIL ORAL CAPSULE 22.5 MG, 7.5 MG		<i>risperidone oral tablet 2 mg, 0.25 mg, 0.5 mg, 1 mg</i>	
.....	1491	1523
RETIN-A.....	1492	<i>risperidone oral tablet 3 mg</i>	1525
RETIN-A MICRO.....	1493	<i>risperidone oral tablet 4 mg</i>	1524
RETIN-A MICRO PUMP.....	1494	<i>risperidone oral tablet dispersible 0.5 mg, 1 mg, 2</i>	
REVATIO INTRAVENOUS*.....	1499	<i>mg</i>	1523
		<i>risperidone oral tablet dispersible 3 mg</i>	1525

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

<i>risperidone oral tablet dispersible 4 mg</i>	1524	SEROSTIM SUBCUTANEOUS* SOLUTION	
RITALIN	1529	RECONSTITUTED 5 MG, 4 MG, 6 MG	1567
RITALIN LA ORAL CAPSULE EXTENDED		<i>sertraline hcl oral concentrate</i>	1570
RELEASE 24 HOUR 10 MG, 30 MG	1530	<i>sertraline hcl oral tablet 100 mg</i>	1568
RITALIN LA ORAL CAPSULE EXTENDED		<i>sertraline hcl oral tablet 25 mg</i>	1569
RELEASE 24 HOUR 40 MG, 20 MG	1532	<i>sertraline hcl oral tablet 50 mg</i>	1571
RITALIN LA ORAL CAPSULE EXTENDED		SHAROBEL	1572
RELEASE 24 HOUR 60 MG	1531	SIGNIFOR	1573
<i>rivastigmine</i>	1533	SIGNIFOR LAR	1574
<i>rivastigmine tartrate</i>	1534	<i>sildenafil citrate oral</i>	1575
RIXUBIS	1535	SIMCOR ORAL TABLET EXTENDED	
<i>rizatriptan benzoate</i>	1536	RELEASE 24 HR* 1000-20 MG, 500-20 MG,	
<i>ropinirole hcl er oral tablet extended release 24</i>		750-20 MG	1576
<i>hr* 12 mg</i>	1538	SIMCOR ORAL TABLET EXTENDED	
<i>ropinirole hcl er oral tablet extended release 24</i>		RELEASE 24 HR* 1000-40 MG, 500-40 MG	
<i>hr* 2 mg, 6 mg, 8 mg, 4 mg</i>	1537	1577
<i>rosuvastatin calcium</i>	1539	SIMPONI ARIA	1579
ROZEREM	1540	SIMPONI SUBCUTANEOUS*	1578
ROZEREM	1541	<i>simvastatin oral</i>	1580
RUCONEST	1542	SINGULAIR	1581
RYTHMOL SR	1543	SINGULAIR	1582
SABRIL	1544	SIRTURO	1583
SABRIL	1545	SKYLA	1584
SAFYRAL	1546	<i>sm nicotine transdermal</i>	1585
SAIZEN	1547	SMART SENSE VALUE TEST	1586
SAMSCA ORAL TABLET 15 MG	1548	SMARTEST BLOOD GLUCOSE TEST	1587
SAMSCA ORAL TABLET 30 MG	1549	SMARTEST EJECT	1588
SANCTURA	1550	SMARTEST PROTEGE	1589
SANCTURA XR	1551	<i>sodium phenylbutyrate oral powder 3 gm/tsp</i>	
SANCUSO	1552	1590
SAPHRIS	1553	SOLARAZE	1591
SAVAYSA	1554	<i>solia</i>	1592
SAVELLA	1555	SOLIRIS	1593
SAVELLA TITRATION PACK	1556	SOLUS V2 TEST	1594
SEEBRI NEOHALER	1557	SOMAVERT	1595
SELZENTRY ORAL TABLET 150 MG	1558	SONATA ORAL CAPSULE 10 MG	1597
SENSIPAR	1559	SONATA ORAL CAPSULE 5 MG	1596
SEREVENT DISKUS	1560	SOOLANTRA	1598
SEROQUEL ORAL TABLET 200 MG	1561	SORIATANE ORAL CAPSULE 10 MG, 17.5	
SEROQUEL ORAL TABLET 25 MG	1562	MG, 25 MG	1599
SEROQUEL ORAL TABLET 300 MG, 400 MG		SOVALDI	1600
.....	1563	SPIRIVA HANDIHALER	1601
SEROQUEL ORAL TABLET 50 MG, 100 MG		SPIRIVA RESPIMAT	1602
.....	1564	SPORANOX ORAL CAPSULE	1603
SEROQUEL XR ORAL TABLET EXTENDED		SPORANOX PULSEPAK	1604
RELEASE 24 HR* 150 MG, 200 MG	1566	<i>sprintec 28</i>	1605
SEROQUEL XR ORAL TABLET EXTENDED		SPRITAM	1606
RELEASE 24 HR* 50 MG, 300 MG, 400 MG		SPRIX	1607
.....	1565	SPRYCEL ORAL TABLET 100 MG, 140 MG	
		1609

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

SPRYCEL ORAL TABLET 140 MG, 100 MG	1610	SURE EDGE TEST	1654
SPRYCEL ORAL TABLET 140 MG, 100 MG	1613	SURECHEK BLOOD GLUCOSE MONITOR DEVICE	1655
SPRYCEL ORAL TABLET 20 MG, 50 MG, 80 MG, 70 MG	1612	SURECHEK BLOOD GLUCOSE TEST	1656
SPRYCEL ORAL TABLET 80 MG, 50 MG, 70 MG, 20 MG	1611	SURE-TEST EASYPLUS MINI METER	1657
SPRYCEL ORAL TABLET 80 MG, 70 MG, 20 MG, 50 MG	1608	SURE-TEST EASYPLUS MINI TEST	1658
<i>sronyx</i>	1614	SUTENT	1659
STELARA SUBCUTANEOUS*	1615	<i>syeda</i>	1660
STIOLTO RESPIMAT	1616	SYLATRON SUBCUTANEOUS* KIT 200 MCG, 4 X 200 MCG, 4 X 300 MCG, 300 MCG, 600 MCG	1661
STIVARGA	1617	SYMBICORT	1662
STRATTERA	1618	SYMBYAX ORAL CAPSULE 6-25 MG, 6-50 MG, 12-50 MG, 12-25 MG	1663
STRENSIQ	1619	SYMLIN	1664
STRIANT	1620	SYMLINPEN 120 SUBCUTANEOUS*	1665
STRIBILD	1621	SYMLINPEN 60 SUBCUTANEOUS*	1666
STRIVERDI RESPIMAT	1622	SYNAGIS	1667
SUBOXONE SUBLINGUAL FILM 12-3 MG	1625	SYNJARDY	1668
SUBOXONE SUBLINGUAL FILM 2-0.5 MG, 4-1 MG, 8-2 MG	1623	SYNRIBO	1669
SUBOXONE SUBLINGUAL TABLET SUBLINGUAL	1627	SYNRIBO	1670
SUBSYS	1629	SYNRIBO	1671
SUBSYS	1631	SYNVISC INTRA-ARTICULAR*	1672
SUBSYS	1633	SYNVISC ONE INTRA-ARTICULAR*	1673
SUBSYS	1635	TACLONEX EXTERNAL OINTMENT	1674
SUBSYS	1637	<i>tacrolimus external</i>	1675
SUBSYS	1639	<i>tacrolimus external</i>	1677
SULAR ORAL TABLET EXTENDED RELEASE 24 HR* 8.5 MG, 17 MG, 34 MG	1641	TAFINLAR	1679
<i>sulfasalazine oral</i>	1642	TAGRISSO	1680
<i>sulfazine</i>	1643	<i>take action</i>	1681
SULFAZINE EC	1644	TALTZ	1682
<i>sumatriptan nasal</i>	1645	TAMIFLU ORAL CAPSULE	1683
<i>sumatriptan succinate oral</i>	1647	TAMIFLU ORAL SUSPENSION RECONSTITUTED 6 MG/ML	1684
<i>sumatriptan succinate refill subcutaneous*</i>	1649	TANZEUM	1685
<i>sumatriptan succinate subcutaneous* 4 mg/0.5ml, 6 mg/0.5ml</i>	1646	TARCEVA	1686
<i>sumatriptan succinate subcutaneous* solution 4 mg/0.5ml</i>	1646	TASIGNA	1687
<i>sumatriptan succinate subcutaneous* solution 6 mg/0.5ml</i>	1648	TASIGNA	1688
SUMAVEL DOSEPRO SUBCUTANEOUS* 4 MG/0.5ML	1650	TASIGNA	1689
SUPARTZ INTRA-ARTICULAR*	1651	TAZORAC EXTERNAL CREAM 0.05 %	1691
SUPREME TEST	1652	TAZORAC EXTERNAL CREAM 0.05 %	1692
SURE EDGE GLUCOSE MONITOR	1653	TAZORAC EXTERNAL CREAM 0.1 %	1690
		TAZORAC EXTERNAL GEL 0.05 %	1690
		TAZORAC EXTERNAL GEL 0.1 %	1691
		TAZORAC EXTERNAL GEL 0.1 %	1692
		<i>taztia xt oral capsule extended release 24 hour</i>	240
		<i>mg</i>	1693
		<i>taztia xt oral capsule extended release 24 hour</i>	360
		<i>mg, 300 mg, 120 mg, 180 mg</i>	1694
		TECFIDERA	1695

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

TECFIDERA	1696	TIAZAC ORAL CAPSULE EXTENDED	
TECFIDERA	1697	RELEASE 24 HOUR 240 MG	1733
TECFIDERA	1698	<i>tilia fe</i>	1734
TECFIDERA	1699	TIROSINT	1735
TECFIDERA	1700	TIVICAY	1736
TECHNIVIE	1701	TIVICAY	1737
TECHNIVIE	1702	TIVORBEX	1738
TECHNIVIE	1703	TOBI	1739
TEKAMLO	1704	TOBI PODHALER	1740
TEKURNA	1705	<i>tobramycin inhalation</i>	1741
TEKURNA HCT	1706	<i>tolterodine tartrate er</i>	1742
TELCARE BLOOD GLUCOSE TEST	1707	TOPAMAX SPRINKLE	1743
<i>telmisartan</i>	1708	TOPICORT SPRAY	1744
<i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5</i>		<i>topiramate oral capsule sprinkle</i>	1745
<i>mg</i>	1709	TOPROL XL ORAL TABLET EXTENDED	
<i>telmisartan-amlodipine oral tablet 80-10 mg, 80-5</i>		RELEASE 24 HR* 100 MG, 50 MG	1747
<i>mg</i>	1710	TOPROL XL ORAL TABLET EXTENDED	
<i>telmisartan-hctz</i>	1711	RELEASE 24 HR* 200 MG	1746
<i>temazepam oral capsule 22.5 mg, 7.5 mg</i>	1712	TOPROL XL ORAL TABLET EXTENDED	
<i>temozolomide</i>	1713	RELEASE 24 HR* 25 MG	1748
TESTIM	1714	TOUJEO SOLOSTAR	1749
<i>testosterone cypionate intramuscular* solution 100</i>		TOVIAZ	1750
<i>mg/ml</i>	1716	TOVIAZ	1751
<i>testosterone cypionate intramuscular* solution 200</i>		TRADJENTA	1752
<i>mg/ml</i>	1717	<i>tramadol hcl er (biphasic)</i>	1755
<i>testosterone cypionate intramuscular* solution 250</i>		<i>tramadol hcl er oral capsule extended release 24</i>	
<i>mg/ml</i>	1718	<i>hour 100 mg, 200 mg, 300 mg</i>	1753
<i>testosterone transdermal gel 12.5 mg/act (1%), 25</i>		<i>tramadol hcl er oral tablet extended release 24 hr*</i>	
<i>mg/2.5gm (1%), 10 mg/act (2%), 50 mg/5gm (1%)</i>		1754
.....	1715	<i>tramadol-acetaminophen</i>	1756
<i>tetrabenazine oral tablet 12.5 mg</i>	1719	<i>tranexamic acid oral</i>	1757
<i>tetrabenazine oral tablet 25 mg</i>	1720	<i>travoprost</i>	1758
TEVETEN HCT ORAL TABLET 600-12.5 MG		<i>tretinoin external cream</i>	1759
.....	1723	<i>tretinoin external gel 0.01 %</i>	1760
TEVETEN HCT ORAL TABLET 600-25 MG		<i>tretinoin external gel 0.025 %</i>	1759
.....	1721	<i>tretinoin microsphere</i>	1761
TEVETEN HCT ORAL TABLET 600-25 MG		<i>tretinoin microsphere pump</i>	1762
.....	1722	TRETIN-X EXTERNAL CREAM 0.0375 %	
TEV-TROPIN	1724	1765
TGT BLOOD GLUCOSE MONITORING	1725	TRETIN-X EXTERNAL CREAM 0.075 %	1766
<i>tgt nicotine step one</i>	1726	TRETIN-X EXTERNAL KIT 0.05 % CREAM,	
<i>tgt nicotine step three</i>	1727	0.025 % CREAM, 0.1 % CREAM	1763
<i>tgt nicotine step two</i>	1728	TRETIN-X EXTERNAL KIT 0.05 % CREAM,	
<i>thrive mouth/throat gum 2 mg</i>	1729	0.025 % CREAM, 0.1 % CREAM	1764
<i>tiagabine hcl oral tablet 2 mg</i>	1730	TRETTEN	1767
<i>tiagabine hcl oral tablet 4 mg</i>	1731	TRIBENZOR	1768
TIAZAC ORAL CAPSULE EXTENDED		TRICOR	1769
RELEASE 24 HOUR 120 MG, 180 MG, 360 MG,		TRIGLIDE ORAL TABLET 160 MG	1770
300 MG, 420 MG	1732	<i>tri-legest fe</i>	1771
		<i>tri-linyah</i>	1772

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016

TRILIPIX	1773	UNISTRIP1 GENERIC	1819
<i>trinessa</i> (28)	1774	UPTRAVI ORAL	1821
TRI-NORINYL (28)	1775	UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 800 MCG, 1600 MCG, 400 MCG, 600 MCG	1820
TRINTELLIX	1776	UPTRAVI ORAL TABLET 200 MCG	1821
<i>tri-previfem</i>	1778	UTIBRON NEOHALER	1822
<i>tri-sprintec</i>	1779	VALCHLOR	1823
TRIUMEQ	1780	VALCYTE ORAL TABLET	1824
<i>trivora</i> (28)	1781	<i>valganciclovir hcl oral tablet</i>	1825
TROKENDI XR	1782	<i>valsartan</i>	1826
<i>trospium chloride</i>	1783	<i>valsartan-hydrochlorothiazide</i>	1827
<i>trospium chloride er</i>	1784	VARUBI	1828
TRUE METRIX BLOOD GLUCOSE TEST	1785	VASCEPA	1829
TRUE2GO BLOOD GLUCOSE MONITOR	1786	VECAMYL	1830
		VELETRI	1832
TRUERESULT BLOOD GLUCOSE	1787	<i>velivet</i>	1833
TRUETEST TEST	1788	VELTASSA	1834
TRUETRACK BLOOD GLUCOSE KIT	1789	VELTIN	1835
TRUETRACK SMART SYSTEM	1790	VENCLEXTA ORAL TABLET 10 MG	1838
TRUETRACK TEST	1791	VENCLEXTA ORAL TABLET 100 MG	1837
TRULICITY	1792	VENCLEXTA ORAL TABLET 50 MG	1836
TUDORZA PRESSAIR INHALATION AEROSOL POWDER, BREATH ACTIVATED		VENCLEXTA STARTING PACK	1839
400 MCG/ACT	1793	<i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg</i>	1844
TUSSICAPS	1794	<i>venlafaxine hcl er oral capsule extended release 24 hour 75 mg, 37.5 mg</i>	1847
TWYNSTA	1795	<i>venlafaxine hcl er oral tablet extended release 24 hr* 150 mg</i>	1845
TYBOST	1796	<i>venlafaxine hcl er oral tablet extended release 24 hr* 225 mg, 37.5 mg, 75 mg</i>	1846
TYKERB	1797	<i>venlafaxine hcl oral tablet 25 mg, 100 mg</i>	1842
TYSABRI	1798	<i>venlafaxine hcl oral tablet 37.5 mg</i>	1840
TYSABRI	1799	<i>venlafaxine hcl oral tablet 50 mg</i>	1843
TYSABRI	1800	<i>venlafaxine hcl oral tablet 75 mg</i>	1841
TYVASO	1801	VENTAVIS	1848
TYVASO REFILL	1802	VERAMYST	1849
TYVASO STARTER	1803	<i>verapamil hcl er oral capsule extended release 24 hour 200 mg</i>	1850
TYZEKA	1804	<i>verapamil hcl er oral capsule extended release 24 hour 300 mg, 100 mg</i>	1851
UCERIS	1806	VERSACLOZ	1852
UCERIS ORAL	1805	VESICARE	1853
ULESFIA	1807	<i>vestura</i>	1854
ULORIC	1808	VIBERZI	1855
ULTIMA TEST	1809	VICTORY AGM-4000 TEST	1856
ULTRACET	1810	VICTORY BLOOD GLUCOSE SYSTEM	1857
ULTRAM ER ORAL TABLET EXTENDED RELEASE 24 HR* 200 MG	1812	VICTOZA SUBCUTANEOUS*	1858
ULTRAM ER ORAL TABLET EXTENDED RELEASE 24 HR* 300 MG, 100 MG	1811	VICTRELIS	1859
ULTRATRAK ACTIVE	1813	VICTRELIS	1860
ULTRATRAK PRO	1814		
ULTRATRAK PRO TEST	1815		
ULTRATRAK ULTIMATE MONITOR	1816		
ULTRATRAK ULTIMATE TEST	1817		
ULTRESA	1818		

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

VICTRELIS	1861	WIDE-SEAL DIAPHRAGM 75	1908
VIEKIRA PAK	1862	WIDE-SEAL DIAPHRAGM 80	1909
VIEKIRA PAK	1863	WIDE-SEAL DIAPHRAGM 85	1910
VIEKIRA PAK	1864	WIDE-SEAL DIAPHRAGM 90	1911
VIEKIRA XR	1865	WIDE-SEAL DIAPHRAGM 95	1912
VIEKIRA XR	1866	WILATE INTRAVENOUS* KIT	1913
VIEKIRA XR	1867	WILATE INTRAVENOUS* SOLUTION	
VIIIBRYD ORAL TABLET	1868	RECONSTITUTED 1000-1000 UNIT, 500-500	
VIIIBRYD ORAL TABLET	1869	UNIT	1913
VIMIZIM	1870	<i>wymzya fe</i>	1914
VIMOVO	1871	XALATAN	1915
VIMPAT ORAL SOLUTION	1872	XALATAN	1916
VIMPAT ORAL TABLET	1873	XALKORI	1917
VIKACE	1874	XANAX XR	1918
<i>viorele</i>	1875	XARTEMIS XR	1919
VIRAMUNE XR ORAL TABLET EXTENDED		XELJANZ	1920
RELEASE 24 HR* 100 MG	1876	XELJANZ XR	1921
VIRAMUNE XR ORAL TABLET EXTENDED		XENAZINE ORAL TABLET 12.5 MG	1922
RELEASE 24 HR* 400 MG	1877	XENAZINE ORAL TABLET 25 MG	1923
VIREAD ORAL TABLET	1878	XEOMIN	1924
VISTOGARD	1879	XGEVA	1925
VIVELLE	1880	XIFAXAN ORAL TABLET 200 MG	1927
VIVELLE-DOT	1881	XIFAXAN ORAL TABLET 550 MG	1926
VIVLODEX	1882	XIGDUO XR ORAL TABLET EXTENDED	
VOCAL POINT BLOOD GLUCOSE TEST	1883	RELEASE 24 HR* 10-1000 MG, 10-500 MG,	
VOGELXO PUMP	1886	5-500 MG	1928
VOGELXO TRANSDERMAL GEL 50 MG/5GM		XIGDUO XR ORAL TABLET EXTENDED	
(1%)	1884	RELEASE 24 HR* 5-1000 MG	1929
VOLTAREN TRANSDERMAL	1887	XIIDRA	1930
VONVENDI	1888	XOLAIR	1931
VOTRIENT	1889	XOPENEX HFA	1932
VPRIV	1890	XTAMPZA ER	1933
VRAYLAR ORAL	1891	XTANDI	1934
VRAYLAR ORAL CAPSULE 1.5 MG	1894	XULANE	1935
VRAYLAR ORAL CAPSULE 3 MG	1893	XURIDEN	1936
VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG		XYNTHA INTRAVENOUS* KIT 1000 UNIT,	
	1892	500 UNIT, 2000 UNIT, 250 UNIT	1937
VYTORIN	1895	XYNTHA SOLOFUSE	1938
VYTORIN	1896	XYREM	1939
VYTORIN	1897	XYZAL ORAL TABLET	1940
VYVANSE	1898	YASMIN 28	1941
WAVESENSE KEYNOTE PRO METER	1899	YAZ	1942
WAVESENSE PRESTO	1900	YERVOY	1943
WELLBUTRIN	1901	<i>zaleplon</i>	1944
WELLBUTRIN SR	1902	<i>zarah</i>	1945
WELLBUTRIN XL	1903	ZAVESCA	1946
<i>wera</i>	1904	ZAVESCA	1947
WIDE-SEAL DIAPHRAGM 60	1905	ZAVESCA	1948
WIDE-SEAL DIAPHRAGM 65	1906	ZECUITY	1949
WIDE-SEAL DIAPHRAGM 70	1907	ZEGERID OTC	1950

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary

Updated 10/2016

Next expected update 11/2016

ZELAPAR	1951	ZYTIGA	2000
ZELBORAF	1952	ZYVOX ORAL SUSPENSION	
ZEMBRACE SYMTOUCH	1953	RECONSTITUTED	2001
ZEMPLAR ORAL	1954	ZYVOX ORAL TABLET	2002
<i>zenatane oral capsule 20 mg, 10 mg, 40 mg</i>	1955		
<i>zenchent</i>	1956		
<i>zenchent fe</i>	1957		
ZEPATIER	1958		
ZETIA	1959		
ZETONNA	1960		
ZIANA	1961		
ZINBRYTA	1962		
ZIOPTAN	1963		
ZIOPTAN	1964		
<i>ziprasidone hcl</i>	1965		
ZOCOR	1966		
ZOFRAN ORAL TABLET 8 MG	1967		
ZOHYDRO ER	1968		
ZOLINZA	1969		
<i>zolmitriptan oral tablet 2.5 mg</i>	1971		
<i>zolmitriptan oral tablet 5 mg</i>	1970		
<i>zolmitriptan oral tablet dispersible 2.5 mg</i>	1972		
<i>zolmitriptan oral tablet dispersible 5 mg</i>	1970		
ZOLOFT ORAL TABLET 100 MG	1974		
ZOLOFT ORAL TABLET 25 MG	1973		
ZOLOFT ORAL TABLET 50 MG	1975		
<i>zolpidem tartrate er</i>	1978		
<i>zolpidem tartrate oral</i>	1976		
<i>zolpidem tartrate sublingual</i>	1977		
ZOMACTON	1979		
ZOMETA	1980		
ZOMIG NASAL SOLUTION 5 MG	1981		
ZOMIG ORAL	1982		
ZOMIG ZMT	1983		
ZONTIVITY	1984		
ZORBTIVE	1985		
ZORBTIVE	1986		
ZORBTIVE	1987		
ZORVOLEX	1988		
<i>zovia 1/35e (28)</i>	1989		
<i>zovia 1/50e (28)</i>	1990		
ZUBSOLV	1991		
ZURAMPIC	1993		
ZYBAN	1994		
ZYDELIG	1995		
ZYKADIA	1996		
ZYPREXA ORAL TABLET 2.5 MG	1998		
ZYPREXA ORAL TABLET 7.5 MG, 5 MG, 15			
MG, 20 MG, 10 MG	1997		
ZYPREXA ZYDIS	1999		

2017 Innovation Health Drug Guide - Value Plus Small Group Five Tier Formulary
Updated 10/2016
Next expected update 11/2016